{"PMC7248682": [["Social Distancing Solidarity Via SongOne mental health consequence of social distancing is the terrible loneliness thatcan prevail, as people are necessitated to remain inside our homes and away from thecommunal comradery of our daily lives, which we may have taken for granted untilnow.", [["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141]]], ["Our worlds can feel eerily quiet and small when mandated to work and schoolfrom home, avoid restaurants and bars, and stay at a six-foot distance from othersfor weeks or months to come.", [["small", "OBSERVATION_MODIFIER", 37, 42]]], ["Physical distancing can certainly be experienced as apsychological distancing without intentional efforts to offset the isolation.", [["the isolation", "TREATMENT", 116, 129]]], ["Historically, musichas been used by people to remain motivated, resilient, and united in the face ofcollective challenge, from the Sea Shantis that sailors in the 18thcentury chanted together as they labored to weather harsh ocean tides, to thefreedom songs sung by the Black community in the 20th century amid the tiring fightfor civil rights.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["Tracey Nicholls(2014) writes about music\u2019s emotional power to join people in solidarityand build movements together:it is because of the way music feeds into our emotional lives and because ofthe sense of social well-being we get from sharing emotional states withothers that music so frequently accompanies movements that build, and dependupon, solidarity.Social Distancing Solidarity Via SongWhereby solidarity is defined as \u201cthe harmony of interests and responsibilities amongindividuals in a group, especially as manifested in unanimous support and collectiveaction for something\u201d (Laurence& Urbain, 2011, p.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73]]], ["5), musical solidarity has the therapeutic abilityto puncture the isolation of social distancing, to foster resiliency by lifting thecollective spirit, and to move people\u2019s emotions toward spiritedaction\u2014even if that action, in these circumstances, meansstaying home to save the lives of others.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["the therapeutic abilityto puncture", "TREATMENT", 27, 61]]], ["Music can also assuage the stressinflicted by social distancing and the COVID-19 pandemic by soothing the autonomicnervous system through rhythm and melody (Thoma et al., 2013).Social Distancing Solidarity Via SongIn this time of coronavirus, examples of therapeutic music-making unceasingly flow.As a psychology professor who teaches art therapy, my undergraduate students and Iwere supposed to do a music therapy lesson last week and engage in animprovisational jam-session together in the classroom.", [["the COVID", "TEST", 68, 77], ["coronavirus", "PROBLEM", 230, 241], ["art therapy", "TREATMENT", 335, 346], ["a music therapy", "TREATMENT", 399, 414]]], ["Yet social distancing did not impede ourmusical solidarity.", [["solidarity", "OBSERVATION", 48, 58]]], ["Of course,the rhythm was slightly delayed because of the Internet\u2019s lag-time.", [["slightly delayed", "PROBLEM", 25, 41]]], ["A video was circulating of thepeople in Italy, who are currently undergoing a national quarantine because of therapid, uncontainable spread of the infection across their nation at a capacity thatfar overwhelms their health care capacities and has led to dire life-and-deathdecisions in the hospitals (with warning that the United States may follow suit ifwe do not social distance now).", [["infection", "DISEASE", 147, 156], ["a national quarantine", "TREATMENT", 76, 97], ["therapid", "PROBLEM", 109, 117], ["the infection", "PROBLEM", 143, 156], ["infection", "OBSERVATION", 147, 156]]], ["The situation in Italy is tragic;there can be no denying the collective trauma among COVID-19 patients and healthcare providers and self-isolated citizens alike.", [["trauma", "DISEASE", 72, 78], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["The video capturesthem congregating on the balconies of their apartments, strumming and shakingwhatever instruments are available to them, and joining the voices to sing togetherinto the wide open air.", [["The video capturesthem", "TEST", 0, 22], ["air", "OBSERVATION", 197, 200]]], ["The antidote ofmusical solidarity in a time of coronavirus provides a joyful reminder of the deephuman will to always find our way back to one another.", [["coronavirus", "DISEASE", 47, 58], ["coronavirus", "ORGANISM", 47, 58], ["coronavirus", "PROBLEM", 47, 58]]], ["In the days to come, I imagine these bonds ofmusic will exponentially grow to remind each of us that we are not alone.Imaging the Virus Via the Visual ArtsOne challenge in mobilizing the masses to understand the severity of threat ofCOVID-19 and the importance of social distancing is the invisibility of the disease.Our eyes cannot literally see how the coronavirus spreads fromperson to person.", [["eyes", "ANATOMY", 321, 325], ["Virus", "ORGANISM", 130, 135], ["masses", "CANCER", 187, 193], ["eyes", "ORGAN", 321, 325], ["coronavirus", "ORGANISM", 355, 366], ["person", "SPECIES", 389, 395], ["Imaging", "TEST", 118, 125], ["the Visual ArtsOne challenge", "TREATMENT", 140, 168], ["the masses", "PROBLEM", 183, 193], ["threat ofCOVID", "TEST", 224, 238], ["the disease", "PROBLEM", 305, 316], ["masses", "OBSERVATION", 187, 193], ["disease", "OBSERVATION", 309, 316]]], ["In the United States, at the time of writing this essay, many ofus can also not yet see the tragic effect of the disease on ourcommunity members or loved ones, with the exception of the major epicenters of theoutbreak such as Washington and New York.", [["the disease", "PROBLEM", 109, 120]]], ["At this point, the pandemic remainsshrouded in invisibility to most American eyes, lest we find the courage to watchnews clips of the traumatic hospital scenarios in China and Italy.", [["eyes", "ANATOMY", 77, 81], ["traumatic", "DISEASE", 134, 143], ["eyes", "ORGAN", 77, 81], ["clips", "OBSERVATION", 121, 126], ["traumatic", "OBSERVATION_MODIFIER", 134, 143]]], ["Similar to apsychological understanding of climate change apathy, it is difficult to holdtangible concern for a future calamity that appears intangible to us in present day.Thus, health care professionals\u2019 pleas for American citizens to take seriously theadoption of health precautions and social distancing practices can fall on apatheticears and eyes.", [["apatheticears", "ANATOMY", 330, 343], ["eyes", "ANATOMY", 348, 352], ["apathy", "DISEASE", 58, 64], ["eyes", "ORGAN", 348, 352], ["climate change apathy", "PROBLEM", 43, 64], ["a future calamity", "PROBLEM", 110, 127], ["health precautions", "TREATMENT", 267, 285], ["eyes", "ANATOMY", 348, 352]]], ["What can help people reverse apathy and confront reality is therestoration of vision\u2014of literally seeing the coronavirus and itsimpact on us and our loved ones: \u201cvision is . . . one of the means by which weinteract with and relate to the world, and by increasing our visual awareness, weextend and intensify our relationship to life\u201d (McNiff, 1981, p.", [["apathy", "DISEASE", 29, 35], ["coronavirus", "DISEASE", 109, 120], ["people", "ORGANISM", 14, 20], ["coronavirus", "ORGANISM", 109, 120], ["people", "SPECIES", 14, 20], ["apathy", "PROBLEM", 29, 35], ["the coronavirus", "PROBLEM", 105, 120]]], ["155).Imaging the Virus Via the Visual ArtsAs a therapeutic vehicle, the visual arts help make the unconscious conscious.Creating an image brings tangible form to psychological realities, which remaintypically unseen to the human eye, thereby allowing us to become aware of andconfront these realities.", [["eye", "ANATOMY", 229, 232], ["human", "ORGANISM", 223, 228], ["eye", "ORGAN", 229, 232], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 223, 228], ["Imaging", "TEST", 5, 12], ["human eye", "ANATOMY", 223, 232]]], ["During crisis experiences that are emotionally difficultto confront such as the threat of COVID-19, an image can act as an externalcontainer within which to \u201cplace\u201d our inner disturbances so we can safely understandand work through them.", [["COVID", "TEST", 90, 95], ["our inner disturbances", "PROBLEM", 165, 187]]], ["As McNiff(1998) states,The art of placing a troublesome experience or thought into a creative spacewe have made literally changes its place within our lives.", [["spacewe", "CANCER", 94, 101]]], ["74)Imaging the Virus Via the Visual ArtsAfter making visual artwork, we can then examine our image at a safe distance so anew perspective can be discovered, which allows our feelings and relationship to thecrisis to transform.", [["Imaging the Virus", "TEST", 3, 20]]], ["As tangible products, our artwork can also be shared withothers, inviting them to dialogue with our image, discover personal meanings in it,and emotionally connect to it as shared human experience; thus visual artwork canoffer collective healing.", [["human", "ORGANISM", 180, 185], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["our image", "TEST", 96, 105], ["collective healing", "PROBLEM", 227, 245], ["healing", "OBSERVATION_MODIFIER", 238, 245]]], ["Memorialmaking during times of collective crisis can bring healing.Imaging the Virus Via the Visual ArtsPrior to most countries enforcing or strongly encouraging social distancing, it isamazing to witness the coronavirus street art that sprung up as if overnight.", [["coronavirus", "ORGANISM", 209, 220], ["collective crisis", "PROBLEM", 31, 48], ["Imaging", "TEST", 67, 74], ["healing", "OBSERVATION_MODIFIER", 59, 66]]], ["InLondon, street artist Pegasus painted a mural on a street corner featuring PrimeMinister Boris Johnson urging people to stop panic-buying supplies in grocery storesas they prepare to social distance, he wanted to remind them to be considerate toothers during this crisis.", [["panic", "DISEASE", 127, 132], ["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["panic", "PROBLEM", 127, 132], ["this crisis", "PROBLEM", 261, 272], ["mural", "OBSERVATION_MODIFIER", 42, 47]]], ["In Rome, street artist Laika painted a mural above apopular restaurant to address the ignorance and xenophobia toward Chinese people inItaly as a result of COVID-19; the image includes a Chinese woman dressed insurgical attire and a face mask with a speech bubble that reads: \u201cThere\u2019s anepidemic of ignorance going around . . . we must protect ourselves!\u201d", [["xenophobia", "DISEASE", 100, 110], ["people", "ORGANISM", 126, 132], ["woman", "ORGANISM", 195, 200], ["people", "SPECIES", 126, 132], ["woman", "SPECIES", 195, 200], ["COVID", "TEST", 156, 161], ["a face mask", "TREATMENT", 231, 242], ["ignorance", "OBSERVATION", 299, 308]]], ["In Naples,artist Nello Petrucci erected a giant street mural of the Simpsonsfamily wearing face masks on their couch with the words \u201cSTAY HOME!\u201d spray-paintedonto the image.", [["giant", "OBSERVATION_MODIFIER", 42, 47], ["mural", "OBSERVATION_MODIFIER", 55, 60]]], ["From within their homes, adults and children are transformingboredom into creativity by crafting their own images to share with the public.", [["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44]]], ["In the United States, where a national quarantine has not(yet) been administered, the visual arts are embraced to make the invisible visible,remind Americans of the gravity of the situation, and offer encouragement andprecaution.", [["encouragement andprecaution", "TREATMENT", 201, 228]]], ["I painted an acrylic painting called \u201cSocial Distancing Blues,\u201d whichvisualizes the coronavirus hovering across the sky in bright red paint outside myapartment windows.", [["coronavirus", "ORGANISM", 84, 95], ["the coronavirus", "PROBLEM", 80, 95], ["acrylic painting", "OBSERVATION", 13, 29], ["coronavirus", "OBSERVATION", 84, 95]]], ["A few days later my mother, a senior citizen who isin the high-risk category of COVID-19, was inspired to create her own graphic imageas a public service announcement.", [["COVID", "TEST", 80, 85]]], ["In the comic strip, sheoffers healing greetings and safety strategies to help others cope with COVID-19:\u201cGood day.\u201d", [["healing greetings", "TREATMENT", 30, 47], ["safety strategies", "TREATMENT", 52, 69]]], ["\u201cDon\u2019t panic,\u201d \u201cWe can do it!\u201d", [["panic", "DISEASE", 7, 12]]], ["What is so moving about theseexamples is that in the process of making and sharing coronavirus art, a shift seemsto occur where we become empowered to do something about theCOVID-19 crisis.", [["coronavirus", "ORGANISM", 83, 94]]], ["We seem to be creating images to help slow the virus down, spreadreminders of kindness, and nurture collective resiliency.", [["slow the virus", "PROBLEM", 38, 52], ["kindness", "PROBLEM", 78, 86], ["kindness", "OBSERVATION", 78, 86]]], ["Just as McNiff suggestedthat placing a troublesome experience into an artistic container can transform ourrelationship to it, making visual art about coronavirus and social distancing canhelp transform collective anxiety into collective support and action.", [["coronavirus", "DISEASE", 150, 161], ["anxiety", "DISEASE", 213, 220], ["coronavirus", "ORGANISM", 150, 161], ["coronavirus", "PROBLEM", 150, 161], ["collective support", "TREATMENT", 226, 244]]], ["Thus, thistime in history may forever be memorialized as a moment of precious humansolidarity.Imaging the Virus Via the Visual Arts", [["humansolidarity", "DISEASE", 78, 93], ["precious humansolidarity", "PROBLEM", 69, 93], ["Imaging", "TEST", 94, 101]]]], "PMC7135818": [["IntroductionAvian flu (H5N1) and severe acute respiratory syndrome (SARS) are the latest communicable diseases to come to our attention [1], [2], [3].", [["H5N1", "DISEASE", 23, 27], ["acute respiratory syndrome", "DISEASE", 40, 66], ["SARS", "DISEASE", 68, 72], ["IntroductionAvian flu (H5N1", "ORGANISM", 0, 27], ["[2]", "SIMPLE_CHEMICAL", 141, 144], ["IntroductionAvian flu (H5N1", "PROBLEM", 0, 27], ["severe acute respiratory syndrome", "PROBLEM", 33, 66], ["the latest communicable diseases", "PROBLEM", 78, 110], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66]]], ["Avian flu (H5N1) is particularly important currently because of the following findings:1.evidence of probable person-to-person transmission [1];2.recent spread to poultry outside Southeast Asia [4];3.increasing mammalian pathogenicity;4.transmission through an intermediary host, the pig.", [["Avian flu", "DISEASE", 0, 9], ["H5N1", "DISEASE", 11, 15], ["Avian flu (H5N1", "ORGANISM", 0, 15], ["pig", "ORGANISM", 284, 287], ["Avian flu", "SPECIES", 0, 9], ["person", "SPECIES", 110, 116], ["person", "SPECIES", 120, 126], ["pig", "SPECIES", 284, 287], ["Avian flu (H5N1)", "SPECIES", 0, 16], ["pig", "SPECIES", 284, 287], ["increasing mammalian pathogenicity", "PROBLEM", 200, 234], ["probable", "UNCERTAINTY", 101, 109], ["mammalian pathogenicity", "OBSERVATION", 211, 234], ["intermediary host", "OBSERVATION", 261, 278]]]], "ee7ca6508a57f08830c7ba011feedaf75756a93f": [["With much of the globe rushing to respond to coronavirus disease 2019 (COVID- 19) , clinical trials to evaluate safe and effective options for treatment and prevention are critical.", [["coronavirus disease", "DISEASE", 45, 64], ["the globe rushing", "PROBLEM", 13, 30], ["coronavirus disease", "PROBLEM", 45, 64], ["COVID", "TEST", 71, 76], ["clinical trials", "TEST", 84, 99], ["treatment", "TREATMENT", 143, 152], ["globe", "ANATOMY", 17, 22]]], ["The trials are diverse, examining new and repurposed drugs and vaccines at various stages of development, and involving a variety of designs with a range of opportunity for direct benefit.", [["new and repurposed drugs", "TREATMENT", 34, 58], ["vaccines", "TREATMENT", 63, 71]]], ["A wide variety and number of research participants are needed to enroll in these trials, reflecting a spectrum of experience with COVID-19-including healthy individuals, individuals exposed to the virus, individuals experiencing different levels of disease severity, and recovered individuals-as well a diversity of age, sex, race and ethnicity, socioeconomic status, medical comorbidities, and more.", [["individuals", "ORGANISM", 157, 168], ["participants", "SPECIES", 38, 50], ["COVID", "TEST", 130, 135], ["healthy individuals", "PROBLEM", 149, 168], ["the virus", "PROBLEM", 193, 202], ["disease severity", "PROBLEM", 249, 265], ["medical comorbidities", "PROBLEM", 368, 389], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14]]]], "df01e9d0558a4d3db5c463b11cb2e3647422bf92": [["time-to-initiate-treatment affecting survival and increasing anxiety among patients 4 and finally a long drawn course of oncological treatment, that can get significantly affected during the pandemic.", [["anxiety", "DISEASE", 61, 68], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["treatment", "TREATMENT", 17, 26], ["increasing anxiety", "PROBLEM", 50, 68], ["oncological treatment", "TREATMENT", 121, 142]]], ["The resultant immune suppression 5 poses a greater risk to COVID-19 infection, more so if they have received treatment within the previous month.", [["infection", "DISEASE", 68, 77], ["COVID-19", "CELL", 59, 67], ["COVID-19", "SPECIES", 59, 67], ["The resultant immune suppression", "TREATMENT", 0, 32], ["COVID", "TEST", 59, 64], ["19 infection", "PROBLEM", 65, 77], ["treatment", "TREATMENT", 109, 118], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["immune suppression", "OBSERVATION", 14, 32], ["infection", "OBSERVATION", 68, 77]]], ["6 An estimated 192 000 patients are likely to have delays in the timely diagnosis of cancer as projected by the Indian Council of Medical Research, 7 adding to the backlog of patients who await treatment at many oncology institutes.", [["cancer", "ANATOMY", 85, 91], ["cancer", "DISEASE", 85, 91], ["patients", "ORGANISM", 23, 31], ["cancer", "CANCER", 85, 91], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 175, 183], ["cancer", "PROBLEM", 85, 91], ["treatment", "TREATMENT", 194, 203], ["cancer", "OBSERVATION", 85, 91]]]], "27c7590bd3f2d5dbb0d48578e0af8cbb9511238f": [["IntroductionState complexity is a measure of complexity defined on regular operations.", [["regular operations", "TREATMENT", 67, 85]]], ["It allows to write the size of the minimal automaton recognizing the output as a function of the sizes of the minimal automata recognizing the inputs.", [["size", "OBSERVATION_MODIFIER", 23, 27], ["minimal", "OBSERVATION_MODIFIER", 35, 42], ["automaton", "OBSERVATION", 43, 52], ["sizes", "OBSERVATION_MODIFIER", 97, 102], ["minimal", "OBSERVATION_MODIFIER", 110, 117], ["automata", "OBSERVATION", 118, 126]]], ["The topic dates back to the 70s, from the seminal paper of Maslov [14] describing, explicitly but without any proof, the state complexities of several operations.", [["several operations", "TREATMENT", 143, 161], ["seminal", "ANATOMY", 42, 49]]], ["Since the 90s, this area of research became very active and the state complexity of numerous operations has been computed.", [["very active", "PROBLEM", 44, 55], ["numerous operations", "TREATMENT", 84, 103], ["very", "OBSERVATION_MODIFIER", 44, 48], ["active", "OBSERVATION", 49, 55]]], ["See, for example, [6, [11] [12] [13] 15] and [8] for a survey of the subject.IntroductionHowever, a few general methods are commonly used in order to compute state complexities.", [["[6, [11] [12] [13] 15", "SIMPLE_CHEMICAL", 18, 39], ["a few general methods", "TREATMENT", 98, 119]]], ["The most common method consists in providing a witness, which is a specific example reaching what is proven to be an upper bound.", [["an upper bound", "PROBLEM", 114, 128], ["upper", "ANATOMY_MODIFIER", 117, 122]]], ["The witness itself is, in general, found by trial and error, sometimes using a witness that worked for a number of other operations and modifying it to fit the specific needs of the operation considered.", [["other operations", "TREATMENT", 115, 131], ["the operation", "TREATMENT", 178, 191]]], ["In many cases, for example [1, 7] or [4] , the witness is constructed by considering, explicitly or implicitly, the whole monoid of the transformations acting on the states of the minimal automata recognizing the input languages.", [["[4]", "SIMPLE_CHEMICAL", 37, 40]]], ["More precisely, the approach consists, on the one hand, in describing states as combinatorial objects and finding upper bounds using combinatorial tools, and, on the other hand, in building a huge witness, called a monster, chosen in a set of automata having as many transition functions as possible.", [["upper", "ANATOMY_MODIFIER", 114, 119]]], ["This method can be applied to obtain the state complexity to the wide range of 1-uniform operations that are associated to operators, called modifiers, that act on automata to produce an automaton in a certain restrictive way.", [["This method", "TREATMENT", 0, 11]]], ["We investigate many properties of this class and in particular we completely describe the set of the regular operations that can be encoded by product modifiers.", [["the regular operations", "TREATMENT", 97, 119]]], ["4, we define product modifiers and characterize the regular operations they encode in Sect.", [["product modifiers", "TREATMENT", 13, 30], ["the regular operations", "TREATMENT", 48, 70]]], ["5.Operations over SetsThe set of subsets of E is denoted by 2 E and the set of mappings of E into itself is denoted by E E .", [["E E", "SIMPLE_CHEMICAL", 119, 122], ["E", "DNA", 44, 45], ["E", "DNA", 91, 92], ["E E", "DNA", 119, 122]]], ["The symmetric difference of two sets E 1 and E 2 is denoted by \u2295 and defined byOperations over SetsLet (E 1 , . . . , E k ) be a k-tuple of finite sets, and let (\u03b4 1 , . . . , \u03b4 k ) be a ktuple such that \u03b4 i is a function from E i to E i for every i \u2208 {1, . . . , k}.", [["E 1 and E 2", "DNA", 37, 48], ["finite sets", "TEST", 140, 151], ["symmetric", "OBSERVATION_MODIFIER", 4, 13], ["difference", "OBSERVATION_MODIFIER", 14, 24]]], ["For any k-tuple (e 1 , . . . , e k ) such that e i \u2208 E i for all i \u2208 {1, . . . , k}, we denote by (\u03b4 1 , . . . , \u03b4 k )(e 1 , . . . , e k ) the k-tuple (\u03b4 1 (e 1 ), . . . , \u03b4 k (e k )).Operations over SetsLet E be a set, f :Operations over Sets. . , e p\u22121 , g(e p , . . . , e p+k\u22121 ), e p+k , . . . , e j+k\u22121 ), for any e 1 , . . . , e j+k\u22121 \u2208 E.Languages and AutomataLet \u03a3 be a finite alphabet.", [["k", "TEST", 115, 116], ["k-tuple", "TEST", 143, 150], ["Operations", "TEST", 184, 194], ["E.Languages", "TEST", 343, 354], ["AutomataLet", "TEST", 359, 370]]], ["A word w over \u03a3 is a finite sequence of symbols of \u03a3.", [["\u03a3", "DNA", 14, 15]]], ["We define the complement of a language L \u2286 \u03a3 * by L c = \u03a3 * \u00a0L.Languages and AutomataA complete and deterministic finite automaton (DFA) is a 5-tuple A = (\u03a3, Q, i, F, \u03b4) where \u03a3 is the input alphabet, Q is a finite set of states, i \u2208 Q is the initial state, F \u2282 Q is the set of final states and \u03b4 is the transition function from Q \u00d7 \u03a3 to Q that is defined for every q \u2208 Q and every a \u2208 \u03a3.", [["\u03a3", "PROTEIN", 176, 177], ["\u03b4", "PROTEIN", 295, 296]]], ["We can extend transition functions in a natural way to functions from Q \u00d7 \u03a3 * to Q, and again to functions from 2 Q \u00d7 \u03a3 * to Q. For any word w, we denote by \u03b4 w the function q \u2192 \u03b4(q, w).Languages and AutomataThe language recognized by a DFA A is the set L(A) of words recognized by A. By Kleene's theorem, a language is regular if and only if it is recognized by a DFA.", [["DFA", "CHEMICAL", 365, 368]]], ["It is well known that for any DFA, there exists a unique minimal one (up to isomorphism) among all DFAs recognizing the same language ([10]).State ComplexityA unary regular operation is a function from regular languages of \u03a3 into regular languages of \u03a3.", [["DFA", "CHEMICAL", 30, 33], ["any DFA", "PROBLEM", 26, 33], ["operation", "OBSERVATION", 173, 182]]], ["A k-ary regular operation is a function from the set of k-tuples of regular languages over \u03a3 into regular languages over \u03a3.State ComplexityThe state complexity of a regular language L denoted by sc(L) is the number of states of its minimal DFA.", [["DFA", "CHEMICAL", 240, 243], ["A k-ary regular operation", "TREATMENT", 0, 25], ["operation", "OBSERVATION", 16, 25], ["minimal", "OBSERVATION_MODIFIER", 232, 239], ["DFA", "OBSERVATION", 240, 243]]], ["This notion extends to regular operations: the state complexity of a unary regular operation \u2297 is the function sc \u2297 such that, for all n \u2208 N, sc \u2297 (n) is the maximum of all the state complexities of \u2297(L) when L is of state complexity n, i.e. sc \u2297 (n) = max{sc(\u2297(L))|sc(L) = n}.State ComplexityThis can be generalized, and the state complexity of a k-ary operation \u2297 is the k-ary function sc \u2297 such that, for all (n 1 , . . . , n k ) \u2208 (N) k ,State ComplexityThen, a witness for \u2297 is a way to assign to each (n 1 , . . . , n k ), where each n i is assumed sufficiently big, a k-tuple of languages (L 1 , . . . , L k ) with sc(L i ) = n i , for all i \u2208 {1, . . . , k}, satisfying sc \u2297 (n 1 , . . . , n k ) = sc(\u2297(L 1 , . . . , L k )).Modifiers and 1-uniform OperationsWe describe a class of regular operations, called 1-uniform which are interesting for the study of state complexity [3, 5] .", [["N", "CHEMICAL", 139, 140], ["a unary regular operation", "TREATMENT", 67, 92], ["a k-ary operation", "TREATMENT", 346, 363], ["k}", "TEST", 663, 665], ["k", "TEST", 700, 701], ["sc", "TEST", 706, 708], ["\u2297", "TEST", 709, 710], ["L", "TEST", 711, 712], ["regular operations", "TREATMENT", 789, 807], ["the study", "TEST", 852, 861], ["operation", "OBSERVATION", 83, 92], ["generalized", "OBSERVATION_MODIFIER", 305, 316]]], ["We then define operations on DFA called modifiers, and describe a subset of these operations that correspond to the set of 1-uniform regular operations.Definition and First PropertiesDefinition 1.", [["these operations", "TREATMENT", 76, 92], ["operations", "OBSERVATION", 82, 92], ["operations", "OBSERVATION", 141, 151]]], ["Let \u03a3 and \u0393 be two alphabets.", [["Let \u03a3", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Notice that \u03c6 is completely defined by its value on letters.", [["\u03c6", "DNA", 12, 13]]], ["A morphism \u03c6 is 1-uniform if the image by \u03c6 of any letter is a letter.Definition and First PropertiesThe preimage \u03c6 \u22121 (L) of a regular language L by a morphism \u03c6 is regular, see, e.g., [9] .", [["preimage \u03c6", "DNA", 105, 115], ["The preimage", "TEST", 101, 113]]], ["This allows us to introduce the notion of 1-uniform regular operation.Definition 2.", [["uniform regular operation", "TREATMENT", 44, 69], ["operation", "OBSERVATION", 60, 69]]], ["A k-ary regular operationObviously, 1-uniformity is stable by composition.", [["stable", "OBSERVATION_MODIFIER", 52, 58]]], ["Many well-known regular operations are 1-uniform.", [["operations", "OBSERVATION", 24, 34]]], ["See [5] for a non-exhaustive list of examples like the complement, the Kleene star, the reverse, the cyclic shift, and the mirror, all boolean operations and catenation among others.Definition 2.", [["all boolean operations", "TREATMENT", 131, 153], ["catenation", "TREATMENT", 158, 168]]], ["A k-ary regular operationEach 1-uniform regular k-ary operation corresponds to a construction over DFAs, which is handy when we need to compute the state complexity of its elements.", [["A k-ary regular operation", "TREATMENT", 0, 25], ["uniform regular k-ary operation", "TREATMENT", 32, 63], ["a construction over DFAs", "TREATMENT", 79, 103], ["operation", "OBSERVATION", 16, 25], ["operation", "OBSERVATION", 54, 63]]], ["The state configuration of a DFAA = (\u03a3, Q, i, F, \u03b4) is the triplet (Q, i, F ).Definition 4.", [["DFAA", "CHEMICAL", 29, 33], ["(\u03a3, Q, i, F, \u03b4", "CHEMICAL", 36, 50], ["DFAA", "SIMPLE_CHEMICAL", 29, 33]]], ["A k-modifier is a k-ary operation acting on a k-tuple of DFAsExample 1.", [["a k-ary operation", "TREATMENT", 16, 33]]], ["For any DFA A = (\u03a3, Q, i, F, \u03b4), define Star(A) = (\u03a3, 2 Q , \u2205, {E|E \u2229 F = \u2205} \u222a {\u2205}, \u03b4 1 ), where for any a \u2208 \u03a3, \u03b4 a 1 (\u2205) = \u03b4 a (i) if \u03b4 a (i) / \u2208 F and \u03b4 a 1 (\u2205) = \u03b4 a (i) otherwise, and, for all E = \u2205, \u03b4 a 1 (E) = \u03b4 a (E) if \u03b4 a (E) \u2229 F = \u2205 and \u03b4 a 1 (E) = \u03b4 a (E) \u222aExample 2.", [["\u2205", "PROTEIN", 60, 61], ["{E", "PROTEIN", 63, 65], ["\u03b4 1", "PROTEIN", 84, 87], ["any DFA", "TEST", 4, 11], ["\u222a", "TEST", 77, 78], ["{\u2205}", "TEST", 79, 82], ["a", "TEST", 155, 156], ["otherwise", "TEST", 173, 182], ["a", "TEST", 206, 207], ["Example", "TEST", 268, 275]]], ["For any DFAsWe easily check that, for modifiers, the 1-uniformity is stable by composition.Example 2.", [["DFAsWe", "DNA", 8, 14], ["stable", "OBSERVATION_MODIFIER", 69, 75]]], ["Let m 1 and m 2 be respectively a j-modifier and a k-modifier describing, respectively, operations \u2297 1 and \u2297 2 .", [["Let m 1", "GENE_OR_GENE_PRODUCT", 0, 7]]], ["For any DFAsThe correspondence between 1-uniform modifiers and 1-uniform operations is stated in the following Theorem proved in [3] .Example 2.", [["DFAs", "DNA", 8, 12]]], ["For any DFAsModifiers have been defined, for the first time, in [2] as a tool to compute state complexity of 1-uniform operations.Functional NotationsWhen there is no ambiguity, for any character X and any integer k given by the context, we write X for (X 1 , \u00b7 \u00b7 \u00b7 , X k ).", [["DFAsModifiers", "DNA", 8, 21], ["ambiguity", "PROBLEM", 167, 176], ["no", "UNCERTAINTY", 164, 166]]], ["The number k will often be the arity of the regular operation or of the modifier we are considering.Functional NotationsFrom Definition 4, any k-modifier m can be seen as a 4-tuple of mappings F , \u03b4 a ) .", [["the regular operation", "TREATMENT", 40, 61]]], ["Below we revisit the definition of Xor according to this formalism.Product ModifiersIn this section, we study a kind of simple modifier called product modifiers and show that they are closely linked to boolean operations.Definition 6.A k-modifier m = (Q, i, f, d) is a product modifier if, for any k-tuple of finite sets Q, for any k-tuple of finite sets F such that F j \u2286 Q j for all j, and for any i \u2208 Q 1 \u00d7 \u00b7 \u00b7 \u00b7 \u00d7 Q kDefinition 6.with \u03b4 a (q) = (\u03b4 a 1 (q 1 ), \u03b4 a 2 (q 2 ), ..., \u03b4 a k (q k )).", [["boolean operations", "TREATMENT", 202, 220], ["kDefinition", "TEST", 420, 431], ["a", "TEST", 466, 467], ["a k", "TEST", 485, 488]]], ["We can easily check that the class of product modifiers is stable by composition.Definition 6.For the sake of simplicity, in this section, m denotes any k-ary product (but not necessarily 1-uniform) modifier and A = (A 1 , . . . , A k ) any sequence of k DFAs, with A j = (\u03a3, Q j , i j , F j , \u03b4 j ).", [["k-ary product", "PROTEIN", 153, 166], ["any sequence", "TEST", 237, 249], ["DFAs", "TEST", 255, 259], ["stable", "OBSERVATION_MODIFIER", 59, 65]]], ["Recall that i = (i 1 , . . . , i k ), Q = (Q 1 , . . . , Q k ) and F = (F 1 , . . . , F k ) .", [["k", "TEST", 59, 60]]], ["We also denote mA = (\u03a3, Q , i , F , \u03b4) .Definition 6.We define the complementary product to get an easier access to the intersection of languages and their complement.Definition 7.For any k-tuple P of finite sets, for any k-tuple G of finite sets such that G j \u2286 P j for all j, and for any d \u2286 {1, 2, ..., k}, we define cp(d, G, P ) = Proof.", [["k-tuple P", "DNA", 188, 197], ["k-tuple G", "PROTEIN", 222, 231], ["P j", "DNA", 263, 266], ["any d \u2286", "TEST", 286, 293], ["k}", "TEST", 306, 308], ["cp", "TEST", 320, 322], ["G", "TEST", 326, 327]]], ["For any element q \u2208 cp(d, F , Q), we have q j \u2208 F j and, for any element q \u2208 cp(d , F , Q), we haveDefinition 7.Furthermore, consider an element q \u2208 Q and set d = {j | q j \u2208 F j }.", [["haveDefinition 7", "DNA", 95, 111], ["any element q \u2208 cp", "PROBLEM", 4, 22], ["cp", "PROBLEM", 77, 79], ["an element q \u2208 Q", "TEST", 134, 150]]], ["The idea of the proof is to construct, with the states in G, two k-tuple of automata B and C that recognize the same languages, and such that L(mB) and L(mC) are different.Definition 7.We distinguish two cases :Definition 7.\u2022 First, suppose that i \u2208 G. If i \u2208 F then we choose j \u2208 G, otherwise we choose j \u2208 G \u2229 F .", [["L(mB)", "GENE_OR_GENE_PRODUCT", 142, 147]]], ["Consider the two k-tuples of DFAs B and C such that B l = ({a}, Q l , i l , F l , \u03b2 l ) and C l = ({a}, Q l , i l , F l , \u03b3 l ), where, for all positive integer l \u2264 k, \u03b2 a l (i l ) = j l if x = i l , \u03b2 a l (x) = x if x \u2208 Q i l \u00a0{i l }, and \u03b3 a l (x) = x, for any x \u2208 Q i l .", [["DFAs B and C", "CHEMICAL", 29, 41], ["C", "CHEMICAL", 92, 93], ["C l =", "SIMPLE_CHEMICAL", 92, 97], ["DFAs B", "PROTEIN", 29, 35], ["the two k-tuples", "TEST", 9, 25], ["DFAs", "TEST", 29, 33], ["such", "TEST", 42, 46], ["k", "TEST", 165, 166], ["j", "TEST", 183, 184], ["\u2208", "TEST", 219, 220], ["any", "TEST", 259, 262], ["l", "ANATOMY_MODIFIER", 172, 173], ["l", "ANATOMY", 204, 205], ["l", "ANATOMY", 244, 245], ["l", "ANATOMY_MODIFIER", 271, 272]]], ["Let us remark that, as i, j \u2208 G = cp(d, F , Q), i l and j l are either both in F l (if l / \u2208 d), or both not in F l (if l \u2208 d) by definition of cp.", [["cp", "PROBLEM", 34, 36], ["cp", "PROBLEM", 144, 146]]], ["Therefore, i l and j l have the same finality in B l , which is also their finality in C l , and either B l and C l recognize a * , or B l and C l recognize \u2205.", [["B l", "GENE_OR_GENE_PRODUCT", 49, 52], ["C l", "GENE_OR_GENE_PRODUCT", 87, 90], ["B l", "GENE_OR_GENE_PRODUCT", 104, 107], ["C l", "GENE_OR_GENE_PRODUCT", 112, 115], ["B l", "GENE_OR_GENE_PRODUCT", 135, 138], ["C l", "GENE_OR_GENE_PRODUCT", 143, 146]]], ["As described in Fig. 1 , the transition functions \u03b2 of mB and \u03b3 of mC satisfy \u03b2 a (i) = j and \u03b3 a (i) = i.", [["mB", "SIMPLE_CHEMICAL", 55, 57], ["mB", "PROTEIN", 55, 57], ["the transition functions", "TEST", 25, 49], ["mB", "TEST", 55, 57]]], ["The finality of i is the same in mB and mC.", [["mB", "CELL", 33, 35]]], ["However, it is not the same finality as j in mB and mC.", [["mB", "CELL", 45, 47]]], ["Therefore, we have (a \u2208 L(mB) \u2227 a / \u2208 L(mC)) or (a / \u2208 L(mB) \u2227 a \u2208 L(mC)).", [["a \u2208 L(mB", "TEST", 20, 28]]], ["As a consequence, L(mB) = L(mC) and this implies that m is not 1-uniform.Definition 7.\u2022 Suppose now that i / \u2208 G. Let j \u2208 G, and let j \u2208 G \u2229 F .", [["G \u2229 F", "GENE_OR_GENE_PRODUCT", 137, 142], ["L(mB)", "TEST", 18, 23]]], ["Consider the two k-tuple of DFAs B and C such that B l = ({a, b}, Q l , i l , F l , \u03b2 l ) and C l = ({a, b}, Q l , i l , F l , \u03b3 l ), where, for all letters u \u2208 {a, b}, for all positive integer l \u2264 k and all x \u2208 Q l , For any positive integer l \u2264 k, B l and C l recognize the same language.", [["DFAs B and C", "CHEMICAL", 28, 40], ["B l = ({a", "SIMPLE_CHEMICAL", 51, 60], ["C l = ({a", "SIMPLE_CHEMICAL", 94, 103], ["B l", "GENE_OR_GENE_PRODUCT", 250, 253], ["C l", "GENE_OR_GENE_PRODUCT", 258, 261], ["DFAs B", "PROTEIN", 28, 34], ["DFAs", "TEST", 28, 32], ["all letters u", "TEST", 145, 158], ["{a", "TEST", 161, 163], ["b}", "TEST", 165, 167], ["k", "TEST", 198, 199]]], ["Indeed, from Fig. 2 , as j, j \u2208 G = cp(d, F , Q), j l and j l have the same finality in B l and C l by definition of cp, we distinguish the cases :Definition 7.As mB and mC are cartesian products of the B l and the C l respectively, if we call \u03b2 the transition function of mB and \u03b3 the transition function of mC, we have \u03b2 a (i) = j, \u03b2 b (j) = j , \u03b3 a (i) = j , and \u03b3 b (j ) = j.", [["mB", "GENE_OR_GENE_PRODUCT", 163, 165], ["mC", "SIMPLE_CHEMICAL", 170, 172], ["B l", "GENE_OR_GENE_PRODUCT", 203, 206], ["mB", "GENE_OR_GENE_PRODUCT", 273, 275], ["mC", "SIMPLE_CHEMICAL", 309, 311], ["cartesian products", "PROTEIN", 177, 195], ["\u03b2", "PROTEIN", 244, 245], ["mB", "PROTEIN", 273, 275], ["\u03b3", "PROTEIN", 280, 281], ["the same finality", "TEST", 67, 84], ["cp", "PROBLEM", 117, 119], ["mB", "TEST", 273, 275], ["mC", "TEST", 309, 311], ["j", "TEST", 358, 359]]], ["The finality of j is the same in mB and mC.", [["mB", "CELL", 33, 35]]], ["However, it is different from the finality of j in mB and mC.", [["mB", "CELL", 51, 53], ["mC", "SIMPLE_CHEMICAL", 58, 60], ["different", "OBSERVATION_MODIFIER", 15, 24]]], ["Therefore, we have (ab \u2208 L(mB) \u2227 ab / \u2208 L(mC)) or (ab / \u2208 L(mB) \u2227 ab \u2208 L(mC)).", [["ab", "TEST", 20, 22], ["ab", "TEST", 33, 35], ["ab / \u2208 L(mB", "TEST", 51, 62], ["ab", "TEST", 66, 68]]], ["As a consequence, L(mB) = L(mC) which implies that m is not 1-uniform.Definition 7.The following two lemmas state that, for product modifiers, we can set i = i without changing the regular operation associated to m.", [["L(mB)", "TEST", 18, 23], ["the regular operation", "TREATMENT", 177, 198]]], ["Consider the two k-tuples of DFAs B and C such that B l = ({a}, Q l , i l , F l , \u03b2 l ) and C l = ({a}, Q l , i l , F l , \u03b3 l ), where, for any l \u2208 {1, . . . , k}, \u03b2 a l (i l ) = i l , \u03b2 a l (q) = q when q = i l and \u03b3 a l (q) = q.", [["DFAs B and C", "CHEMICAL", 29, 41], ["C", "CHEMICAL", 92, 93], ["C l = ({a}", "SIMPLE_CHEMICAL", 92, 102], ["DFAs B", "PROTEIN", 29, 35], ["the two k-tuples", "TEST", 9, 25], ["DFAs", "TEST", 29, 33], ["such", "TEST", 42, 46], ["k}", "TEST", 160, 162], ["i l", "TEST", 179, 182], ["l", "ANATOMY_MODIFIER", 168, 169]]], ["Let us remark that B l and C l recognize {a} * if i l \u2208 F l , and \u2205 otherwise.", [["B l", "GENE_OR_GENE_PRODUCT", 19, 22], ["C l", "GENE_OR_GENE_PRODUCT", 27, 30]]], ["In any case, they recognize the same language.Definition 7.If we denote by \u03b2 the transition function of mB and by \u03b3 the transition function of mC, we have \u03b2 a (i ) = i and \u03b3 a (i ) = i .", [["mB", "GENE_OR_GENE_PRODUCT", 104, 106], ["\u03b2", "PROTEIN", 75, 76], ["mB", "PROTEIN", 104, 106], ["\u03b3", "PROTEIN", 114, 115]]], ["Recall that i is the initial state of mB and mC.", [["mB", "GENE_OR_GENE_PRODUCT", 38, 40], ["mB", "PROTEIN", 38, 40]]], ["We define an equivalence relation on states of the output of product modifiers whose relationship with the finality of states is examined in Lemma 4.Definition 8.Let j and j be two k-tuples.", [["Let j", "GENE_OR_GENE_PRODUCT", 162, 167], ["the output of product modifiers", "TREATMENT", 47, 78]]], ["We define the equivalence relation \u223c j,j on k-tuples by (x 1 , . . . , x k ) \u223c j,j (y 1 , . . . , y k ) if and only if for all l \u2208 {1, . . . , k}, j l = j l implies x l = y l .Definition 8.Example 5.", [["k-tuples", "TEST", 44, 52], ["all", "TEST", 123, 126], ["k}", "TEST", 143, 145], ["j", "TEST", 147, 148], ["j l implies", "TEST", 153, 164], ["j", "ANATOMY", 147, 148], ["y l", "ANATOMY_MODIFIER", 171, 174]]], ["We have (3, 3, 2, 5, 1) \u223c (1,4,3,2,3),(2,4,2,2,6) (1, 3, 5, 5, 2).Definition 8.We do not have (3, 3, 2, 5, 1) \u223c (1,4,3,2,3),(2,4,2,2,6) (1, 3, 5, 1, 2) .Lemma 4.If m is 1-uniform then L(mA) = L((\u03a3, Q , i, F , \u03b4)).Lemma 4.Proof.", [["3, 2, 5, 1) \u223c (1,4,3,2,3),(2,4,2,2,6) (1, 3", "SIMPLE_CHEMICAL", 12, 55], ["3, 3, 2, 5, 1) \u223c (1,4,3,2,3),(2,4,2,2,6) (1, 3, 5", "SIMPLE_CHEMICAL", 95, 144]]], ["Consider the two k-tuples of DFAs B and C such that B l = ({a}, Q l , i l , F l , \u03b2 l ) and C l = ({a}, Q l , i l , F l , \u03b3 l ), where for all l \u2208 {1, . . . , k} and all q \u2208 Q l , \u03b2 a l (q) = q l if q = i l q otherwise and \u03b3 a l (q) = q l if q = i l q otherwise.Lemma 4.Let us remark that either i l = i l , which implies q l = q l , and B l = C l , or i l = i l , and B l and C l recognize {a} * if i l \u2208 F l and \u2205 otherwise.", [["DFAs B and C", "CHEMICAL", 29, 41], ["C", "CHEMICAL", 92, 93], ["C l =", "SIMPLE_CHEMICAL", 92, 97], ["B l", "SIMPLE_CHEMICAL", 369, 372], ["C l", "SIMPLE_CHEMICAL", 377, 380], ["DFAs B", "PROTEIN", 29, 35], ["the two k-tuples", "TEST", 9, 25], ["DFAs", "TEST", 29, 33], ["all", "TEST", 139, 142], ["k}", "TEST", 159, 161], ["otherwise", "TEST", 209, 218], ["\u03b3", "TEST", 223, 224]]], ["Recall that \u03b2 is the transition function of mB and \u03b3 is the transition function of mC.", [["mB", "GENE_OR_GENE_PRODUCT", 44, 46], ["\u03b3", "GENE_OR_GENE_PRODUCT", 51, 52], ["mC", "SIMPLE_CHEMICAL", 83, 85], ["\u03b2", "DNA", 12, 13], ["mB", "PROTEIN", 44, 46], ["\u03b3", "PROTEIN", 51, 52]]], ["Thus we have a \u2208 L(mB) and a / \u2208 L(mC).", [["a / \u2208 L(mC)", "TREATMENT", 27, 38]]], ["Therefore, L(mB) = L(mC) and m is not 1-uniform.Lemma 4.\u2022 For any two states q, q \u2208 Q , q \u223c i,i q implies that q and q have the same finality.Lemma 4.First, for any letter a \u2208 \u03a3, any two states q, q \u2208 Q , the equivalence q \u223c i,i q implies \u03b4 a (q) = (\u03b4 a 1 (q 1 ), \u03b4 a 2 (q 2 ), . . . , \u03b4 a k (q k )) \u223c i,i (\u03b4 a 1 (q 1 ), \u03b4 a 2 (q 2 ), . . . , \u03b4 a k (q k )) = \u03b4 a (q ).Lemma 4.This property extends inductively to any word w \u2208 \u03a3 * , i.e. q \u223c i,i q implies \u03b4 w (q) \u223c i,i \u03b4 w (q ).", [["L(mB)", "TEST", 11, 16]]], ["As a direct consequence, the languages recognized by the two automata are the same.Quasi-boolean OperationsBefore stating our main result, we need to clarify what is meant by a boolean operation.", [["Quasi-boolean Operations", "TREATMENT", 83, 107], ["a boolean operation", "TREATMENT", 175, 194]]], ["A boolean operation is an operation associated to an expression involving only the operators union, intersection and complement.", [["A boolean operation", "TREATMENT", 0, 19], ["an operation", "TREATMENT", 23, 35], ["boolean operation", "OBSERVATION", 2, 19], ["operation", "OBSERVATION", 26, 35]]], ["A k-ary boolean operation \u2297 over regular languages L 1 , . . . , L k is defined asQuasi-boolean Operationsfor some E \u2286 2 {1,...,k} .", [["A k-ary boolean operation", "TREATMENT", 0, 25], ["boolean operation", "OBSERVATION", 8, 25]]], ["Notice that there is a one-to-one correspondence between the boolean k-ary operations and the sets E \u2286 2 {1,...,k} .", [["the boolean k-ary operations", "TREATMENT", 57, 85], ["the sets E \u2286", "TEST", 90, 102]]], ["The classical boolean operation union can be written this way: for any two regular languages L 1 and L 2 ,Quasi-boolean OperationsWe easily check that boolean operations are 1-uniform and can be associated to some product modifiers.", [["The classical boolean operation", "TREATMENT", 0, 31], ["Quasi-boolean Operations", "TREATMENT", 106, 130], ["boolean operations", "TREATMENT", 151, 169]]], ["More formally, From Definition 9, we construct a wider class of operators that we prove to be in correspondence with product modifiers.Definition 10.For any k-ary regular operation \u2297, for any v \u2208 {0, 1} k , we denote by \u2297 v the restriction of \u2297 to the setDefinition 10.We say that \u2297 is a k-ary quasi-boolean operation if for all v \u2208 {0, 1} k , \u2297 v is a boolean operation, i.e. for any v, there exists a boolean operation \u2297 1 such that for any L \u2208 L v we have \u2297 1 L = \u2297 v L. Example 7.", [["any k-ary regular operation", "TREATMENT", 153, 180], ["a k-ary quasi-boolean operation", "TREATMENT", 286, 317], ["a boolean operation", "TREATMENT", 351, 370], ["a boolean operation", "TREATMENT", 401, 420], ["boolean operation", "OBSERVATION", 353, 370]]], ["Consider the unary operator defined by \u2297L = L if \u2208 L and L c otherwise.", [["L c", "GENE_OR_GENE_PRODUCT", 57, 60], ["L", "ANATOMY_MODIFIER", 57, 58]]], ["This operation is clearly not boolean.", [["This operation", "TREATMENT", 0, 14]]], ["Nevertheless, since for each L \u2208 L (0) we have \u2297L = L and for each L \u2208 L (1) we have \u2297L = L c , the operation \u2297 is quasi-boolean.Definition 10.These operations do not have a higher state complexity than boolean operations, as we show in the following statement.Proposition 1.For any quasi-boolean k-ary operation \u2297, we have sc \u2297 (n 1 , . . . , n k ) \u2264 n 1 \u00b7 \u00b7 \u00b7 n k .Proposition 1.Proof.", [["each L \u2208 L", "TREATMENT", 62, 72], ["the operation", "TREATMENT", 96, 109], ["boolean operations", "TREATMENT", 203, 221], ["any quasi-boolean k-ary operation", "TREATMENT", 279, 312], ["operation", "OBSERVATION", 100, 109]]], ["Lemma 5 implies that sc \u2297 (n 1 , . . . , n k ) \u2264 n 1 \u00b7 \u00b7 \u00b7 n k for any boolean operation \u2297.", [["Lemma", "TEST", 0, 5], ["k", "TEST", 43, 44], ["n", "TEST", 49, 50], ["any boolean operation", "TREATMENT", 67, 88]]], ["We we prove our statement, by remarking that, for any quasi-boolean operation \u2297, we have sc \u2297 (n 1 , . . . ,Proposition 1.We now introduce our main result that characterizes the operations encoded by 1-uniform product modifiers.Theorem 2.", [["any quasi-boolean operation", "TREATMENT", 50, 77], ["the operations", "TREATMENT", 174, 188]]], ["An operation \u2297 is quasi-boolean if and only if there exists a 1-Proof.", [["An operation", "TREATMENT", 0, 12], ["operation", "OBSERVATION", 3, 12]]], ["Let \u2297 be a k-ary quasi-boolean operation.", [["a k-ary quasi-boolean operation", "TREATMENT", 9, 40]]], ["We consider the product modifier m = (Q, i, f, d) such that i(Q, i, F ) = i and,Theorem 2.", [["the product modifier m", "TREATMENT", 12, 34]]], ["An operation \u2297 is quasi-boolean if and only if there exists a 1-Let L \u2208 L v for some v \u2208 {0, 1} k .", [["An operation", "TREATMENT", 0, 12]]], ["For any k-tuple of DFAs A such that A j = (\u03a3, Q j , i j , F j , \u03b4 j ) recognizes L j , we have i j \u2208 F j if and only if v j = 0.", [["L", "ANATOMY_MODIFIER", 81, 82], ["j", "ANATOMY", 83, 84]]], ["From Lemma 5, one has L(mA) = \u2297 v L. Hence, m is 1 \u2212 unif orm and \u2297 = \u2297 m .", [["L", "ANATOMY_MODIFIER", 22, 23]]], ["Let \u2297 be a regular operation such that there exists a 1-uniform product modifier m satisfying \u2297 m = \u2297.", [["Let \u2297", "GENE_OR_GENE_PRODUCT", 0, 5], ["a regular operation", "TREATMENT", 9, 28]]], ["We use a reductio ad absurdum argument by assuming that \u2297 is not quasi-boolean.", [["a reductio ad absurdum argument", "TREATMENT", 7, 38]]], ["Let v \u2208 {0, 1} k be such that \u2297 v is not a boolean operation.", [["\u2297 v", "GENE_OR_GENE_PRODUCT", 30, 33], ["Let v \u2208 {0", "TEST", 0, 10], ["a boolean operation", "TREATMENT", 41, 60], ["boolean operation", "OBSERVATION", 43, 60]]], ["Let A be a k-tuple of DFAs We have to examine two cases.", [["DFAs", "CHEMICAL", 22, 26], ["Let A", "GENE_OR_GENE_PRODUCT", 0, 5], ["DFAs", "GENE_OR_GENE_PRODUCT", 22, 26], ["DFAs", "DNA", 22, 26]]], ["Either there exists p \u2208 F such that p / \u2208 d\u2208E cp(d, F , Q ), or there exists p \u2208 d\u2208E cp(d, F , Q ) such that p / \u2208 F .", [["cp", "PROBLEM", 46, 48], ["d\u2208E cp", "PROBLEM", 81, 87]]], ["We only describe the first case, as the other one is treated symmetrically.", [["treated", "OBSERVATION", 53, 60]]], ["Therefore, Lemma 1 implies that there exists d \u2208 H \u00a0E such that p \u2208 cp(d, F , Q ).", [["d \u2208 H \u00a0E", "CHEMICAL", 45, 53], ["cp", "PROBLEM", 68, 70]]], ["Let p \u2208 cp(d, F , Q).", [["cp", "PROBLEM", 8, 10]]], ["Notice that p \u2208 F while each p l has the same finality in B l as p l in B l .", [["B l", "GENE_OR_GENE_PRODUCT", 72, 75], ["l", "ANATOMY_MODIFIER", 60, 61], ["B", "ANATOMY", 72, 73], ["l", "ANATOMY_MODIFIER", 74, 75]]], ["Also remark that, as (L(A 1 ), . . . , L(A k )) and (L(A 1 ), . . . , L(A k )) are in L v , for all l \u2208 {1, . . . , k}, v l = 0 implies i l \u2208 F l and i l \u2208 F l , and v l = 1 implies i l / \u2208 F l and i l / \u2208 F l .", [["all l \u2208", "TEST", 96, 103], ["k}", "TEST", 116, 118], ["v l", "TEST", 166, 169], ["F l", "ANATOMY_MODIFIER", 206, 209]]], ["Now consider the two k-tuples of DFAs B and B such that B l = ({a}, Q l , i l , F l , \u03b2 l ) and B l = ({a}, Q l , i l , F l , \u03b2 l ), where \u03b2 l and \u03b2 l are defined, for all positive integer l \u2264 k and all (q, q ) \u2208 Q l \u00d7 Q l , by : \u03b2 a l (q) = p l if q = i l q otherwise. and \u03b2 a l (q ) = p l if q = i l q otherwise.Theorem 2.", [["DFAs B and B", "CHEMICAL", 33, 45], ["B l = ({a}", "SIMPLE_CHEMICAL", 96, 106], ["DFAs B", "PROTEIN", 33, 39], ["B", "PROTEIN", 44, 45], ["\u03b2 l", "PROTEIN", 147, 150], ["k-tuples", "TEST", 21, 29], ["DFAs", "TEST", 33, 37], ["k", "TEST", 193, 194]]], ["An operation \u2297 is quasi-boolean if and only if there exists a 1-We notice that, for all l \u2208 {1, . . . , k}, B l and B l recognize the same language L l .", [["B l", "GENE_OR_GENE_PRODUCT", 116, 119], ["An operation", "TREATMENT", 0, 12], ["operation", "OBSERVATION", 3, 12], ["l", "ANATOMY_MODIFIER", 150, 151]]], ["Furthermore, we have \u03b2 a (i) = p \u2208 F , and \u03b2 a (i ) = p \u2208 F , which means that a \u2208 L(mB) and a \u2208 L(mB ), which contradicts the 1-uniformity of m.", [["mB", "PROTEIN", 99, 101], ["means", "TEST", 68, 73], ["mB", "TEST", 85, 87], ["a \u2208 L(mB )", "TEST", 93, 103], ["contradicts", "TEST", 111, 122], ["m.", "ANATOMY", 143, 145]]], ["Common values of L(B l ) and L(B l ).ConclusionWe have shown that some very simple modifiers, namely product modifiers, encode a class of very low state complexity operations.", [["Common values", "TEST", 0, 13], ["L", "ANATOMY_MODIFIER", 17, 18], ["L", "ANATOMY_MODIFIER", 29, 30], ["l", "ANATOMY_MODIFIER", 33, 34]]], ["This is a non-trivial example of a set of modifiers closed by composition whose associated regular operations are completely described.ConclusionThe proof techniques open perspectives to explore other classes of modifiers closed by composition.", [["a set of modifiers", "TREATMENT", 33, 51], ["regular operations", "TREATMENT", 91, 109], ["modifiers", "TREATMENT", 212, 221], ["operations", "OBSERVATION", 99, 109]]]], "PMC7088034": [["Introduction\u2014what is needed?This article addresses instrumentation that is designed to perform biological assays (\u201cbioassays\u201d), and one overriding question in the design of any instrument that is to perform a bioassay is, simply put, \u201cWho cares?\u201d", [["instrumentation", "TREATMENT", 51, 66], ["biological assays", "TEST", 95, 112]]], ["These considerations drive everything \u201cupstream\u201d and greatly influence the selection of the sample(s), the processing of the sample, and the selection of assay(s) that are applied to the problem.", [["the sample", "TEST", 121, 131], ["the selection of assay", "TEST", 137, 159]]], ["Numerous of us who work with microfluidics-based systems have expressed optimism that some day we will have a self-powered, credit-card-sized, microfluidics-based, disposable cartridge that relatively untrained third parties can contact with a sample in some manner and, thereupon, the cartridge will transport and prepare the sample, mix it with reagents and execute other necessary sample processing steps, and then proceed to perform one or more identification-capable (ID-capable) multiplex biological assays, reporting its results for easy interpretation and action.", [["sample", "ANATOMY", 384, 390], ["reagents", "TREATMENT", 347, 355]]], ["We are not there, today, in general.Introduction\u2014what is needed?A useful example of a \u201csimple,\u201d single-target bioassay that nominally requires no sample preparation or user training is found in the very popular home pregnancy test (HPT) kits, which typically employ two monoclonal antibodies for human chorionic gonadotropin (hCG) in a lateral-flow, \u201csandwich\u201d assay format.", [["human", "ORGANISM", 296, 301], ["chorionic gonadotropin", "GENE_OR_GENE_PRODUCT", 302, 324], ["hCG", "GENE_OR_GENE_PRODUCT", 326, 329], ["monoclonal antibodies", "PROTEIN", 270, 291], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 296, 301], ["sample preparation", "TREATMENT", 146, 164], ["user training", "TREATMENT", 168, 181], ["two monoclonal antibodies", "TEST", 266, 291], ["human chorionic gonadotropin", "TREATMENT", 296, 324], ["hCG", "TEST", 326, 329], ["a lateral-flow", "TEST", 334, 348]]], ["With this implementation, no formal instrumentation is required and the colorimetric readout is performed by eye.", [["eye", "ANATOMY", 109, 112], ["eye", "ORGAN", 109, 112], ["formal instrumentation", "TREATMENT", 29, 51], ["the colorimetric readout", "TEST", 68, 92], ["instrumentation", "OBSERVATION", 36, 51], ["eye", "ANATOMY", 109, 112]]], ["Bastian et al. have reviewed the use of such HPT Kits (Bastian et al. 1998) and cited studies that found nearly 24% to 50% false negatives, and \u201cThe main explanation for such high rate of false-negative results was difficulty in understanding the instruction in the HPT kits...,\u201d Some information that is provided is:The urine should be the first urine of the morning when hCG levels are highest [Urine becomes much more dilute after ingestion of liquids (tea, coffee, juice, water, etc.) and urine hCG concentrations may become too low to register as positive], but no particular sample preparation is typically employed.", [["urine", "ANATOMY", 321, 326], ["urine", "ANATOMY", 347, 352], ["juice", "ANATOMY", 469, 474], ["urine", "ANATOMY", 493, 498], ["HPT", "DISEASE", 266, 269], ["tea, coffee, juice, water", "CHEMICAL", 456, 481], ["urine", "ORGANISM_SUBSTANCE", 321, 326], ["urine", "ORGANISM_SUBSTANCE", 347, 352], ["hCG", "GENE_OR_GENE_PRODUCT", 373, 376], ["Urine", "ORGANISM_SUBSTANCE", 397, 402], ["tea", "ORGANISM_SUBDIVISION", 456, 459], ["juice", "ORGANISM_SUBSTANCE", 469, 474], ["urine", "ORGANISM_SUBSTANCE", 493, 498], ["hCG", "SIMPLE_CHEMICAL", 499, 502], ["such HPT Kits", "TEST", 40, 53], ["cited studies", "TEST", 80, 93], ["The urine", "TEST", 317, 326], ["hCG levels", "TEST", 373, 383], ["urine hCG concentrations", "TEST", 493, 517], ["urine", "OBSERVATION", 321, 326]]], ["The antigen/antibody binding is particularly strong and confounding compounds/non-specific binding is normally not a problem.", [["antigen", "GENE_OR_GENE_PRODUCT", 4, 11], ["The antigen/antibody binding", "TEST", 0, 28], ["non-specific binding", "PROBLEM", 78, 98], ["antibody binding", "OBSERVATION", 12, 28]]], ["If a woman questions the result, she can wait until the next morning to repeat the measurement, normally with little in the way of negative consequence to a false positive or negative, while she waits.", [["woman", "ORGANISM", 5, 10], ["woman", "SPECIES", 5, 10], ["repeat the measurement", "TEST", 72, 94], ["a false positive", "PROBLEM", 155, 171]]]], "PMC3349948": [["INTRODUCTIONInfluenza A viruses belong to the Orthomyxoviridae family, and have a genome composed of eight segments of single-stranded, negative-sense RNA.", [["INTRODUCTIONInfluenza A viruses", "ORGANISM", 0, 31], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 46, 62], ["Orthomyxoviridae family", "PROTEIN", 46, 69], ["single-stranded, negative-sense RNA", "RNA", 119, 154], ["INTRODUCTIONInfluenza A viruses", "SPECIES", 0, 31], ["sense RNA", "OBSERVATION_MODIFIER", 145, 154]]], ["Their surfaces are composed by a lipid envelope, originated from the plasmatic membrane of infected epithelial cells, and two antigenic proteins: Hemagglutinin (HA) and Neuraminidase (NA); these two antigens exhibit higher variability compared with their remaining proteins [1].", [["plasmatic membrane", "ANATOMY", 69, 87], ["epithelial cells", "ANATOMY", 100, 116], ["plasmatic membrane", "CELLULAR_COMPONENT", 69, 87], ["epithelial cells", "CELL", 100, 116], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 146, 159], ["HA", "GENE_OR_GENE_PRODUCT", 161, 163], ["Neuraminidase", "SIMPLE_CHEMICAL", 169, 182], ["NA", "SIMPLE_CHEMICAL", 184, 186], ["infected epithelial cells", "CELL_TYPE", 91, 116], ["antigenic proteins", "PROTEIN", 126, 144], ["Hemagglutinin", "PROTEIN", 146, 159], ["HA", "PROTEIN", 161, 163], ["Neuraminidase", "PROTEIN", 169, 182], ["a lipid envelope", "PROBLEM", 31, 47], ["infected epithelial cells", "PROBLEM", 91, 116], ["two antigenic proteins", "TEST", 122, 144], ["Hemagglutinin (HA)", "TREATMENT", 146, 164], ["Neuraminidase (NA)", "TEST", 169, 187], ["these two antigens", "TEST", 189, 207], ["higher variability", "PROBLEM", 216, 234], ["lipid envelope", "OBSERVATION", 33, 47], ["infected epithelial cells", "OBSERVATION", 91, 116]]], ["Depending on the extent of variability of two surface proteins, until now are known 16 HA (H1-H16), and 9 NA genotypes (N1-N9), respectively, which can be combined in different combinations [1, 2].INTRODUCTIONIn early April 2009, authorities from the Mexican public health observed a high number of influenza-like illnesses in their territory, and informed about this outbreak to the regional office of the World Health Organization (WHO).", [["surface", "ANATOMY", 46, 53], ["influenza-like illnesses", "DISEASE", 299, 323], ["H1-H16", "GENE_OR_GENE_PRODUCT", 91, 97], ["surface proteins", "PROTEIN", 46, 62], ["H1", "PROTEIN", 91, 93], ["H16", "PROTEIN", 94, 97], ["two surface proteins", "TEST", 42, 62], ["influenza", "PROBLEM", 299, 308], ["influenza", "OBSERVATION", 299, 308]]], ["In mid April, the Centers for Disease Control from USA identified the new virus in two cases from California.", [["Disease Control from USA", "PROBLEM", 30, 54], ["the new virus", "PROBLEM", 66, 79], ["mid", "ANATOMY_MODIFIER", 3, 6], ["new", "OBSERVATION_MODIFIER", 70, 73], ["virus", "OBSERVATION", 74, 79]]], ["The new virus spread rapidly throughout the world, and as a consequence the WHO authorities declared the \u201cPandemic (H1N1) 2009\u201d on June 11, 2009 [3].", [["Pandemic", "DISEASE", 106, 114], ["The new virus spread", "PROBLEM", 0, 20], ["new", "OBSERVATION_MODIFIER", 4, 7], ["virus", "OBSERVATION", 8, 13], ["spread", "OBSERVATION_MODIFIER", 14, 20], ["rapidly", "OBSERVATION_MODIFIER", 21, 28]]], ["It is thought that the new 2009 H1N1 pandemic virus (from here, 2009 H1N1pdm) has emerged through at least four reassortment and transmission events among swine, avian and human H1N1 lineages, probably in Asia and North America [4].", [["H1N1pdm", "DISEASE", 69, 76], ["2009 H1N1 pandemic virus", "ORGANISM", 27, 51], ["swine", "ORGANISM", 155, 160], ["human", "ORGANISM", 172, 177], ["H1N1 pandemic virus", "SPECIES", 32, 51], ["swine", "SPECIES", 155, 160], ["human", "SPECIES", 172, 177], ["H1N1", "SPECIES", 178, 182], ["2009 H1N1 pandemic virus", "SPECIES", 27, 51], ["swine", "SPECIES", 155, 160], ["human H1N1", "SPECIES", 172, 182], ["the new 2009 H1N1 pandemic virus", "PROBLEM", 19, 51]]], ["Particularly, the HA segment of 2009 H1N1pdm was originated from American swine lineage, whereas the NA segment derived from the European swine lineage [5, 6].", [["H1N1pdm", "DISEASE", 37, 44], ["swine", "SPECIES", 74, 79], ["swine", "SPECIES", 138, 143], ["American swine", "SPECIES", 65, 79], ["European swine", "SPECIES", 129, 143]]], ["It is believed that the ancestors of this pandemic strain remained undetected for approximately one decade due to lack of a surveillance system in pigs, the historical \u201cmixing vessel\u201d for new influenza viruses.", [["vessel", "ANATOMY", 176, 182], ["influenza viruses", "DISEASE", 192, 209], ["pigs", "ORGANISM", 147, 151], ["vessel", "MULTI-TISSUE_STRUCTURE", 176, 182], ["pigs", "SPECIES", 147, 151], ["pigs", "SPECIES", 147, 151], ["this pandemic strain", "PROBLEM", 37, 57], ["a surveillance system", "TEST", 122, 143], ["new influenza viruses", "PROBLEM", 188, 209], ["vessel", "ANATOMY", 176, 182], ["influenza viruses", "OBSERVATION", 192, 209]]], ["Furthermore, the closest ancestors of the new pandemic strains emerged probably in January 2009 [4].INTRODUCTIONThe objective of this study was to analyze a dataset of complete nucleotide (nt) sequences of HA and NA genes, in order to assess the extent of diversity among circulating 2009-2010 strains, estimate if these genes evolved through positive, negative, or neutral selection models of evolution during the pandemic phase, and analyze the worldwide percentage of detection of important amino acid mutations that could enhance the viral performance, such as transmissibility or resistance to drugs.INTRODUCTIONComplete CoDing Sequences (CDS) of HA (1701 nt) and NA (1410 nt) genes corresponding to 2009 H1N1pdm, isolated from humans, were downloaded from the Influenza Virus Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU /SwineFlu.html) from the National Center for Biotechnology Information, by the year of sequence repository.", [["pandemic", "DISEASE", 46, 54], ["nucleotide", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 494, 504], ["nucleotide", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 494, 504], ["amino acid", "AMINO_ACID", 494, 504], ["humans", "ORGANISM", 733, 739], ["nucleotide (nt) sequences", "DNA", 177, 202], ["HA and NA genes", "DNA", 206, 221], ["CoDing Sequences", "DNA", 626, 642], ["CDS", "DNA", 644, 647], ["HA", "DNA", 652, 654], ["NA (1410 nt) genes", "DNA", 669, 687], ["humans", "SPECIES", 733, 739], ["humans", "SPECIES", 733, 739], ["the new pandemic strains", "PROBLEM", 38, 62], ["this study", "TEST", 129, 139], ["complete nucleotide (nt)", "TREATMENT", 168, 192], ["HA", "PROBLEM", 206, 208], ["NA genes", "TEST", 213, 221], ["the pandemic phase", "TEST", 411, 429], ["important amino acid mutations", "PROBLEM", 484, 514], ["the viral performance", "PROBLEM", 534, 555], ["drugs", "TREATMENT", 599, 604], ["HA", "PROBLEM", 652, 654], ["NA", "TEST", 669, 671]]], ["The first dataset consisted of 3765 HA and 2996 NA sequences, respectively, which were reported in the period 2009-2010.", [["3765 HA and 2996 NA sequences", "DNA", 31, 60], ["NA sequences", "TEST", 48, 60]]], ["After discarding exact duplicates in sequence using a Perl script, we obtained 2038 HA and 1273 NA sequences, respectively; these sequences were different in at least one nucleotide among all representatives.", [["nucleotide", "CHEMICAL", 171, 181], ["2038 HA and 1273 NA sequences", "DNA", 79, 108], ["a Perl script", "TEST", 52, 65], ["HA and 1273 NA sequences", "TEST", 84, 108], ["these sequences", "TEST", 124, 139]]], ["Reassortant strains were discarded, as well as incomplete CDS sequences.INTRODUCTIONNucleotide sequences were manually edited in FASTA format, using BioEdit v7.0.5 [7], and aligned with CLUSTAL W [8].", [["CDS sequences", "DNA", 58, 71], ["INTRODUCTIONNucleotide sequences", "DNA", 72, 104], ["Reassortant strains", "PROBLEM", 0, 19], ["incomplete CDS sequences", "TEST", 47, 71], ["INTRODUCTIONNucleotide sequences", "TREATMENT", 72, 104]]], ["Sequence information (GenBank accession number, strain, and year of isolation) for each sample used in this study are available for HA (Table S1) and NA genes (Table S2), respectively.", [["HA (Table S1", "GENE_OR_GENE_PRODUCT", 132, 144], ["NA genes", "DNA", 150, 158], ["each sample", "TEST", 83, 94], ["this study", "TEST", 103, 113], ["HA", "PROBLEM", 132, 134]]], ["The percentages of identities were calculated by applying the formula 100 - (pairwise distance value x 100).", [["percentages", "OBSERVATION_MODIFIER", 4, 15]]], ["A graph was constructed by plotting the percentage identities in the abscissa (x axis) vs the frequency of each of the calculated pairwise identities in the ordinate (y axis).", [["A graph", "TEST", 0, 7]]], ["The graphs were prepared in the R environment, using ggplot2 package (www.r-project.org).INTRODUCTIONThe models of nucleotide substitution that best fitted each dataset were determined with MEGA v5 [9], and were: GTR+I model for HA genes, and T92+G model for NA genes, respectively.", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["GTR+I", "GENE_OR_GENE_PRODUCT", 213, 218], ["T92+G", "GENE_OR_GENE_PRODUCT", 243, 248], ["HA genes", "DNA", 229, 237], ["T92", "DNA", 243, 246], ["NA genes", "DNA", 259, 267], ["ggplot2 package", "TREATMENT", 53, 68], ["nucleotide substitution", "TREATMENT", 115, 138], ["GTR+I model", "TREATMENT", 213, 224], ["HA genes", "TREATMENT", 229, 237], ["T92", "TEST", 243, 246]]], ["Phylogenetic relationships were reconstructed by the Neighbor-Joining method [10], with the appropriate models of nucleotide substitution for each dataset (as described above) and bootstrap analysis of 1000 replicates, as incorporated in MEGA v5 [9].", [["nucleotide", "CHEMICAL", 114, 124], ["nucleotide", "CHEMICAL", 114, 124], ["nucleotide substitution", "TREATMENT", 114, 137], ["bootstrap analysis", "TEST", 180, 198]]], ["Outgroup sequences for HA and NA genes corresponded to strain A/Puerto Rico/8/1934.INTRODUCTIONMutations in each CDS were analyzed by the method of Nei and Gojobori [11].", [["HA", "GENE_OR_GENE_PRODUCT", 23, 25], ["HA and NA genes", "DNA", 23, 38], ["CDS", "DNA", 113, 116], ["Outgroup sequences", "TEST", 0, 18], ["HA", "PROBLEM", 23, 25], ["NA genes", "PROBLEM", 30, 38]]], ["Codon aligned sequences for each dataset were analyzed using the Perl-based SNAP program (http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html) [12] in order to calculate the variability of each CDS.", [["CDS", "DNA", 198, 201]]], ["The selective pressure was measured by comparing the rate of non-synonymous nucleotide substitutions per non-synonymous site (dN) against that of synonymous substitutions per synonymous site (dS).", [["nucleotide", "CHEMICAL", 76, 86], ["nucleotide", "CHEMICAL", 76, 86], ["The selective pressure", "TEST", 0, 22], ["non-synonymous nucleotide substitutions", "TREATMENT", 61, 100], ["non-synonymous site", "TREATMENT", 105, 124], ["synonymous substitutions", "PROBLEM", 146, 170], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["synonymous substitutions", "OBSERVATION", 146, 170], ["synonymous site", "OBSERVATION", 175, 190]]], ["The ratio dN/dS was used as an index to assess positive selection.", [["The ratio dN/dS", "TREATMENT", 0, 15], ["an index", "TEST", 28, 36]]], ["A ratio dN/dS >1 means positive (diversifying) selection, =1 means neutral selection, and <1 means negative (purifying) selection.INTRODUCTIONThe analysis of pairwise identity frequencies showed high percentage of similarities among circulating 2009-2010 pandemic influenza strains (Fig. 1).", [["influenza", "DISEASE", 264, 273], ["A ratio", "TEST", 0, 7], ["dS", "TEST", 11, 13], ["neutral selection", "TEST", 67, 84], ["pairwise identity frequencies", "TEST", 158, 187], ["pandemic influenza strains", "PROBLEM", 255, 281], ["high", "OBSERVATION_MODIFIER", 195, 199]]], ["The average percentage of identity was 99.7% for both HA and NA genes.", [["HA and NA genes", "DNA", 54, 69], ["identity", "TEST", 26, 34], ["average", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22]]], ["Thus, in this period of pandemic circulation, both genes did not segregate into different clusters, but on the contrary showed a constant and stable evolution.INTRODUCTIONThe high percentages of nucleotide identity were in accordance with the single clustering of all 2009-2010 strains in the phylogenetic tree of HA and NA genes (Fig. 2), without temporal or geographical distribution.", [["nucleotide", "CHEMICAL", 195, 205], ["nucleotide", "CHEMICAL", 195, 205], ["HA and NA genes", "DNA", 314, 329], ["pandemic circulation", "PROBLEM", 24, 44], ["nucleotide identity", "PROBLEM", 195, 214], ["HA", "PROBLEM", 314, 316], ["stable", "OBSERVATION_MODIFIER", 142, 148], ["high", "OBSERVATION_MODIFIER", 175, 179], ["percentages", "OBSERVATION_MODIFIER", 180, 191], ["tree", "ANATOMY_MODIFIER", 306, 310], ["without", "UNCERTAINTY", 340, 347], ["temporal", "ANATOMY_MODIFIER", 348, 356], ["geographical distribution", "OBSERVATION", 360, 385]]], ["It is interesting to note that the overall genetic diversity among 2009 H1N1pdm was less than typically observed among seasonal influenza.", [["H1N1pdm", "DISEASE", 72, 79], ["influenza", "DISEASE", 128, 137], ["seasonal influenza", "PROBLEM", 119, 137], ["influenza", "OBSERVATION", 128, 137]]], ["This is in accordance with its short period of time of circulation in humans [13].", [["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76]]], ["The single clustering of 2009 H1N1pdm observed in this report, however, is in contrast with other studies [14], in which the authors observe differences by using small datasets of sequences.", [["H1N1pdm", "DISEASE", 30, 37], ["other studies", "TEST", 92, 105], ["small datasets of sequences", "TEST", 162, 189]]], ["The single clustering of 2009 H1N1pdm, furthermore, agrees with serological data in which it was observed that antigenically, the new pandemic viruses were all similar [6], and thus not requiring a new update of the vaccine (strain A/California/07/2009) until now.INTRODUCTIONGiven that 2009 H1N1pdm constituted a homogeneous phylogenetic group, it was hypothesized that the diversity in nucleotide sequences localized (in average) in the 0.3% of differences within each analyzed gene.", [["pandemic", "DISEASE", 134, 142], ["H1N1pdm", "DISEASE", 292, 299], ["nucleotide", "CHEMICAL", 388, 398], ["nucleotide", "CHEMICAL", 388, 398], ["A/California/07/2009", "SPECIES", 232, 252], ["serological data", "TEST", 64, 80], ["the new pandemic viruses", "PROBLEM", 126, 150], ["the vaccine", "TREATMENT", 212, 223], ["the diversity in nucleotide sequences", "PROBLEM", 371, 408]]], ["Taking into account the complete CDS for HA and NA genes, this percentage of differences constitutes approximately four to five nucleotide random variations among circulating strains.INTRODUCTIONCalculation of average dN/dS rates of evolution showed that both HA and NA genes evolved through negative (purifying) selection (Table 1), with dN/dS values of 0.2762 and 0.1939, respectively.", [["nucleotide", "CHEMICAL", 128, 138], ["nucleotide", "CHEMICAL", 128, 138], ["HA", "GENE_OR_GENE_PRODUCT", 260, 262], ["CDS", "DNA", 33, 36], ["HA and NA genes", "DNA", 41, 56], ["HA and NA genes", "DNA", 260, 275], ["HA", "PROBLEM", 41, 43], ["NA genes", "PROBLEM", 48, 56], ["circulating strains", "PROBLEM", 163, 182], ["dS rates", "TEST", 221, 229], ["both HA and NA genes", "PROBLEM", 255, 275], ["dN/dS values", "TEST", 339, 351]]], ["Even though in general, both genes underwent negative selection, some positions can evolve through positive selection.", [["negative", "OBSERVATION", 45, 53]]], ["For example, an early study showed that two sites involved in receptor binding specificity of HA (220 and 278) were under positive selection, and these sites were not found in swine or seasonal H1N1 viruses [15].", [["HA", "GENE_OR_GENE_PRODUCT", 94, 96], ["swine", "ORGANISM", 176, 181], ["seasonal H1N1 viruses", "ORGANISM", 185, 206], ["swine", "SPECIES", 176, 181], ["swine", "SPECIES", 176, 181], ["seasonal H1N1 viruses", "SPECIES", 185, 206], ["an early study", "TEST", 13, 27], ["HA", "PROBLEM", 94, 96], ["seasonal H1N1 viruses", "PROBLEM", 185, 206]]], ["Thus, changes in receptor binding sites could lead to alterations in receptor binding specificities.INTRODUCTIONIn other viruses such as SARS-CoV, it was observed that they can develop through positive selection through the cross-species transmission in early epidemics, and negative selection during late epidemics [16].", [["SARS", "DISEASE", 137, 141], ["SARS-CoV", "ORGANISM", 137, 145], ["SARS-CoV", "SPECIES", 137, 145], ["changes in receptor binding sites", "PROBLEM", 6, 39], ["alterations in receptor binding specificities", "PROBLEM", 54, 99], ["other viruses", "PROBLEM", 115, 128], ["viruses", "OBSERVATION", 121, 128]]], ["It is possible that the same mechanism was the driven force of evolution of 2009 H1N1pdm, with positive selection at least during cross-species transmission.INTRODUCTIONA number of different amino acid mutations that could confer new functionalities to the new virus were reported worldwide, including those related to increased pathogenicity or antiviral resistance (Table 2).INTRODUCTIONPolymorphism at position 239 in HA has been associated with severe clinical outcomes, especially in immunocompromised patients; in particular, substitution 239G was found to correlate with fatal outcomes in different countries [17, 18].", [["H1N1pdm", "DISEASE", 81, 88], ["amino acid", "CHEMICAL", 191, 201], ["amino acid", "CHEMICAL", 191, 201], ["amino acid", "AMINO_ACID", 191, 201], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 507, 515], ["positive selection", "PROBLEM", 95, 113], ["different amino acid mutations", "TREATMENT", 181, 211], ["the new virus", "PROBLEM", 253, 266], ["increased pathogenicity or antiviral resistance", "PROBLEM", 319, 366], ["HA", "PROBLEM", 421, 423], ["severe clinical outcomes", "PROBLEM", 449, 473], ["substitution", "TREATMENT", 532, 544], ["antiviral resistance", "OBSERVATION", 346, 366], ["severe", "OBSERVATION_MODIFIER", 449, 455]]], ["Furthermore, this mutation can arise de novo from wildtype (D239) virus in the same patient throughout the disease course [19].", [["wildtype (D239) virus", "ORGANISM", 50, 71], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["this mutation", "PROBLEM", 13, 26], ["wildtype (D239) virus", "TREATMENT", 50, 71]]], ["Mutation at position 239 can induce alterations in the receptor binding site, and 239G mutants bind a broader range of \u03b12-3-linked sialyl receptors sequences expressed on cells from the lower respiratory tract, which suggested that its presence could be responsible for the exacerbation of disease [20].", [["cells", "ANATOMY", 171, 176], ["lower respiratory tract", "ANATOMY", 186, 209], ["sialyl", "CHEMICAL", 131, 137], ["239G", "GENE_OR_GENE_PRODUCT", 82, 86], ["\u03b12-3", "GENE_OR_GENE_PRODUCT", 119, 123], ["sialyl receptors", "GENE_OR_GENE_PRODUCT", 131, 147], ["cells", "CELL", 171, 176], ["lower respiratory", "ORGANISM_SUBDIVISION", 186, 203], ["tract", "ORGANISM_SUBDIVISION", 204, 209], ["receptor binding site", "DNA", 55, 76], ["239G mutants", "PROTEIN", 82, 94], ["\u03b12-3-linked sialyl receptors sequences", "PROTEIN", 119, 157], ["Mutation at position", "PROBLEM", 0, 20], ["alterations in the receptor binding site", "PROBLEM", 36, 76], ["\u03b12", "TEST", 119, 121], ["sialyl receptors sequences", "TREATMENT", 131, 157], ["the exacerbation of disease", "PROBLEM", 270, 297], ["lower", "ANATOMY_MODIFIER", 186, 191], ["respiratory tract", "ANATOMY", 192, 209]]], ["Mutants 239E target mainly non-ciliated cells.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["239E", "PROTEIN", 8, 12], ["non-ciliated cells", "CELL_TYPE", 27, 45], ["non-ciliated cells", "OBSERVATION", 27, 45]]], ["We found no significant difference between sequences bearing mutations 239G (2.6%) and 239E (5.5%).", [["sequences bearing mutations", "TEST", 43, 70], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The low percentage of global circulation of mutants 239G found in this study is in accordance with its lower potential to transmit to other individuals [21].INTRODUCTIONPositions 239 and 220 are localized within the HA antigenic site called Ca.", [["Ca", "CHEMICAL", 241, 243], ["Ca", "CHEMICAL", 241, 243], ["mutants 239G", "PROTEIN", 44, 56], ["HA antigenic site", "DNA", 216, 233], ["this study", "TEST", 66, 76], ["INTRODUCTIONPositions", "TEST", 157, 178], ["low", "OBSERVATION_MODIFIER", 4, 7], ["percentage", "OBSERVATION_MODIFIER", 8, 18], ["global", "OBSERVATION_MODIFIER", 22, 28], ["circulation", "OBSERVATION_MODIFIER", 29, 40], ["Ca", "OBSERVATION", 241, 243]]], ["The amino acid S220, though not exposed to the surface, is localized in the receptor binding domain (RBD), and its change could affect the transmissibility and infectivity of H1N1 in humans.", [["surface", "ANATOMY", 47, 54], ["amino acid", "CHEMICAL", 4, 14], ["H1N1", "DISEASE", 175, 179], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["S220", "AMINO_ACID", 15, 19], ["surface", "CELLULAR_COMPONENT", 47, 54], ["humans", "ORGANISM", 183, 189], ["amino acid S220", "PROTEIN", 4, 19], ["receptor binding domain", "PROTEIN", 76, 99], ["RBD", "PROTEIN", 101, 104], ["humans", "SPECIES", 183, 189], ["humans", "SPECIES", 183, 189], ["The amino acid", "TEST", 0, 14], ["H1N1", "PROBLEM", 175, 179], ["surface", "OBSERVATION_MODIFIER", 47, 54]]], ["The fixed mutation, S220T, has been found at high percentage (76.7%) in this study.", [["The fixed mutation", "PROBLEM", 0, 18], ["this study", "TEST", 72, 82], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["mutation", "OBSERVATION", 10, 18]]], ["To test whether change 220T could contribute to antigenic drift, it would be interesting to compare its antigenic profile against a wildtype isolate (S220).", [["S220", "CANCER", 150, 154], ["antigenic drift", "PROBLEM", 48, 63], ["antigenic drift", "OBSERVATION", 48, 63]]], ["This mutation, probably, has become fixed in all pandemic strains through optimization of viral fitness, rather than immune selection or adaptation to the host.INTRODUCTIONSubstitution S101N has been proposed previously as a reversion to the seasonal H1N1 residue 101N and thus possibly an adaptation to the human host, being found in some studies at high frequencies.", [["S101N", "CHEMICAL", 185, 190], ["human", "ORGANISM", 308, 313], ["S101N", "PROTEIN", 185, 190], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 308, 313], ["This mutation", "PROBLEM", 0, 13], ["all pandemic strains", "PROBLEM", 45, 65], ["viral fitness", "PROBLEM", 90, 103], ["immune selection", "TREATMENT", 117, 133], ["the seasonal H1N1 residue", "PROBLEM", 238, 263], ["fixed", "OBSERVATION_MODIFIER", 36, 41], ["viral fitness", "OBSERVATION", 90, 103]]], ["Its global impact, however, is controvertible because it was found in only 0.2% of our sequences.", [["our sequences", "TEST", 83, 96], ["global", "OBSERVATION_MODIFIER", 4, 10], ["impact", "OBSERVATION_MODIFIER", 11, 17]]], ["Substitution E391K, found at 15.6% in our study, has been identified as part of a highly conserved epitope in the 1918 H1N1 virus with a possible role in membrane fusion [22].", [["membrane", "ANATOMY", 154, 162], ["E391K", "CHEMICAL", 13, 18], ["1918 H1N1 virus", "ORGANISM", 114, 129], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["H1N1 virus", "SPECIES", 119, 129], ["1918 H1N1 virus", "SPECIES", 114, 129], ["our study", "TEST", 38, 47], ["H1N1 virus", "PROBLEM", 119, 129], ["membrane fusion", "TREATMENT", 154, 169], ["membrane fusion", "OBSERVATION", 154, 169]]], ["Another proximal substitution found in other studies, N387H, was found in only 1.7% of our sequences.INTRODUCTIONIn the NA gene, it was showed that mutations V106I and N248D were present in samples at increasing numbers through early pandemic month (April to December 2009) [23].", [["samples", "ANATOMY", 190, 197], ["V106I", "GENE_OR_GENE_PRODUCT", 158, 163], ["N248D", "GENE_OR_GENE_PRODUCT", 168, 173], ["samples", "CANCER", 190, 197], ["NA gene", "DNA", 120, 127], ["Another proximal substitution", "PROBLEM", 0, 29], ["other studies", "TEST", 39, 52], ["our sequences", "TEST", 87, 100], ["mutations V106I", "PROBLEM", 148, 163], ["proximal", "OBSERVATION_MODIFIER", 8, 16], ["substitution", "OBSERVATION", 17, 29]]], ["Change 106I was present in the 20th century cases of H1N1 (in 1918 [pandemic], and 1977), as well as 248D (in 1977).", [["H1N1", "DISEASE", 53, 57], ["H1N1", "PROBLEM", 53, 57]]], ["Since residue at position 248 is located at the drug target domain (DTD) region, as residue 275, it could potentially affect the sensitivity to NA inhibitors.", [["NA", "CHEMICAL", 144, 146], ["position 248", "AMINO_ACID", 17, 29], ["residue 275", "AMINO_ACID", 84, 95], ["NA inhibitors", "SIMPLE_CHEMICAL", 144, 157], ["drug target domain", "PROTEIN", 48, 66], ["DTD", "PROTEIN", 68, 71], ["NA inhibitors", "TREATMENT", 144, 157]]], ["Another substitution of possible interest in NA sequences is D199N, which was previously associated with an increase in oseltamivir resistance in both seasonal and H5N1 virus strains [24].", [["oseltamivir", "CHEMICAL", 120, 131], ["oseltamivir", "CHEMICAL", 120, 131], ["oseltamivir", "SIMPLE_CHEMICAL", 120, 131], ["H5N1 virus", "ORGANISM", 164, 174], ["NA sequences", "DNA", 45, 57], ["H5N1 virus", "SPECIES", 164, 174], ["H5N1 virus", "SPECIES", 164, 174], ["NA sequences", "TEST", 45, 57], ["oseltamivir resistance", "TREATMENT", 120, 142], ["both seasonal and H5N1 virus strains", "PROBLEM", 146, 182], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["oseltamivir resistance", "OBSERVATION", 120, 142]]], ["We found, however, only 4 out of 1273 NA sequences (0.3%) containing this change.", [["NA sequences", "DNA", 38, 50], ["NA sequences", "TEST", 38, 50]]], ["The rare substitution I223R, which was reported in association with resistance to oseltamivir, zanamivir, and peramivir [25], was also found in only 2 out of 1273 NA sequences (0.2%).", [["oseltamivir", "CHEMICAL", 82, 93], ["zanamivir", "CHEMICAL", 95, 104], ["peramivir", "CHEMICAL", 110, 119], ["oseltamivir", "CHEMICAL", 82, 93], ["zanamivir", "CHEMICAL", 95, 104], ["peramivir", "CHEMICAL", 110, 119], ["oseltamivir", "SIMPLE_CHEMICAL", 82, 93], ["zanamivir", "SIMPLE_CHEMICAL", 95, 104], ["peramivir [25]", "SIMPLE_CHEMICAL", 110, 124], ["oseltamivir", "TREATMENT", 82, 93], ["zanamivir", "TREATMENT", 95, 104], ["peramivir", "TREATMENT", 110, 119], ["NA sequences", "TEST", 163, 175], ["rare", "OBSERVATION_MODIFIER", 4, 8], ["substitution", "OBSERVATION", 9, 21]]], ["Substitution H275Y has been related to oseltamivir resistance, especially in immunocompromised or severely ill persons [26].", [["H275Y", "CHEMICAL", 13, 18], ["oseltamivir", "CHEMICAL", 39, 50], ["immunocompromised or severely ill", "DISEASE", 77, 110], ["oseltamivir", "CHEMICAL", 39, 50], ["H275Y", "GENE_OR_GENE_PRODUCT", 13, 18], ["oseltamivir", "SIMPLE_CHEMICAL", 39, 50], ["persons", "SPECIES", 111, 118], ["oseltamivir resistance", "PROBLEM", 39, 61], ["oseltamivir resistance", "OBSERVATION", 39, 61]]], ["In our study, we found 2% of sequences containing this change.INTRODUCTIONIn conclusion, the stable evolution of 2009 H1N1pdm offers an opportunity to control its spread and prevent infections.", [["H1N1pdm", "DISEASE", 118, 125], ["infections", "DISEASE", 182, 192], ["our study", "TEST", 3, 12], ["this change", "PROBLEM", 50, 61], ["infections", "PROBLEM", 182, 192], ["stable", "OBSERVATION_MODIFIER", 93, 99], ["infections", "OBSERVATION", 182, 192]]], ["Reports about new mutations, however, will still be important if those changes can confer an enhanced transmissibility or resistance to drugs.", [["new mutations", "PROBLEM", 14, 27]]], ["Furthermore, a continuous surveillance by public health authorities will be critical to monitor the appearance of new influenza variants, especially in animal reservoirs such as swine and birds, in order to prevent the potential animal-human transmission of viruses with pandemic potential.", [["influenza", "DISEASE", 118, 127], ["pandemic", "DISEASE", 271, 279], ["human", "ORGANISM", 236, 241], ["swine", "SPECIES", 178, 183], ["human", "SPECIES", 236, 241], ["swine", "SPECIES", 178, 183], ["human", "SPECIES", 236, 241], ["new influenza variants", "PROBLEM", 114, 136], ["new", "OBSERVATION_MODIFIER", 114, 117], ["influenza variants", "OBSERVATION", 118, 136]]]], "PMC7400144": [], "3e01d1740656ce4504e2ff38527f02a628803fa8": [["IntroductionThe outbreak of COVID-19, due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in Wuhan, Hubei Province, China, and has subsequently spread all over the world.", [["COVID-19", "CHEMICAL", 28, 36], ["acute respiratory syndrome coronavirus", "DISEASE", 52, 90], ["COVID-19", "ORGANISM", 28, 36], ["SARS-CoV-2", "ORGANISM", 94, 104], ["COVID-19", "SPECIES", 28, 36], ["severe acute respiratory syndrome coronavirus", "SPECIES", 45, 90], ["SARS-CoV-2", "SPECIES", 94, 104], ["COVID", "TEST", 28, 33], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 45, 90], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78]]], ["Up to 30% of patients admitted to hospital with COVID-19 need admission to intensive care units (ICUs) to receive ventilation assistance because they develop acute res piratory distress syndrome (ARDS).", [["acute res piratory distress syndrome", "DISEASE", 158, 194], ["ARDS", "DISEASE", 196, 200], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["ventilation assistance", "TREATMENT", 114, 136], ["acute res piratory distress syndrome", "PROBLEM", 158, 194], ["ARDS", "PROBLEM", 196, 200], ["acute", "OBSERVATION_MODIFIER", 158, 163]]], ["[1] [2] [3] So far, no specific treatment has shown efficacy in preventing worsening of respiratory symptoms in patients admitted to hospital for COVID-19-associated pneu monia requiring oxygen therapy.", [["respiratory", "ANATOMY", 88, 99], ["pneu monia", "ANATOMY", 166, 176], ["respiratory symptoms", "DISEASE", 88, 108], ["COVID-19", "CHEMICAL", 146, 154], ["oxygen", "CHEMICAL", 187, 193], ["COVID-19", "CHEMICAL", 146, 154], ["oxygen", "CHEMICAL", 187, 193], ["patients", "ORGANISM", 112, 120], ["oxygen", "SIMPLE_CHEMICAL", 187, 193], ["patients", "SPECIES", 112, 120], ["specific treatment", "TREATMENT", 23, 41], ["respiratory symptoms", "PROBLEM", 88, 108], ["COVID", "TEST", 146, 151], ["pneu monia", "PROBLEM", 166, 176], ["oxygen therapy", "TREATMENT", 187, 201], ["respiratory", "ANATOMY", 88, 99], ["oxygen therapy", "OBSERVATION", 187, 201]]], ["Finding such a treatment is a public health emergency.IntroductionSimilarly to other types or coronaviruses (eg, Middle East respiratory syndrome coronavirus), the pathogenesis of SARS-CoV-2 infection includes hyperinflammation that resembles cytokine storm syndromes (eg, secondary haemophagocytic lymphohistiocytosis or macrophage activa tion syndrome), involving pro-inflammatory interleukins (IL-1\u03b2 and IL-6) and tumour necrosis factor.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 113, 157], ["SARS-CoV-2 infection", "DISEASE", 180, 200], ["hyperinflammation", "DISEASE", 210, 227], ["haemophagocytic lymphohistiocytosis", "DISEASE", 283, 318], ["tumour necrosis", "DISEASE", 417, 432], ["coronaviruses", "ORGANISM", 94, 107], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 113, 157], ["SARS-CoV-2", "ORGANISM", 180, 190], ["macrophage", "CELL", 322, 332], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 397, 402], ["IL-6", "GENE_OR_GENE_PRODUCT", 407, 411], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 417, 439], ["cytokine", "PROTEIN", 243, 251], ["pro-inflammatory interleukins", "PROTEIN", 366, 395], ["IL-1\u03b2 and IL-6", "PROTEIN", 397, 411], ["tumour necrosis factor", "PROTEIN", 417, 439], ["CoV-2", "SPECIES", 185, 190], ["Middle East respiratory syndrome coronavirus", "SPECIES", 113, 157], ["SARS-CoV-2", "SPECIES", 180, 190], ["coronaviruses (eg", "PROBLEM", 94, 111], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 113, 157], ["SARS", "PROBLEM", 180, 184], ["CoV-2 infection", "PROBLEM", 185, 200], ["hyperinflammation", "PROBLEM", 210, 227], ["cytokine storm syndromes", "PROBLEM", 243, 267], ["secondary haemophagocytic lymphohistiocytosis", "PROBLEM", 273, 318], ["macrophage activa tion syndrome", "PROBLEM", 322, 353], ["pro-inflammatory interleukins", "TEST", 366, 395], ["IL", "TEST", 397, 399], ["IL", "TEST", 407, 409], ["tumour necrosis factor", "PROBLEM", 417, 439], ["cytokine storm", "OBSERVATION", 243, 257], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 283, 318], ["macrophage activa", "OBSERVATION", 322, 339], ["pro-inflammatory", "OBSERVATION_MODIFIER", 366, 382], ["tumour", "ANATOMY", 417, 423], ["necrosis", "OBSERVATION", 424, 432]]], ["3, 4 SARS-CoV-2 is thought to bind to toll-like receptors, which activate the inflammasome and the cleavage of pro-IL-1\u03b2 by caspase-1, followed by the pro duction of active mature IL-1\u03b2, a mediator of fever, lung inflamma tion, and fibrosis.", [["lung", "ANATOMY", 208, 212], ["fever", "DISEASE", 201, 206], ["lung inflamma tion", "DISEASE", 208, 226], ["fibrosis", "DISEASE", 232, 240], ["CoV-2", "GENE_OR_GENE_PRODUCT", 10, 15], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 38, 57], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 111, 120], ["caspase-1", "GENE_OR_GENE_PRODUCT", 124, 133], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 180, 185], ["lung", "ORGAN", 208, 212], ["toll-like receptors", "PROTEIN", 38, 57], ["pro-IL-1\u03b2", "PROTEIN", 111, 120], ["caspase-1", "PROTEIN", 124, 133], ["IL-1\u03b2", "PROTEIN", 180, 185], ["the cleavage of pro-IL", "TREATMENT", 95, 117], ["fever", "PROBLEM", 201, 206], ["lung inflamma tion", "PROBLEM", 208, 226], ["fibrosis", "PROBLEM", 232, 240], ["fever", "OBSERVATION", 201, 206], ["lung", "ANATOMY", 208, 212], ["inflamma", "OBSERVATION", 213, 221], ["fibrosis", "OBSERVATION", 232, 240]]], ["5 Coronaviruses encode viroporins, which facilitate viral dissemination through their interac tion with cellular ion channels.", [["cellular", "ANATOMY", 104, 112], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 2, 15], ["viroporins", "GENE_OR_GENE_PRODUCT", 23, 33], ["cellular", "CELL", 104, 112], ["viroporins", "PROTEIN", 23, 33], ["cellular ion channels", "PROTEIN", 104, 125], ["5 Coronaviruses encode viroporins", "PROBLEM", 0, 33], ["viral dissemination", "PROBLEM", 52, 71], ["cellular ion channels", "TREATMENT", 104, 125], ["viral dissemination", "OBSERVATION", 52, 71], ["ion channels", "OBSERVATION", 113, 125]]], ["Additionally, the viroporins E and open reading frame 3a can induce transcription of the gene encoding pro-IL-1\u03b2 and secretion of IL-1\u03b2 by activa tion of the NLRP3 inflammasome.", [["viroporins E", "GENE_OR_GENE_PRODUCT", 18, 30], ["open reading frame 3a", "GENE_OR_GENE_PRODUCT", 35, 56], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 103, 112], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 130, 135], ["NLRP3", "GENE_OR_GENE_PRODUCT", 158, 163], ["viroporins E", "DNA", 18, 30], ["open reading frame 3a", "DNA", 35, 56], ["pro-IL-1\u03b2", "PROTEIN", 103, 112], ["IL-1\u03b2", "PROTEIN", 130, 135], ["NLRP3 inflammasome", "PROTEIN", 158, 176], ["the viroporins E", "TREATMENT", 14, 30], ["IL", "TEST", 130, 132]]], ["6, 7 Anakinra is a 17 kD recombinant, non-glycosylated human IL-1 receptor antagonist with a short half-life of about 3-4 h and good safety profile.", [["Anakinra", "CHEMICAL", 5, 13], ["human", "ORGANISM", 55, 60], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 61, 85], ["non-glycosylated human IL-1 receptor", "PROTEIN", 38, 74], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["non-glycosylated human IL", "TREATMENT", 38, 63]]], ["After the approval of the subcutaneous formulation to treat patients with rheumatoid arthritis, anakinra was found to have some beneficial effects in severe sepsis, but only in the subgroup of patients with multiple organ dysfunction syn drome, in which the inflammasome pathway is also involved.", [["subcutaneous", "ANATOMY", 26, 38], ["organ", "ANATOMY", 216, 221], ["rheumatoid arthritis", "DISEASE", 74, 94], ["anakinra", "CHEMICAL", 96, 104], ["sepsis", "DISEASE", 157, 163], ["anakinra", "CHEMICAL", 96, 104], ["patients", "ORGANISM", 60, 68], ["anakinra", "SIMPLE_CHEMICAL", 96, 104], ["patients", "ORGANISM", 193, 201], ["organ", "ORGAN", 216, 221], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 193, 201], ["the subcutaneous formulation", "TREATMENT", 22, 50], ["rheumatoid arthritis", "PROBLEM", 74, 94], ["anakinra", "TREATMENT", 96, 104], ["severe sepsis", "PROBLEM", 150, 163], ["multiple organ dysfunction syn drome", "PROBLEM", 207, 243], ["rheumatoid", "OBSERVATION_MODIFIER", 74, 84], ["arthritis", "OBSERVATION", 85, 94], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["sepsis", "OBSERVATION", 157, 163], ["organ", "ANATOMY", 216, 221], ["dysfunction", "OBSERVATION", 222, 233], ["syn drome", "OBSERVATION", 234, 243]]], ["8 Similar positive results were reported in paediatric patients with secondary haemophagocytic lymphohistiocytosis or macrophage activation syndrome, including cases triggered by viral infection.", [["macrophage", "ANATOMY", 118, 128], ["haemophagocytic lymphohistiocytosis", "DISEASE", 79, 114], ["viral infection", "DISEASE", 179, 194], ["patients", "ORGANISM", 55, 63], ["macrophage", "CELL", 118, 128], ["patients", "SPECIES", 55, 63], ["secondary haemophagocytic lymphohistiocytosis", "PROBLEM", 69, 114], ["macrophage activation syndrome", "PROBLEM", 118, 148], ["viral infection", "PROBLEM", 179, 194], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 79, 114], ["macrophage activation syndrome", "OBSERVATION", 118, 148], ["viral", "OBSERVATION_MODIFIER", 179, 184], ["infection", "OBSERVATION", 185, 194]]], ["[8] [9] [10] These data led us to hypothesise that anakinra could represent an efficient treatment for severe forms of COVID-19, predominantly involving the inflam masome pathway.", [["anakinra", "CHEMICAL", 51, 59], ["COVID", "DISEASE", 119, 124], ["anakinra", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 119, 127], ["anakinra", "SIMPLE_CHEMICAL", 51, 59], ["masome", "GENE_OR_GENE_PRODUCT", 164, 170], ["These data", "TEST", 13, 23], ["anakinra", "PROBLEM", 51, 59], ["COVID", "TEST", 119, 124]]], ["Therefore, we aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function.Study design and patientsWe did a retrospective cohort study.", [["respiratory", "ANATOMY", 169, 180], ["anakinra", "CHEMICAL", 51, 59], ["COVID", "DISEASE", 122, 127], ["anakinra", "CHEMICAL", 51, 59], ["anakinra", "SIMPLE_CHEMICAL", 51, 59], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 207, 215], ["anakinra", "TREATMENT", 51, 59], ["COVID", "TEST", 122, 127], ["symptoms", "PROBLEM", 136, 144], ["worsening respiratory function", "PROBLEM", 159, 189], ["Study design", "TEST", 190, 202], ["a retrospective cohort study", "TEST", 222, 250], ["worsening", "OBSERVATION_MODIFIER", 159, 168], ["respiratory function", "OBSERVATION", 169, 189]]], ["The Ana-COVID study included a prospective cohort of patients who received anakinra and a historical com parison group who received standard care.", [["anakinra", "CHEMICAL", 75, 83], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["The Ana-COVID study", "TEST", 0, 19], ["anakinra", "TREATMENT", 75, 83], ["standard care", "TREATMENT", 132, 145]]], ["Patients were included in the prospective cohort if they were aged older than 18 years and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneu monia; were diagnosed with SARS-CoV-2 infec tion confirmed by either a positive result from an RT-PCR assay or a typical aspect on CT scan of the lungs (multiple ground-glass abnormalities with crazy paving, absence of lympha denopathy, and pulmonary nodules); had bilateral lung infiltrates on a lung CT scan or chest x-ray; and had critical pulmonary function defined by oxygen saturation of 93% or less under 6 L/min of oxygen or more or oxygen saturation of less than 93% on 3 L/min with a saturation on ambient air decreasing by 3% in the previous 24 h.Study design and patientsExclusion criteria were the refusal of the patient to participate, patients who were bedridden and near the end of life, patients with respiratory failure explained by an alternative aetiology, and patients already admitted to the ICU.Study design and patientsThe historical comparison group was identified retrospectively from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020, and included all patients with a COVID-19-related disease.", [["lungs", "ANATOMY", 331, 336], ["lympha", "ANATOMY", 404, 410], ["pulmonary nodules", "ANATOMY", 426, 443], ["lung", "ANATOMY", 460, 464], ["lung", "ANATOMY", 482, 486], ["pulmonary", "ANATOMY", 528, 537], ["respiratory", "ANATOMY", 903, 914], ["SARS", "DISEASE", 212, 216], ["lympha denopathy", "DISEASE", 404, 420], ["oxygen", "CHEMICAL", 558, 564], ["oxygen", "CHEMICAL", 608, 614], ["oxygen", "CHEMICAL", 626, 632], ["respiratory failure", "DISEASE", 903, 922], ["oxygen", "CHEMICAL", 558, 564], ["oxygen", "CHEMICAL", 608, 614], ["oxygen", "CHEMICAL", 626, 632], ["Patients", "ORGANISM", 0, 8], ["lungs", "ORGAN", 331, 336], ["pulmonary nodules", "CANCER", 426, 443], ["lung", "ORGAN", 460, 464], ["lung", "ORGAN", 482, 486], ["pulmonary", "ORGAN", 528, 537], ["oxygen", "SIMPLE_CHEMICAL", 558, 564], ["oxygen", "SIMPLE_CHEMICAL", 608, 614], ["oxygen", "SIMPLE_CHEMICAL", 626, 632], ["patients", "ORGANISM", 760, 768], ["patient", "ORGANISM", 811, 818], ["patients", "ORGANISM", 835, 843], ["patients", "ORGANISM", 889, 897], ["patients", "ORGANISM", 966, 974], ["patients", "ORGANISM", 1020, 1028], ["patients", "ORGANISM", 1200, 1208], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 760, 768], ["patient", "SPECIES", 811, 818], ["patients", "SPECIES", 835, 843], ["patients", "SPECIES", 889, 897], ["patients", "SPECIES", 966, 974], ["patients", "SPECIES", 1020, 1028], ["patients", "SPECIES", 1200, 1208], ["severe COVID", "PROBLEM", 146, 158], ["bilateral pneu monia", "PROBLEM", 170, 190], ["SARS", "PROBLEM", 212, 216], ["CoV", "PROBLEM", 217, 220], ["an RT-PCR assay", "TEST", 277, 292], ["CT scan of the lungs", "TEST", 316, 336], ["multiple ground-glass abnormalities", "PROBLEM", 338, 373], ["crazy paving", "PROBLEM", 379, 391], ["lympha denopathy", "PROBLEM", 404, 420], ["pulmonary nodules", "PROBLEM", 426, 443], ["bilateral lung infiltrates", "PROBLEM", 450, 476], ["a lung CT scan", "TEST", 480, 494], ["chest x-ray", "TEST", 498, 509], ["critical pulmonary function", "PROBLEM", 519, 546], ["oxygen saturation", "TEST", 558, 575], ["oxygen", "TREATMENT", 608, 614], ["oxygen saturation", "TEST", 626, 643], ["a saturation", "TEST", 677, 689], ["respiratory failure", "PROBLEM", 903, 922], ["Study design", "TEST", 1003, 1015], ["a COVID", "TREATMENT", 1214, 1221], ["related disease", "PROBLEM", 1225, 1240], ["bilateral", "ANATOMY_MODIFIER", 170, 179], ["pneu monia", "ANATOMY", 180, 190], ["lungs", "ANATOMY", 331, 336], ["multiple", "OBSERVATION_MODIFIER", 338, 346], ["glass abnormalities", "OBSERVATION", 354, 373], ["pulmonary", "ANATOMY", 426, 435], ["nodules", "OBSERVATION", 436, 443], ["bilateral", "ANATOMY_MODIFIER", 450, 459], ["lung", "ANATOMY", 460, 464], ["infiltrates", "OBSERVATION", 465, 476], ["lung", "ANATOMY", 482, 486], ["chest", "ANATOMY", 498, 503], ["pulmonary", "ANATOMY", 528, 537], ["oxygen saturation", "OBSERVATION", 558, 575], ["respiratory failure", "OBSERVATION", 903, 922]]], ["All historical patients had to fulfil the same inclusion and exclusion criteria as those of the anakinra group.Study design and patientsThe COVID cohort protocol has been approved by the institutional ethics com mittee (institutional review board number IRB00012157, initial agreement 401) and registered on the French National Institute of Health Data platform (MR4810020420).", [["anakinra", "CHEMICAL", 96, 104], ["patients", "ORGANISM", 15, 23], ["anakinra", "SIMPLE_CHEMICAL", 96, 104], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 128, 136], ["the anakinra group", "TREATMENT", 92, 110], ["Study design", "TEST", 111, 123], ["The COVID cohort protocol", "TREATMENT", 136, 161], ["anakinra", "OBSERVATION", 96, 104]]], ["All patients were given both oral and written information by their physician about anakinra, and could either accept or refuse this treatment.", [["oral", "ANATOMY", 29, 33], ["anakinra", "CHEMICAL", 83, 91], ["patients", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["anakinra", "SIMPLE_CHEMICAL", 83, 91], ["patients", "SPECIES", 4, 12], ["anakinra", "TREATMENT", 83, 91], ["this treatment", "TREATMENT", 127, 141]]], ["All patients in both groups agreed to have their data used for research purposes.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["research purposes", "TEST", 63, 80]]], ["This study corresponds to an institu tional offlabel drug evaluation.", [["This study", "TEST", 0, 10], ["an institu tional offlabel drug evaluation", "TEST", 26, 68]]], ["In this con text, French research regulation (Journal Officiel de la R\u00e9publique Fran\u00e7aise [Official Journal of the French Republic] 0160, July 13, 2018; paragraph 110, MR-004) states that the patient's written consent is not mandatory but investigators are required to give the patient an information leaflet explaining the purpose of the research.", [["patient", "ORGANISM", 192, 199], ["patient", "ORGANISM", 278, 285], ["patient", "SPECIES", 192, 199], ["patient", "SPECIES", 278, 285], ["MR", "TEST", 168, 170]]], ["The patients' non-opposition to the use of their data for research was also collected in accordance with European regulations (General Data Protection Regulation).ProceduresPatients in the anakinra group received subcutaneous anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) at a dose of 100 mg twice daily for 72 h, followed by 100 mg daily for 7 days, in addition to the standard treatment administered at Groupe Hospitalier Paris Saint-Joseph at the time and supportive care.", [["subcutaneous", "ANATOMY", 213, 225], ["anakinra", "CHEMICAL", 189, 197], ["anakinra", "CHEMICAL", 226, 234], ["patients", "ORGANISM", 4, 12], ["anakinra", "SIMPLE_CHEMICAL", 226, 234], ["patients", "SPECIES", 4, 12], ["the anakinra group", "TREATMENT", 185, 203], ["subcutaneous anakinra", "TREATMENT", 213, 234], ["the standard treatment", "TREATMENT", 375, 397], ["supportive care", "TREATMENT", 468, 483]]], ["The dose ofResearch in contextEvidence before this study With more than 5 103 000 reported cases in the world as of May 23, 2020, the COVID-19 pandemic has become a major cause of acute respiratory distress syndrome and mortality.", [["respiratory", "ANATOMY", 186, 197], ["acute respiratory distress syndrome", "DISEASE", 180, 215], ["The dose ofResearch", "TREATMENT", 0, 19], ["this study", "TEST", 46, 56], ["the COVID", "TEST", 130, 139], ["pandemic", "PROBLEM", 143, 151], ["acute respiratory distress syndrome", "PROBLEM", 180, 215], ["mortality", "PROBLEM", 220, 229], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["respiratory distress", "OBSERVATION", 186, 206]]], ["Analogy with previous outbreaks of other coronaviruses, combined with the accumulating evidence of the pivotal role of the inflammasome pathway in the life-threatening severe acute respiratory distress syndrome coronavirus 2-induced systemic disease, led us to consider interleukin-1 as a target of choice in this particular condition.Added value of this studyIn a cohort of patients with severe forms of COVID-19 who were treated with anakinra, administered subcutaneously at a dose of 100 mg twice daily for 3 days, then 100 mg daily for 7 days, we observed a significant reduction of mortality, along with a significant decrease in the need of mechanical invasive ventilation, with no obvious adverse events, including bacterial infections.Implications of all the available evidenceOur data suggest that an in-depth evaluation of anakinra in patients with an exacerbating form of COVID-19, mainly resulting from an otherwise uncontrolled cytokine storm, is warranted.Implications of all the available evidenceanakinra was adapted to renal function and reduced to one daily injection of 100 mg for 72 h, followed by an injection every other day for the next 7 days, in patients under dialysis or with a glomerular filtration rate of less than 30 mL/min.Implications of all the available evidencePatients in the historical group received the standard treatments and supportive care.", [["subcutaneously", "ANATOMY", 459, 473], ["renal", "ANATOMY", 1036, 1041], ["glomerular", "ANATOMY", 1205, 1215], ["coronaviruses", "DISEASE", 41, 54], ["acute respiratory distress syndrome", "DISEASE", 175, 210], ["systemic disease", "DISEASE", 233, 249], ["anakinra", "CHEMICAL", 436, 444], ["bacterial infections", "DISEASE", 722, 742], ["anakinra", "CHEMICAL", 833, 841], ["COVID-19", "CHEMICAL", 883, 891], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 270, 283], ["patients", "ORGANISM", 375, 383], ["anakinra", "SIMPLE_CHEMICAL", 436, 444], ["anakinra", "SIMPLE_CHEMICAL", 833, 841], ["patients", "ORGANISM", 845, 853], ["evidenceanakinra", "SIMPLE_CHEMICAL", 1004, 1020], ["renal", "ORGAN", 1036, 1041], ["patients", "ORGANISM", 1171, 1179], ["glomerular", "TISSUE", 1205, 1215], ["Patients", "ORGANISM", 1297, 1305], ["interleukin-1", "PROTEIN", 270, 283], ["cytokine", "PROTEIN", 941, 949], ["patients", "SPECIES", 375, 383], ["patients", "SPECIES", 845, 853], ["patients", "SPECIES", 1171, 1179], ["Patients", "SPECIES", 1297, 1305], ["other coronaviruses", "PROBLEM", 35, 54], ["threatening severe acute respiratory distress syndrome coronavirus", "PROBLEM", 156, 222], ["systemic disease", "PROBLEM", 233, 249], ["interleukin", "TREATMENT", 270, 281], ["this study", "TEST", 350, 360], ["severe forms of COVID", "PROBLEM", 389, 410], ["anakinra", "TREATMENT", 436, 444], ["a significant reduction of mortality", "PROBLEM", 560, 596], ["mechanical invasive ventilation", "TREATMENT", 647, 678], ["obvious adverse events", "PROBLEM", 688, 710], ["bacterial infections", "PROBLEM", 722, 742], ["Our data", "TEST", 785, 793], ["an in-depth evaluation", "TEST", 807, 829], ["anakinra", "TREATMENT", 833, 841], ["COVID", "TEST", 883, 888], ["an otherwise uncontrolled cytokine storm", "PROBLEM", 915, 955], ["dialysis", "TREATMENT", 1186, 1194], ["a glomerular filtration rate", "TREATMENT", 1203, 1231], ["the standard treatments", "TREATMENT", 1339, 1362], ["supportive care", "TREATMENT", 1367, 1382], ["coronaviruses", "OBSERVATION", 41, 54], ["inflammasome", "OBSERVATION", 123, 135], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["respiratory distress syndrome", "OBSERVATION", 181, 210], ["systemic", "OBSERVATION_MODIFIER", 233, 241], ["disease", "OBSERVATION", 242, 249], ["significant", "OBSERVATION_MODIFIER", 562, 573], ["reduction", "OBSERVATION_MODIFIER", 574, 583], ["significant", "OBSERVATION_MODIFIER", 611, 622], ["decrease", "OBSERVATION_MODIFIER", 623, 631], ["invasive ventilation", "OBSERVATION", 658, 678], ["no obvious", "UNCERTAINTY", 685, 695], ["bacterial", "OBSERVATION_MODIFIER", 722, 731], ["infections", "OBSERVATION", 732, 742], ["anakinra", "OBSERVATION", 833, 841], ["uncontrolled", "OBSERVATION_MODIFIER", 928, 940], ["cytokine storm", "OBSERVATION", 941, 955], ["renal", "ANATOMY", 1036, 1041]]], ["Standard treatments in Groupe Hospitalier Paris Saint-Joseph at the time included oral hydroxychloroquine 600 mg/day for 10 days, oral azithromycin 250 mg/day for 5 days, and paren teral \u03b2-lactam antibiotics (intravenous ceftriaxone 1 g per day or intravenous amoxicillin 3 g per day) for 7 days, in the absence of their respective contraindica tions.", [["oral", "ANATOMY", 82, 86], ["oral", "ANATOMY", 130, 134], ["intravenous", "ANATOMY", 209, 220], ["intravenous", "ANATOMY", 248, 259], ["hydroxychloroquine", "CHEMICAL", 87, 105], ["azithromycin", "CHEMICAL", 135, 147], ["\u03b2-lactam", "CHEMICAL", 187, 195], ["ceftriaxone", "CHEMICAL", 221, 232], ["amoxicillin", "CHEMICAL", 260, 271], ["hydroxychloroquine", "CHEMICAL", 87, 105], ["azithromycin", "CHEMICAL", 135, 147], ["ceftriaxone", "CHEMICAL", 221, 232], ["amoxicillin", "CHEMICAL", 260, 271], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 87, 105], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["azithromycin", "SIMPLE_CHEMICAL", 135, 147], ["paren teral \u03b2-lactam", "SIMPLE_CHEMICAL", 175, 195], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 209, 220], ["ceftriaxone", "SIMPLE_CHEMICAL", 221, 232], ["oral hydroxychloroquine", "TREATMENT", 82, 105], ["oral azithromycin", "TREATMENT", 130, 147], ["paren teral \u03b2-lactam antibiotics", "TREATMENT", 175, 207], ["intravenous ceftriaxone", "TREATMENT", 209, 232], ["intravenous amoxicillin", "TREATMENT", 248, 271]]], ["All patients received thromboembolic prophylaxis.", [["thromboembolic", "DISEASE", 22, 36], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["thromboembolic prophylaxis", "TREATMENT", 22, 48], ["thromboembolic prophylaxis", "OBSERVATION", 22, 48]]], ["No oral cortico steroids or vasopressors were used, but some patients received an intravenous bolus of methylprednisolone (500 mg).", [["oral", "ANATOMY", 3, 7], ["intravenous", "ANATOMY", 82, 93], ["steroids", "CHEMICAL", 16, 24], ["methylprednisolone", "CHEMICAL", 103, 121], ["steroids", "CHEMICAL", 16, 24], ["methylprednisolone", "CHEMICAL", 103, 121], ["oral", "ORGANISM_SUBDIVISION", 3, 7], ["patients", "ORGANISM", 61, 69], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 93], ["methylprednisolone", "SIMPLE_CHEMICAL", 103, 121], ["patients", "SPECIES", 61, 69], ["oral cortico steroids", "TREATMENT", 3, 24], ["vasopressors", "TREATMENT", 28, 40], ["an intravenous bolus of methylprednisolone", "TREATMENT", 79, 121]]], ["Supportive care included low-flow oxygen therapy (\u22646 L/min through low-flow nasal cannula) or high-flow oxygen therapy (>6 L/min with high-flow nasal cannula or face mask).", [["nasal", "ANATOMY", 76, 81], ["nasal", "ANATOMY", 144, 149], ["face", "ANATOMY", 161, 165], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 104, 110], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 104, 110], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["oxygen", "SIMPLE_CHEMICAL", 104, 110], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 144, 157], ["Supportive care", "TREATMENT", 0, 15], ["low-flow oxygen therapy", "TREATMENT", 25, 48], ["low-flow nasal cannula", "TREATMENT", 67, 89], ["high-flow oxygen therapy", "TREATMENT", 94, 118], ["high-flow nasal cannula", "TREATMENT", 134, 157], ["face mask", "TREATMENT", 161, 170], ["flow oxygen therapy", "OBSERVATION", 29, 48], ["flow oxygen", "OBSERVATION", 99, 110]]], ["None of the patients had invasive or non-invasive mechanical ventila tion at baseline.Implications of all the available evidenceAll data were extracted from our computerised medical record (DxCare [version 12.2.0.1.0], Medasys, Le Plessis-Robinson, France) by two investigators (TH and GD) independently.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Data were confidentially collected and coded according to the local cohort statements responding to all regulatory points in accordance with French regulations (law 78-17 of Jan 6, 1978, relating to data processing, files, and freedoms) and European General Data Protection Regulation regarding patient information and confidential treatment of all data.", [["patient", "ORGANISM", 295, 302], ["patient", "SPECIES", 295, 302]]], ["The study design and data collection were approved by the institutional review board.", [["The study", "TEST", 0, 9], ["data collection", "TEST", 21, 36]]], ["All data were monitored by a representative of Groupe Hospitalier Paris Saint-Joseph.", [["All data", "TEST", 0, 8]]], ["The database was frozen for statistical analysis on April 11, 2020.", [["statistical analysis", "TEST", 28, 48]]], ["The computerised file used for this research was implemented in accordance with French regulations (law 78-17 of Jan 6, 1978, relating to data processing, files, and freedoms) and European General Data Protection Regulation.Implications of all the available evidenceDemographic and medical characteristics, including age, sex, body-mass index (BMI), hypertension, diabetes, cardiopathy, stroke, asthma, emphysema, sleep apnoea, chronic obstructive pulmonary disease, not to be resuscitated status, the severity of the CT lung damage, and the value of the RT-PCR assay at the diagnosis, were recorded from the medical charts.", [["body", "ANATOMY", 327, 331], ["pulmonary", "ANATOMY", 448, 457], ["lung", "ANATOMY", 521, 525], ["hypertension", "DISEASE", 350, 362], ["diabetes", "DISEASE", 364, 372], ["cardiopathy", "DISEASE", 374, 385], ["stroke", "DISEASE", 387, 393], ["asthma", "DISEASE", 395, 401], ["emphysema", "DISEASE", 403, 412], ["sleep apnoea", "DISEASE", 414, 426], ["chronic obstructive pulmonary disease", "DISEASE", 428, 465], ["lung damage", "DISEASE", 521, 532], ["body", "ORGANISM_SUBDIVISION", 327, 331], ["pulmonary", "ORGAN", 448, 457], ["lung", "ORGAN", 521, 525], ["hypertension", "PROBLEM", 350, 362], ["diabetes", "PROBLEM", 364, 372], ["cardiopathy", "PROBLEM", 374, 385], ["stroke", "PROBLEM", 387, 393], ["asthma", "PROBLEM", 395, 401], ["emphysema", "PROBLEM", 403, 412], ["sleep apnoea", "PROBLEM", 414, 426], ["chronic obstructive pulmonary disease", "PROBLEM", 428, 465], ["the CT lung damage", "PROBLEM", 514, 532], ["the RT-PCR assay", "TEST", 551, 567], ["hypertension", "OBSERVATION", 350, 362], ["diabetes", "OBSERVATION", 364, 372], ["cardiopathy", "OBSERVATION", 374, 385], ["stroke", "OBSERVATION", 387, 393], ["asthma", "OBSERVATION", 395, 401], ["emphysema", "OBSERVATION", 403, 412], ["sleep apnoea", "OBSERVATION", 414, 426], ["chronic", "OBSERVATION_MODIFIER", 428, 435], ["obstructive", "OBSERVATION_MODIFIER", 436, 447], ["pulmonary", "ANATOMY", 448, 457], ["disease", "OBSERVATION", 458, 465], ["lung", "ANATOMY", 521, 525], ["damage", "OBSERVATION", 526, 532]]], ["Clinical manifestations, including persistent fever above 38\u00b0C, respiratory rate, oxygen saturation, and oxygen therapy requirement, and bio logical parameters, including neutrophil, lymphocyte, and platelet count, C-reactive protein (CRP), alanine and aspartate aminotransferase, creatinine, lactate dehydro genase, IL-6, serum ferritin, and D dimer, were recorded at baseline and at discharge from hospital or death.Implications of all the available evidenceNot to be resuscitated meant that patient was not eligible for transfer to the ICU.", [["respiratory", "ANATOMY", 64, 75], ["neutrophil", "ANATOMY", 171, 181], ["lymphocyte", "ANATOMY", 183, 193], ["platelet", "ANATOMY", 199, 207], ["serum", "ANATOMY", 323, 328], ["fever", "DISEASE", 46, 51], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 105, 111], ["alanine", "CHEMICAL", 241, 248], ["aspartate", "CHEMICAL", 253, 262], ["creatinine", "CHEMICAL", 281, 291], ["lactate", "CHEMICAL", 293, 300], ["death", "DISEASE", 412, 417], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 105, 111], ["alanine", "CHEMICAL", 241, 248], ["aspartate", "CHEMICAL", 253, 262], ["creatinine", "CHEMICAL", 281, 291], ["lactate", "CHEMICAL", 293, 300], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["neutrophil", "CELL", 171, 181], ["lymphocyte", "CELL", 183, 193], ["platelet", "CELL", 199, 207], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 215, 233], ["CRP", "GENE_OR_GENE_PRODUCT", 235, 238], ["alanine", "AMINO_ACID", 241, 248], ["aspartate aminotransferase", "SIMPLE_CHEMICAL", 253, 279], ["creatinine", "SIMPLE_CHEMICAL", 281, 291], ["lactate dehydro genase", "GENE_OR_GENE_PRODUCT", 293, 315], ["IL-6", "GENE_OR_GENE_PRODUCT", 317, 321], ["serum", "ORGANISM_SUBSTANCE", 323, 328], ["ferritin", "GENE_OR_GENE_PRODUCT", 329, 337], ["D dimer", "SIMPLE_CHEMICAL", 343, 350], ["patient", "ORGANISM", 494, 501], ["neutrophil", "CELL_TYPE", 171, 181], ["lymphocyte", "CELL_TYPE", 183, 193], ["C-reactive protein", "PROTEIN", 215, 233], ["CRP", "PROTEIN", 235, 238], ["aspartate aminotransferase", "PROTEIN", 253, 279], ["lactate dehydro genase", "PROTEIN", 293, 315], ["IL-6", "PROTEIN", 317, 321], ["serum ferritin", "PROTEIN", 323, 337], ["D dimer", "PROTEIN", 343, 350], ["patient", "SPECIES", 494, 501], ["Clinical manifestations", "PROBLEM", 0, 23], ["persistent fever", "PROBLEM", 35, 51], ["respiratory rate", "TEST", 64, 80], ["oxygen saturation", "TEST", 82, 99], ["oxygen therapy requirement", "TREATMENT", 105, 131], ["bio logical parameters", "TEST", 137, 159], ["neutrophil", "TEST", 171, 181], ["lymphocyte", "TEST", 183, 193], ["platelet count", "TEST", 199, 213], ["C", "TEST", 215, 216], ["reactive protein", "TEST", 217, 233], ["CRP", "TEST", 235, 238], ["alanine", "TEST", 241, 248], ["aspartate aminotransferase", "TEST", 253, 279], ["creatinine", "TEST", 281, 291], ["lactate dehydro genase", "TEST", 293, 315], ["IL", "TEST", 317, 319], ["serum ferritin", "TEST", 323, 337], ["persistent", "OBSERVATION_MODIFIER", 35, 45], ["fever", "OBSERVATION", 46, 51], ["oxygen saturation", "OBSERVATION", 82, 99], ["oxygen therapy", "OBSERVATION", 105, 119], ["lymphocyte", "ANATOMY", 183, 193], ["platelet count", "OBSERVATION", 199, 213], ["D dimer", "OBSERVATION_MODIFIER", 343, 350]]], ["The limitation of care was based mainly on age and comorbidities, along with the opinion of the physician in charge of the patient, with the help of an ad hoc ethics committee.Implications of all the available evidenceChest CT was done with a single inspiratory phase with patients in the supine position.", [["patient", "ORGANISM", 123, 130], ["patients", "ORGANISM", 273, 281], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 273, 281], ["Chest CT", "TEST", 218, 226], ["a single inspiratory phase", "TEST", 241, 267]]], ["Radiologists classified the CT as typical, equivocal, or negative for COVID-19 and described the main CT features: groundglass opacity, crazy-paving pattern, and consolidation.", [["COVID-19", "DNA", 70, 78], ["the CT", "TEST", 24, 30], ["COVID", "TEST", 70, 75], ["groundglass opacity", "PROBLEM", 115, 134], ["crazy", "PROBLEM", 136, 141], ["consolidation", "PROBLEM", 162, 175], ["groundglass opacity", "OBSERVATION", 115, 134], ["crazy", "OBSERVATION_MODIFIER", 136, 141], ["paving pattern", "OBSERVATION", 142, 156], ["consolidation", "OBSERVATION", 162, 175]]], ["A semi-quanti tative scoring system was used to estimate the pulmonary involvement of all of these abnormalities on the basis of the area involved: less than 25% (mild involvement); 25-50% (moderate involvement); 51-75% (severe involve ment); or more than 75% (diffuse involvement).", [["pulmonary", "ANATOMY", 61, 70], ["pulmonary", "ORGAN", 61, 70], ["ment", "CANCER", 236, 240], ["the pulmonary involvement", "PROBLEM", 57, 82], ["these abnormalities", "PROBLEM", 93, 112], ["mild involvement)", "PROBLEM", 163, 180], ["moderate involvement)", "PROBLEM", 190, 211], ["diffuse involvement)", "PROBLEM", 261, 281], ["pulmonary", "ANATOMY", 61, 70], ["involvement", "OBSERVATION", 71, 82], ["abnormalities", "OBSERVATION", 99, 112], ["mild", "OBSERVATION_MODIFIER", 163, 167], ["moderate", "OBSERVATION_MODIFIER", 190, 198], ["diffuse", "OBSERVATION_MODIFIER", 261, 268]]], ["11OutcomesThe main outcome was the composite of either need for admission to the ICU with invasive mechanical ventilation or death.", [["death", "DISEASE", 125, 130], ["invasive mechanical ventilation", "TREATMENT", 90, 121], ["death", "PROBLEM", 125, 130], ["main", "OBSERVATION_MODIFIER", 14, 18], ["mechanical ventilation", "OBSERVATION", 99, 121]]], ["The other outcomes were death, need for invasive mechanical ventilation, difference in the mean oxygen therapy requirements between day 0 and day 7, and changes in CRP con centration from day -4 until discharge from hospital or death.", [["death", "DISEASE", 24, 29], ["oxygen", "CHEMICAL", 96, 102], ["death", "DISEASE", 228, 233], ["oxygen", "CHEMICAL", 96, 102], ["oxygen", "SIMPLE_CHEMICAL", 96, 102], ["CRP", "GENE_OR_GENE_PRODUCT", 164, 167], ["CRP", "PROTEIN", 164, 167], ["death", "PROBLEM", 24, 29], ["invasive mechanical ventilation", "TREATMENT", 40, 71], ["the mean oxygen therapy requirements", "TREATMENT", 87, 123], ["CRP", "TEST", 164, 167], ["death", "PROBLEM", 228, 233], ["oxygen therapy", "OBSERVATION", 96, 110]]], ["In the anakinra group, day 0 corresponds to the date of initiation of anakinra.", [["anakinra", "CHEMICAL", 7, 15], ["anakinra", "CHEMICAL", 70, 78], ["anakinra", "SIMPLE_CHEMICAL", 7, 15], ["anakinra", "SIMPLE_CHEMICAL", 70, 78], ["anakinra", "TREATMENT", 70, 78]]], ["In the historical group, day 0 corresponds to the first day during which each patient fulfilled the inclusion criteria defined for the anakinra group.", [["anakinra", "CHEMICAL", 135, 143], ["patient", "ORGANISM", 78, 85], ["anakinra", "SIMPLE_CHEMICAL", 135, 143], ["patient", "SPECIES", 78, 85], ["the anakinra group", "TREATMENT", 131, 149]]], ["Safety outcomes were an increase in liver aminotransferase enzymes (more than three times the upper limit of normal), thromboembolic events (con firmed by a CT pulmonary angiogram for pulmonary embolism and by a venous doppler for deep vein thrombosis of the lower limbs), bacteraemia (confirmed when the patient had a recognised pathogen cultured from one or more blood cultures), and premature dis continuation of treatment.Statistical analysisThe original total sample size of the prospective cohort study was arbitrarily set at 50 patients in the absence of information on treatment effect.", [["liver", "ANATOMY", 36, 41], ["pulmonary", "ANATOMY", 160, 169], ["pulmonary", "ANATOMY", 184, 193], ["venous", "ANATOMY", 212, 218], ["deep vein", "ANATOMY", 231, 240], ["lower limbs", "ANATOMY", 259, 270], ["blood cultures", "ANATOMY", 365, 379], ["thromboembolic", "DISEASE", 118, 132], ["pulmonary embolism", "DISEASE", 184, 202], ["thrombosis", "DISEASE", 241, 251], ["bacteraemia", "DISEASE", 273, 284], ["liver", "ORGAN", 36, 41], ["aminotransferase enzymes", "GENE_OR_GENE_PRODUCT", 42, 66], ["pulmonary", "ORGAN", 160, 169], ["pulmonary", "ORGAN", 184, 193], ["venous", "MULTI-TISSUE_STRUCTURE", 212, 218], ["deep vein", "MULTI-TISSUE_STRUCTURE", 231, 240], ["lower limbs", "ORGANISM_SUBDIVISION", 259, 270], ["patient", "ORGANISM", 305, 312], ["blood", "ORGANISM_SUBSTANCE", 365, 370], ["patients", "ORGANISM", 535, 543], ["liver aminotransferase enzymes", "PROTEIN", 36, 66], ["patient", "SPECIES", 305, 312], ["patients", "SPECIES", 535, 543], ["liver aminotransferase enzymes", "TEST", 36, 66], ["thromboembolic events", "PROBLEM", 118, 139], ["a CT pulmonary angiogram", "TEST", 155, 179], ["pulmonary embolism", "PROBLEM", 184, 202], ["a venous doppler", "TEST", 210, 226], ["deep vein thrombosis of the lower limbs", "PROBLEM", 231, 270], ["bacteraemia", "PROBLEM", 273, 284], ["a recognised pathogen", "PROBLEM", 317, 338], ["blood cultures", "TEST", 365, 379], ["treatment", "TREATMENT", 416, 425], ["Statistical analysis", "TEST", 426, 446], ["the prospective cohort study", "TEST", 480, 508], ["treatment effect", "TREATMENT", 577, 593], ["liver", "ANATOMY", 36, 41], ["upper limit", "OBSERVATION_MODIFIER", 94, 105], ["thromboembolic", "OBSERVATION", 118, 132], ["pulmonary", "ANATOMY", 160, 169], ["pulmonary", "ANATOMY", 184, 193], ["embolism", "OBSERVATION", 194, 202], ["deep vein", "ANATOMY", 231, 240], ["thrombosis", "OBSERVATION", 241, 251], ["lower limbs", "ANATOMY", 259, 270], ["bacteraemia", "OBSERVATION", 273, 284], ["total", "OBSERVATION_MODIFIER", 459, 464], ["size", "OBSERVATION_MODIFIER", 472, 476]]], ["In a classic two-arm trial, with 50 patients per group, there would be 86% power to detect a 50% risk reduction of the primary endpoint, at a two-sided significance level of \u03b1=0\u00b705 and assuming a 60% incidence of the primary endpoint.Statistical analysisWe did the main efficacy analysis on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra).", [["anakinra", "CHEMICAL", 350, 358], ["anakinra", "CHEMICAL", 404, 412], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 334, 342], ["anakinra", "SIMPLE_CHEMICAL", 404, 412], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 334, 342], ["the anakinra group", "TREATMENT", 346, 364], ["anakinra", "TREATMENT", 404, 412], ["arm", "ANATOMY", 17, 20]]], ["We analysed time-dependent events with a two-sided log-rank test, with the hazard ratio (HR) and two-sided 95% CIs based on a Cox proportional hazards model and the associated Kaplan-Meier survival estimates.", [["the hazard ratio", "TEST", 71, 87], ["a Cox proportional hazards model", "PROBLEM", 124, 156]]], ["Patients alive were censored on the date of discharge from hospital.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We used a multivariate Cox proportional hazards model to take into account effect of covariates on the estimate of treatment effect.", [["a multivariate Cox proportional hazards model", "TREATMENT", 8, 53], ["treatment effect", "TREATMENT", 115, 131]]], ["Variables were included in the model when they differed statistically between the two groups (p value threshold of <0\u00b705) or when the absolute difference between the two groups (qualitative variables) was greater than 10%.Statistical analysisWe compared characteristics of the two groups by use of the \u03c7\u00b2 test or Fisher test when appropriate, for categorical variables and the Student's t test for continuous variables.", [["p value threshold", "TEST", 94, 111], ["the \u03c7\u00b2 test", "TEST", 298, 309], ["Fisher test", "TEST", 313, 324], ["the Student's t test", "TEST", 373, 393]]], ["We used a repeated-measures mixed-model testing group effect to analyse CRP concentrations changes over time.", [["CRP", "GENE_OR_GENE_PRODUCT", 72, 75], ["CRP", "PROTEIN", 72, 75], ["a repeated-measures mixed-model testing group effect", "TREATMENT", 8, 60], ["CRP concentrations changes", "PROBLEM", 72, 98]]], ["A p value of less than 0\u00b705 was deemed to be significant.Statistical analysisWe used the SAS (version 9.4) for analyses.Role of the funding sourceThe funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.", [["A p value", "TEST", 0, 9], ["the SAS", "TEST", 85, 92], ["version", "TEST", 94, 101], ["analyses", "TEST", 111, 119], ["the study", "TEST", 160, 169], ["data collection", "TEST", 199, 214], ["data analysis", "TEST", 216, 229], ["data interpretation", "TEST", 231, 250], ["significant", "OBSERVATION_MODIFIER", 45, 56]]], ["TH, HB, SJ, ES, GC, and GH had access to the raw data.", [["TH", "GENE_OR_GENE_PRODUCT", 0, 2], ["HB", "ANATOMY", 4, 6], ["SJ", "ANATOMY", 8, 10]]], ["The corresponding author had full access to all of the data and the final responsibility to submit for publication.ResultsFrom March 24 to April 6, 2020, 52 consecutive patients were included in the anakinra group and 44 historical patients were identified in the Groupe Hospitalier Paris Saint-Joseph COVID cohort study.", [["patients", "ORGANISM", 169, 177], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 232, 240], ["the data", "TEST", 51, 59]]], ["Clinical, biological, and CT-scan characteristics of the patients in the two groups are compared in Data are mean (SD) or n (%). *Pulmonary disease included asthma, emphysema, sleep apnoea, and chronic obstructive pulmonary disease. \u2020Swab RT-PCR was not done for 11 patients in the anakinra group and ten patients in the historical group. \u2021In the historical group, six patients had a chest x-ray that demonstrated bilateral pneumonia, and no chest CT was done. \u00a7Aggravation was defined by a loss of 3% of the oxygen saturation in ambient air over the last 24 h.", [["Pulmonary", "ANATOMY", 130, 139], ["pulmonary", "ANATOMY", 214, 223], ["chest", "ANATOMY", 442, 447], ["Pulmonary disease", "DISEASE", 130, 147], ["asthma", "DISEASE", 157, 163], ["emphysema", "DISEASE", 165, 174], ["sleep apnoea", "DISEASE", 176, 188], ["chronic obstructive pulmonary disease", "DISEASE", 194, 231], ["anakinra", "CHEMICAL", 282, 290], ["pneumonia", "DISEASE", 424, 433], ["oxygen", "CHEMICAL", 509, 515], ["oxygen", "CHEMICAL", 509, 515], ["patients", "ORGANISM", 57, 65], ["Pulmonary", "ORGAN", 130, 139], ["pulmonary", "ORGAN", 214, 223], ["patients", "ORGANISM", 266, 274], ["patients", "ORGANISM", 305, 313], ["patients", "ORGANISM", 369, 377], ["oxygen", "SIMPLE_CHEMICAL", 509, 515], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 266, 274], ["patients", "SPECIES", 305, 313], ["patients", "SPECIES", 369, 377], ["CT-scan characteristics", "TEST", 26, 49], ["Pulmonary disease", "PROBLEM", 130, 147], ["asthma", "PROBLEM", 157, 163], ["emphysema", "PROBLEM", 165, 174], ["sleep apnoea", "PROBLEM", 176, 188], ["chronic obstructive pulmonary disease", "PROBLEM", 194, 231], ["Swab RT-PCR", "TEST", 234, 245], ["the anakinra group", "TREATMENT", 278, 296], ["a chest x-ray", "TEST", 382, 395], ["bilateral pneumonia", "PROBLEM", 414, 433], ["chest CT", "TEST", 442, 450], ["Aggravation", "PROBLEM", 462, 473], ["the oxygen saturation", "TEST", 505, 526], ["Pulmonary", "ANATOMY", 130, 139], ["disease", "OBSERVATION", 140, 147], ["asthma", "OBSERVATION", 157, 163], ["emphysema", "OBSERVATION", 165, 174], ["sleep apnoea", "OBSERVATION", 176, 188], ["chronic", "OBSERVATION_MODIFIER", 194, 201], ["obstructive", "OBSERVATION_MODIFIER", 202, 213], ["pulmonary", "ANATOMY", 214, 223], ["disease", "OBSERVATION", 224, 231], ["chest", "ANATOMY", 384, 389], ["bilateral", "ANATOMY_MODIFIER", 414, 423], ["pneumonia", "OBSERVATION", 424, 433], ["no", "UNCERTAINTY", 439, 441], ["chest", "ANATOMY", 442, 447], ["oxygen saturation", "OBSERVATION", 509, 526], ["ambient air", "OBSERVATION", 530, 541]]], ["Among the 39 patients in the anakinra group who were alive and did not require mechanical ventilation, the mean need for oxygen decreased from a median of 7 L/min (IQR 6-9) at day 0 to a median of 2 L/min (0-4) at day 7 (two missing values).", [["oxygen", "CHEMICAL", 121, 127], ["oxygen", "CHEMICAL", 121, 127], ["patients", "ORGANISM", 13, 21], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["patients", "SPECIES", 13, 21], ["mechanical ventilation", "TREATMENT", 79, 101], ["oxygen", "TREATMENT", 121, 127]]], ["The median difference was -4 L/min (IQR 0-4; p<0\u00b70001, signed-rank test).ResultsFrom day -4 to day 0, there was a sharp increase in CRP concentration followed by a decrease as early as day 4 of treatment in the anakinra group (figure 2).", [["anakinra", "CHEMICAL", 211, 219], ["CRP", "GENE_OR_GENE_PRODUCT", 132, 135], ["anakinra", "SIMPLE_CHEMICAL", 211, 219], ["CRP", "PROTEIN", 132, 135], ["IQR", "TEST", 36, 39], ["a sharp increase in CRP concentration", "PROBLEM", 112, 149], ["treatment in the anakinra group", "TREATMENT", 194, 225], ["sharp", "OBSERVATION_MODIFIER", 114, 119], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["CRP concentration", "OBSERVATION_MODIFIER", 132, 149], ["decrease", "OBSERVATION_MODIFIER", 164, 172]]], ["This result contrasts with the relative stability of CRP concentration over the same time period in the historical group.", [["CRP", "GENE_OR_GENE_PRODUCT", 53, 56], ["CRP", "PROTEIN", 53, 56], ["CRP concentration", "PROBLEM", 53, 70], ["stability", "OBSERVATION_MODIFIER", 40, 49]]], ["The difference between the two groups was significant (p<0\u00b70001; interaction test, mixed model).", [["interaction test", "TEST", 65, 81]]], ["At day 0, 45 (87%) patients in the anakinra group and 36 (82%) patients in the historical group had a CRP concentration higher than 100 mg/L. No patient had a CRP concentration lower than 50 mg/L in both groups.ResultsSeven (13%) patients in the anakinra group and four (9%) patients in the historical group had an increase in liver aminotransferase (more than three times the upper limit of normal).", [["liver", "ANATOMY", 327, 332], ["anakinra", "CHEMICAL", 35, 43], ["anakinra", "CHEMICAL", 246, 254], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 63, 71], ["CRP", "GENE_OR_GENE_PRODUCT", 102, 105], ["patient", "ORGANISM", 145, 152], ["CRP", "GENE_OR_GENE_PRODUCT", 159, 162], ["patients", "ORGANISM", 230, 238], ["patients", "ORGANISM", 275, 283], ["liver", "ORGAN", 327, 332], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 333, 349], ["CRP", "PROTEIN", 102, 105], ["CRP", "PROTEIN", 159, 162], ["liver aminotransferase", "PROTEIN", 327, 349], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 63, 71], ["patient", "SPECIES", 145, 152], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 275, 283], ["a CRP concentration", "TEST", 100, 119], ["a CRP concentration", "TEST", 157, 176], ["an increase in liver aminotransferase", "PROBLEM", 312, 349], ["increase", "OBSERVATION_MODIFIER", 315, 323], ["liver", "ANATOMY", 327, 332], ["upper limit", "OBSERVATION_MODIFIER", 377, 388], ["normal", "OBSERVATION", 392, 398]]], ["Ten (19%) patients in the anakinra group and five (11%) in the historical group developed a thromboembolic event during the hospital stay.", [["anakinra", "CHEMICAL", 26, 34], ["thromboembolic", "DISEASE", 92, 106], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["a thromboembolic event", "PROBLEM", 90, 112], ["thromboembolic", "OBSERVATION", 92, 106]]], ["Among the anakinra group, seven (13%) had a pulmonary embolism, three (6%) had deep vein thrombosis of the lower limbs, and one (2%) had arterial thrombosis.", [["pulmonary", "ANATOMY", 44, 53], ["deep vein", "ANATOMY", 79, 88], ["lower limbs", "ANATOMY", 107, 118], ["arterial", "ANATOMY", 137, 145], ["anakinra", "CHEMICAL", 10, 18], ["pulmonary embolism", "DISEASE", 44, 62], ["vein thrombosis of the lower limbs", "DISEASE", 84, 118], ["arterial thrombosis", "DISEASE", 137, 156], ["pulmonary", "ORGAN", 44, 53], ["vein", "MULTI-TISSUE_STRUCTURE", 84, 88], ["lower limbs", "ORGANISM_SUBDIVISION", 107, 118], ["arterial", "MULTI-TISSUE_STRUCTURE", 137, 145], ["the anakinra group", "TEST", 6, 24], ["a pulmonary embolism", "PROBLEM", 42, 62], ["deep vein thrombosis of the lower limbs", "PROBLEM", 79, 118], ["arterial thrombosis", "PROBLEM", 137, 156], ["anakinra", "OBSERVATION", 10, 18], ["pulmonary", "ANATOMY", 44, 53], ["embolism", "OBSERVATION", 54, 62], ["deep", "ANATOMY_MODIFIER", 79, 83], ["vein", "ANATOMY", 84, 88], ["thrombosis", "OBSERVATION", 89, 99], ["lower limbs", "ANATOMY", 107, 118], ["arterial", "ANATOMY", 137, 145], ["thrombosis", "OBSERVATION", 146, 156]]], ["None of the patients in the anakinra group had a documented bacterial infection during the hospital stay.DiscussionIn this cohort study, anakinra significantly reduced both need for invasive mechanical ventilation in the ICU and mortality among patients with severe COVID-19, without serious side-effects.", [["anakinra", "CHEMICAL", 28, 36], ["bacterial infection", "DISEASE", 60, 79], ["anakinra", "CHEMICAL", 137, 145], ["COVID-19", "CHEMICAL", 266, 274], ["COVID-19", "CHEMICAL", 266, 274], ["patients", "ORGANISM", 12, 20], ["anakinra", "SIMPLE_CHEMICAL", 137, 145], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 245, 253], ["a documented bacterial infection", "PROBLEM", 47, 79], ["this cohort study", "TEST", 118, 135], ["anakinra", "TREATMENT", 137, 145], ["invasive mechanical ventilation", "TREATMENT", 182, 213], ["severe COVID", "PROBLEM", 259, 271], ["serious side-effects", "PROBLEM", 284, 304], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["infection", "OBSERVATION", 70, 79]]], ["So far, no specific treatment has been shown to reduce the need for invasive mechanical ventilation and intensive care in patients admitted for COVID-19-associated pneumonia requiring oxygen therapy.", [["COVID-19", "CHEMICAL", 144, 152], ["pneumonia", "DISEASE", 164, 173], ["oxygen", "CHEMICAL", 184, 190], ["COVID-19", "CHEMICAL", 144, 152], ["oxygen", "CHEMICAL", 184, 190], ["patients", "ORGANISM", 122, 130], ["oxygen", "SIMPLE_CHEMICAL", 184, 190], ["patients", "SPECIES", 122, 130], ["specific treatment", "TREATMENT", 11, 29], ["invasive mechanical ventilation", "TREATMENT", 68, 99], ["intensive care", "TREATMENT", 104, 118], ["COVID", "TREATMENT", 144, 149], ["pneumonia", "PROBLEM", 164, 173], ["oxygen therapy", "TREATMENT", 184, 198], ["pneumonia", "OBSERVATION", 164, 173], ["oxygen therapy", "OBSERVATION", 184, 198]]], ["A number of ongoing trials are currently testing various pharmacological approaches.", [["ongoing trials", "TREATMENT", 12, 26]]], ["12 A randomised, controlled, open-label trial of lopinavirritonavir in adults with confirmed COVID-19 did not show any beneficial effect in terms of either clinical improvement or mortality.", [["lopinavirritonavir", "CHEMICAL", 49, 67], ["lopinavirritonavir", "CHEMICAL", 49, 67], ["COVID-19", "CHEMICAL", 93, 101], ["lopinavirritonavir", "SIMPLE_CHEMICAL", 49, 67], ["lopinavirritonavir", "TREATMENT", 49, 67], ["COVID", "TEST", 93, 98]]], ["13 Remdesivir, a new nucleoside analogue prodrug that inhibits RNA polymerase, was administered to 61 patients on a compassionate-use basis, with a clinical improvement seen in 36 (68%) of 53 patients with available data, but a randomised, Table 2 : Estimation of anakinra effect on the composite of invasive mechanical ventilation in the ICU or death, after adjustment for potential confounding factors, using a multivariable Cox proportional hazards modelFigure 1: Kaplan-Meier cumulative estimates of probability of death or invasive mechanical ventilation in the ICU (A), death (B) and invasive mechanical ventilation in the ICU (C) in the anakinra group compared with the historical groupHR=hazard ratio.", [["Remdesivir", "CHEMICAL", 3, 13], ["nucleoside", "CHEMICAL", 21, 31], ["death", "DISEASE", 346, 351], ["death", "DISEASE", 519, 524], ["death", "DISEASE", 576, 581], ["anakinra", "CHEMICAL", 644, 652], ["Remdesivir", "CHEMICAL", 3, 13], ["nucleoside", "CHEMICAL", 21, 31], ["Remdesivir", "SIMPLE_CHEMICAL", 3, 13], ["nucleoside analogue prodrug", "SIMPLE_CHEMICAL", 21, 48], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 192, 200], ["RNA polymerase", "PROTEIN", 63, 77], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 192, 200], ["Remdesivir", "TREATMENT", 3, 13], ["a new nucleoside analogue prodrug", "TREATMENT", 15, 48], ["RNA polymerase", "PROBLEM", 63, 77], ["anakinra effect", "PROBLEM", 264, 279], ["invasive mechanical ventilation", "TREATMENT", 300, 331], ["death", "PROBLEM", 346, 351], ["potential confounding factors", "PROBLEM", 374, 403], ["a multivariable Cox proportional hazards model", "TREATMENT", 411, 457], ["death", "PROBLEM", 519, 524], ["invasive mechanical ventilation", "TREATMENT", 528, 559], ["invasive mechanical ventilation", "TREATMENT", 590, 621], ["the anakinra group", "TREATMENT", 640, 658], ["mechanical ventilation", "OBSERVATION", 309, 331], ["invasive", "OBSERVATION_MODIFIER", 528, 536], ["mechanical ventilation", "OBSERVATION", 537, 559], ["invasive", "OBSERVATION_MODIFIER", 590, 598], ["mechanical ventilation", "OBSERVATION", 599, 621]]], ["ICU=intensive care unit.Number at risk (number censored)Anakinra group double-blind, placebo-controlled trial, which included 237 patients, found no clinical benefit of remdesivir versus placebo.", [["remdesivir", "CHEMICAL", 169, 179], ["remdesivir", "CHEMICAL", 169, 179], ["patients", "ORGANISM", 130, 138], ["remdesivir", "SIMPLE_CHEMICAL", 169, 179], ["patients", "SPECIES", 130, 138], ["Anakinra group double-blind", "TREATMENT", 56, 83], ["placebo", "TREATMENT", 85, 92], ["remdesivir", "TREATMENT", 169, 179], ["placebo", "TREATMENT", 187, 194]]], ["14, 15 The current absence of evidence for antiviral drug efficacy, along with the high mortality associated with severe COVID-19, raises the question of the respective roles of the virus itself and the subsequent occurrence of hyperinflammation, or the so-called cytokine storm.", [["hyperinflammation", "DISEASE", 228, 245], ["COVID-19", "CHEMICAL", 121, 129], ["cytokine", "PROTEIN", 264, 272], ["antiviral drug efficacy", "PROBLEM", 43, 66], ["the high mortality", "PROBLEM", 79, 97], ["severe COVID", "PROBLEM", 114, 126], ["the virus", "PROBLEM", 178, 187], ["hyperinflammation", "PROBLEM", 228, 245], ["evidence for", "UNCERTAINTY", 30, 42], ["antiviral drug", "OBSERVATION", 43, 57], ["virus", "OBSERVATION", 182, 187], ["cytokine storm", "OBSERVATION", 264, 278]]], ["In a study of 150 confirmed COVID-19 cases, predictors of mortality included elevated concentrations of ferritin and IL-6, suggesting a virally driven hyper inflammation, 16 sharing common features with other auto inflammatory disorders, either inherited or acquired (such as adult Still's disease, macrophage activation syndrome, haemophagocytic lymphohistiocytosis, or chimeric antigen receptor [CAR] T-cell-mediated cytokine release syndrome).", [["macrophage", "ANATOMY", 299, 309], ["T-cell", "ANATOMY", 403, 409], ["hyper inflammation", "DISEASE", 151, 169], ["inflammatory disorders", "DISEASE", 214, 236], ["Still's disease", "DISEASE", 282, 297], ["haemophagocytic lymphohistiocytosis", "DISEASE", 331, 366], ["ferritin", "GENE_OR_GENE_PRODUCT", 104, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["macrophage", "CELL", 299, 309], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 371, 396], ["CAR", "GENE_OR_GENE_PRODUCT", 398, 401], ["ferritin", "PROTEIN", 104, 112], ["IL-6", "PROTEIN", 117, 121], ["chimeric antigen receptor", "PROTEIN", 371, 396], ["CAR", "PROTEIN", 398, 401], ["cytokine", "PROTEIN", 419, 427], ["a study", "TEST", 3, 10], ["COVID", "TEST", 28, 33], ["elevated concentrations of ferritin", "PROBLEM", 77, 112], ["IL", "TEST", 117, 119], ["a virally driven hyper inflammation", "PROBLEM", 134, 169], ["other auto inflammatory disorders", "PROBLEM", 203, 236], ["adult Still's disease", "PROBLEM", 276, 297], ["macrophage activation syndrome", "PROBLEM", 299, 329], ["haemophagocytic lymphohistiocytosis", "PROBLEM", 331, 366], ["chimeric antigen receptor", "PROBLEM", 371, 396], ["CAR] T-cell-mediated cytokine release syndrome", "TREATMENT", 398, 444], ["inflammation", "OBSERVATION", 157, 169], ["macrophage activation syndrome", "OBSERVATION", 299, 329], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 331, 366]]], ["Furthermore, pul monary involve ment (including ARDS) has been des cribed in secondary haemophagocytic lympho histio cytosis and in CAR T-cell-mediated cytokine release syndrome.", [["T-cell", "ANATOMY", 136, 142], ["ARDS", "DISEASE", 48, 52], ["cytosis", "DISEASE", 117, 124], ["pul monary", "GENE_OR_GENE_PRODUCT", 13, 23], ["ment", "CANCER", 32, 36], ["CAR T-cell", "CELL", 132, 142], ["cytokine", "PROTEIN", 152, 160], ["pul monary involve ment", "PROBLEM", 13, 36], ["ARDS", "PROBLEM", 48, 52], ["secondary haemophagocytic lympho histio cytosis", "PROBLEM", 77, 124], ["cytokine release syndrome", "PROBLEM", 152, 177], ["haemophagocytic lympho histio", "OBSERVATION", 87, 116], ["cytokine release syndrome", "OBSERVATION", 152, 177]]], ["17, 18 Despite the absence of data from randomised controlled trials, the use of the IL-1 inhibitor anakinra seems to be promising in both haemophagocytic lymphohistiocytosis and CAR T-cell-mediated cytokine release syndrome.", [["T-cell", "ANATOMY", 183, 189], ["anakinra", "CHEMICAL", 100, 108], ["lymphohistiocytosis", "DISEASE", 155, 174], ["IL-1", "GENE_OR_GENE_PRODUCT", 85, 89], ["anakinra", "SIMPLE_CHEMICAL", 100, 108], ["CAR T-cell", "CELL", 179, 189], ["cytokine", "PROTEIN", 199, 207], ["randomised controlled trials", "TREATMENT", 40, 68], ["the IL-1 inhibitor anakinra", "TREATMENT", 81, 108], ["both haemophagocytic lymphohistiocytosis", "PROBLEM", 134, 174], ["CAR T", "TEST", 179, 184], ["cytokine release syndrome", "PROBLEM", 199, 224], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 139, 174]]], ["9, [19] [20] [21] All these data led us to hypothesise that anakinra could represent an efficient treatment for severe forms of COVID-19.", [["anakinra", "CHEMICAL", 60, 68], ["anakinra", "CHEMICAL", 60, 68], ["COVID-19", "CHEMICAL", 128, 136], ["anakinra", "SIMPLE_CHEMICAL", 60, 68], ["anakinra", "PROBLEM", 60, 68], ["COVID", "TEST", 128, 133]]], ["Depending on the reported series, the dose of anakinra that was administered in patients with macrophage activation syndrome, haemophagocytic lympho histiocytosis, or CAR T-cell-mediated cytokine release syndrome varied from 100 mg to 400 mg per day.", [["macrophage", "ANATOMY", 94, 104], ["haemophagocytic lympho histiocytosis", "ANATOMY", 126, 162], ["T-cell", "ANATOMY", 171, 177], ["anakinra", "CHEMICAL", 46, 54], ["haemophagocytic lympho histiocytosis", "DISEASE", 126, 162], ["anakinra", "CHEMICAL", 46, 54], ["anakinra", "SIMPLE_CHEMICAL", 46, 54], ["patients", "ORGANISM", 80, 88], ["macrophage", "CELL", 94, 104], ["CAR T-cell", "CELL", 167, 177], ["cytokine", "PROTEIN", 187, 195], ["patients", "SPECIES", 80, 88], ["anakinra", "TREATMENT", 46, 54], ["macrophage activation syndrome", "PROBLEM", 94, 124], ["haemophagocytic lympho histiocytosis", "PROBLEM", 126, 162], ["CAR T-cell-mediated cytokine release syndrome", "TREATMENT", 167, 212], ["haemophagocytic lympho histiocytosis", "OBSERVATION", 126, 162]]], ["9, 19, 22, 23 Concerning a new indication, in a condition in which the persistence of SARS-CoV-2 cannot be ruled out, we decided to select an intermediate dose of anakinra for treating our patients.", [["SARS", "DISEASE", 86, 90], ["anakinra", "CHEMICAL", 163, 171], ["anakinra", "SIMPLE_CHEMICAL", 163, 171], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 86, 94], ["SARS", "PROBLEM", 86, 90], ["anakinra", "TREATMENT", 163, 171], ["new", "OBSERVATION_MODIFIER", 27, 30], ["SARS", "OBSERVATION", 86, 90]]], ["The dose we chose was irrespective of bodyweight or BMI because the pharmacokinetic profile investigated in healthy individuals of various bodyweights demonstrated modest pharmacokinetic changes.", [["BMI", "PROBLEM", 52, 55], ["the pharmacokinetic profile", "TEST", 64, 91], ["various bodyweights", "TEST", 131, 150], ["modest pharmacokinetic changes", "PROBLEM", 164, 194], ["modest", "OBSERVATION_MODIFIER", 164, 170], ["pharmacokinetic", "OBSERVATION", 171, 186]]], ["24 Additionally, given the large therapeutic index of anakinra, we argued that the benefits of fixed dosing (excepting patients under haemo dialysis), which reduced the risk of medication error, outweighed the potential reduction in pharmacokinetic variance relative to individuals of heavier bodyweight.Number at risk (number censored)Considering the reduction in both the need for invasive mechanical ventilation and mortality, our study suggests that anakinra might represent an effective treatment for the hyperinflammatory phase of COVID-19.", [["anakinra", "CHEMICAL", 54, 62], ["anakinra", "CHEMICAL", 454, 462], ["COVID-19", "CHEMICAL", 537, 545], ["anakinra", "SIMPLE_CHEMICAL", 54, 62], ["patients", "ORGANISM", 119, 127], ["anakinra", "SIMPLE_CHEMICAL", 454, 462], ["patients", "SPECIES", 119, 127], ["anakinra", "TREATMENT", 54, 62], ["fixed dosing", "TREATMENT", 95, 107], ["patients under haemo dialysis", "TREATMENT", 119, 148], ["medication error", "PROBLEM", 177, 193], ["pharmacokinetic variance", "PROBLEM", 233, 257], ["invasive mechanical ventilation", "TREATMENT", 383, 414], ["our study", "TEST", 430, 439], ["anakinra", "PROBLEM", 454, 462], ["an effective treatment", "TREATMENT", 479, 501], ["COVID", "TEST", 537, 542], ["large", "OBSERVATION_MODIFIER", 27, 32], ["therapeutic", "OBSERVATION_MODIFIER", 33, 44], ["anakinra", "OBSERVATION", 54, 62], ["medication error", "OBSERVATION", 177, 193], ["reduction", "OBSERVATION_MODIFIER", 220, 229], ["pharmacokinetic variance", "OBSERVATION", 233, 257], ["reduction", "OBSERVATION_MODIFIER", 352, 361], ["anakinra", "OBSERVATION", 454, 462], ["effective", "OBSERVATION_MODIFIER", 482, 491]]], ["The efficacy of inhibition of IL-1 in patients who received anakinra is reflected by the significant decrease in CRP concentration in the anakinra group, as compared with the historical group (figure 2).", [["anakinra", "CHEMICAL", 60, 68], ["anakinra", "CHEMICAL", 138, 146], ["IL-1", "GENE_OR_GENE_PRODUCT", 30, 34], ["patients", "ORGANISM", 38, 46], ["anakinra", "SIMPLE_CHEMICAL", 60, 68], ["CRP", "GENE_OR_GENE_PRODUCT", 113, 116], ["anakinra", "SIMPLE_CHEMICAL", 138, 146], ["IL-1", "PROTEIN", 30, 34], ["CRP", "PROTEIN", 113, 116], ["patients", "SPECIES", 38, 46], ["inhibition of IL", "TREATMENT", 16, 32], ["anakinra", "TREATMENT", 60, 68], ["the significant decrease in CRP concentration", "PROBLEM", 85, 130], ["the anakinra group", "TREATMENT", 134, 152], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["decrease", "OBSERVATION_MODIFIER", 101, 109], ["CRP concentration", "OBSERVATION_MODIFIER", 113, 130], ["anakinra", "OBSERVATION", 138, 146]]], ["The concomitant clinical and biological improvements might provide indirect support for a causal relationship between anakinra treat ment and both reduced mortality and admission to ICU for invasive mechanical ventilation.Number at risk (number censored)Notably, a previous Italian study evaluating high-dose intravenous anakinra in patients with severe COVID-19, ARDS, and hyperinflammation also reported significant, comparable benefits for survival and clinical outcomes.", [["intravenous", "ANATOMY", 309, 320], ["anakinra", "CHEMICAL", 118, 126], ["anakinra", "CHEMICAL", 321, 329], ["COVID", "DISEASE", 354, 359], ["ARDS", "DISEASE", 364, 368], ["hyperinflammation", "DISEASE", 374, 391], ["anakinra", "SIMPLE_CHEMICAL", 118, 126], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 309, 320], ["anakinra", "SIMPLE_CHEMICAL", 321, 329], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["indirect support", "TREATMENT", 67, 83], ["anakinra treat ment", "TREATMENT", 118, 137], ["invasive mechanical ventilation", "TREATMENT", 190, 221], ["a previous Italian study", "TEST", 263, 287], ["high-dose intravenous anakinra", "TREATMENT", 299, 329], ["severe COVID", "PROBLEM", 347, 359], ["ARDS", "PROBLEM", 364, 368], ["hyperinflammation", "PROBLEM", 374, 391], ["mechanical ventilation", "OBSERVATION", 199, 221], ["ARDS", "OBSERVATION", 364, 368]]], ["25 Obviously, both treated and historical groups reported here are not representative of all patients with COVID-19 but correspond to a subpopulation with altered pulmonary function and hyperinflammation, since the majority of our patients had a CRP concentration higher than 100 mg/L. We believe that anakinra should be tested in patients who are admitted to hospital, when clinical and biological parameters are becoming suggestive of a hyperinflammatory status.", [["pulmonary", "ANATOMY", 163, 172], ["hyperinflammation", "DISEASE", 186, 203], ["anakinra", "CHEMICAL", 302, 310], ["patients", "ORGANISM", 93, 101], ["pulmonary", "ORGAN", 163, 172], ["patients", "ORGANISM", 231, 239], ["CRP", "GENE_OR_GENE_PRODUCT", 246, 249], ["anakinra", "SIMPLE_CHEMICAL", 302, 310], ["patients", "ORGANISM", 331, 339], ["CRP", "PROTEIN", 246, 249], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 331, 339], ["COVID", "TEST", 107, 112], ["altered pulmonary function", "PROBLEM", 155, 181], ["hyperinflammation", "PROBLEM", 186, 203], ["a CRP concentration", "TEST", 244, 263], ["anakinra", "TREATMENT", 302, 310], ["a hyperinflammatory status", "PROBLEM", 437, 463], ["altered", "OBSERVATION_MODIFIER", 155, 162], ["pulmonary function", "OBSERVATION", 163, 181], ["anakinra", "OBSERVATION", 302, 310], ["suggestive of", "UNCERTAINTY", 423, 436], ["hyperinflammatory status", "OBSERVATION", 439, 463]]], ["However, some questions remain, particularly about the optimal situation and time to prescribe this biologic agent, since it is potentially useless in the vast majority of patients with COVID-19, who will only have a benign influenza-like syndrome.", [["influenza-like syndrome", "DISEASE", 224, 247], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["this biologic agent", "TREATMENT", 95, 114], ["a benign influenza-like syndrome", "PROBLEM", 215, 247], ["benign", "OBSERVATION_MODIFIER", 217, 223], ["influenza", "OBSERVATION", 224, 233]]], ["A rapid and substantial increase in CRP concentration could represent the best predictor of an evolution from a common viral disease to a systemic and life-threatening disorder.Number at risk (number censored)Assessment of the side-effects of a specific treatment remains difficult in the context of a systemic disease, even more so when a great number of other drugs are prescribed simultaneously to the same patient.", [["viral disease", "DISEASE", 119, 132], ["systemic and life-threatening disorder", "DISEASE", 138, 176], ["CRP", "GENE_OR_GENE_PRODUCT", 36, 39], ["patient", "ORGANISM", 410, 417], ["CRP", "PROTEIN", 36, 39], ["patient", "SPECIES", 410, 417], ["A rapid and substantial increase in CRP concentration", "PROBLEM", 0, 53], ["a common viral disease", "PROBLEM", 110, 132], ["a systemic and life-threatening disorder", "PROBLEM", 136, 176], ["a specific treatment", "TREATMENT", 243, 263], ["a systemic disease", "PROBLEM", 300, 318], ["other drugs", "TREATMENT", 356, 367], ["rapid", "OBSERVATION_MODIFIER", 2, 7], ["substantial", "OBSERVATION_MODIFIER", 12, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["CRP concentration", "OBSERVATION_MODIFIER", 36, 53], ["common", "OBSERVATION_MODIFIER", 112, 118], ["viral disease", "OBSERVATION", 119, 132], ["systemic", "OBSERVATION_MODIFIER", 138, 146], ["systemic", "OBSERVATION_MODIFIER", 302, 310], ["disease", "OBSERVATION", 311, 318]]], ["In this context, we only noticed an increase in liver aminotransferase levels of more than three times the upper normal limit in seven (13%) patients in the anakinra group and in four (9%) patients in the historical group.", [["liver", "ANATOMY", 48, 53], ["anakinra", "CHEMICAL", 157, 165], ["liver", "ORGAN", 48, 53], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 54, 70], ["upper", "ORGANISM_SUBDIVISION", 107, 112], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 189, 197], ["liver aminotransferase", "PROTEIN", 48, 70], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 189, 197], ["an increase in liver aminotransferase levels", "PROBLEM", 33, 77], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["liver", "ANATOMY", 48, 53], ["aminotransferase levels", "OBSERVATION", 54, 77], ["upper", "OBSERVATION_MODIFIER", 107, 112], ["normal limit", "OBSERVATION_MODIFIER", 113, 125]]], ["The transient increase in liver enzymes is mentioned in the summary of anakinra characteristics and some cases of reversible druginduced hepatitis have been reported with this biologic.", [["liver", "ANATOMY", 26, 31], ["hepatitis", "DISEASE", 137, 146], ["liver", "ORGAN", 26, 31], ["liver enzymes", "PROTEIN", 26, 39], ["The transient increase in liver enzymes", "PROBLEM", 0, 39], ["anakinra characteristics", "PROBLEM", 71, 95], ["reversible druginduced hepatitis", "PROBLEM", 114, 146], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["liver", "ANATOMY", 26, 31], ["anakinra", "OBSERVATION", 71, 79], ["reversible", "OBSERVATION_MODIFIER", 114, 124], ["druginduced hepatitis", "OBSERVATION", 125, 146]]], ["26 However, the frequency of elevated liver enzymes in this study was similar between patients who received anakinra and historical controls.", [["liver", "ANATOMY", 38, 43], ["anakinra", "CHEMICAL", 108, 116], ["liver", "ORGAN", 38, 43], ["patients", "ORGANISM", 86, 94], ["anakinra", "SIMPLE_CHEMICAL", 108, 116], ["liver enzymes", "PROTEIN", 38, 51], ["patients", "SPECIES", 86, 94], ["elevated liver enzymes", "PROBLEM", 29, 51], ["this study", "TEST", 55, 65], ["anakinra", "TREATMENT", 108, 116], ["historical controls", "TREATMENT", 121, 140], ["elevated", "OBSERVATION", 29, 37], ["liver", "ANATOMY", 38, 43]]], ["Similar findings in an Italian study suggest that it is unlikely that ana kinra might be causally linked to such abnormalities in these patients.", [["ana kinra", "ORGANISM", 70, 79], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["an Italian study", "TEST", 20, 36], ["ana kinra", "PROBLEM", 70, 79], ["such abnormalities in these patients", "PROBLEM", 108, 144]]], ["25 The implication of a coagulopathy in patients with COVID-19 strengthens the importance of the detection and management of thromboembolic events.", [["coagulopathy", "DISEASE", 24, 36], ["thromboembolic", "DISEASE", 125, 139], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["a coagulopathy", "PROBLEM", 22, 36], ["COVID", "TREATMENT", 54, 59], ["the detection", "TEST", 93, 106], ["management", "TREATMENT", 111, 121], ["thromboembolic events", "PROBLEM", 125, 146], ["coagulopathy", "OBSERVATION", 24, 36], ["thromboembolic", "OBSERVATION", 125, 139]]], ["27 Although such events were not systematically investigated in our study, ten (19%) patients in the anakinra group and five (11%) in the historical group developed such a complication during the hospital stay.", [["anakinra", "CHEMICAL", 101, 109], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["our study", "TEST", 64, 73], ["a complication", "PROBLEM", 170, 184], ["complication", "OBSERVATION", 172, 184]]], ["Our data did not allow us to determine whether the inhibition of IL-1 was beneficial or detrimental respective to COVID-19-related coagulopathy.", [["COVID-19", "CHEMICAL", 114, 122], ["coagulopathy", "DISEASE", 131, 143], ["COVID-19", "CHEMICAL", 114, 122], ["IL-1", "GENE_OR_GENE_PRODUCT", 65, 69], ["IL-1", "PROTEIN", 65, 69], ["COVID", "TEST", 114, 119], ["coagulopathy", "PROBLEM", 131, 143], ["coagulopathy", "OBSERVATION", 131, 143]]], ["Although it has been established that IL-1 increases the level of tissue factor, one of the main activators of coagulation, published data are somewhat contradictory about the effect of blocking IL-1 on coagulability.", [["IL-1", "GENE_OR_GENE_PRODUCT", 38, 42], ["tissue factor", "GENE_OR_GENE_PRODUCT", 66, 79], ["IL-1", "GENE_OR_GENE_PRODUCT", 195, 199], ["IL-1", "PROTEIN", 38, 42], ["tissue factor", "PROTEIN", 66, 79], ["IL-1", "PROTEIN", 195, 199], ["blocking IL", "TREATMENT", 186, 197]]], ["28, 29 Our study has several limitations.", [["Our study", "TEST", 7, 16]]], ["Taking into account the poor prognosis of COVID-19-related ARDS and the devastating progression of the pandemic, we decided an off-label use of anakinra for all patients with severe forms of the disease.", [["COVID-19", "CHEMICAL", 42, 50], ["ARDS", "DISEASE", 59, 63], ["anakinra", "CHEMICAL", 144, 152], ["COVID-19", "CANCER", 42, 50], ["anakinra", "SIMPLE_CHEMICAL", 144, 152], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["COVID", "TEST", 42, 47], ["ARDS", "PROBLEM", 59, 63], ["anakinra", "TREATMENT", 144, 152], ["the disease", "PROBLEM", 191, 202], ["ARDS", "OBSERVATION", 59, 63], ["devastating", "OBSERVATION_MODIFIER", 72, 83], ["progression", "OBSERVATION_MODIFIER", 84, 95], ["disease", "OBSERVATION", 195, 202]]], ["Therefore, the anakinra cohort was compared with an historical group of patients.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the anakinra cohort", "TREATMENT", 11, 30]]], ["However, the recruitment of historical patients in the same institution, during a very short 2-week period is likely to limit this bias.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["recruitment", "OBSERVATION_MODIFIER", 13, 24]]], ["Second, the historical group differed sizeably from the anakinra group for several potentially confounding variables.", [["anakinra", "CHEMICAL", 56, 64], ["anakinra", "SIMPLE_CHEMICAL", 56, 64], ["the anakinra group", "TREATMENT", 52, 70], ["anakinra", "OBSERVATION", 56, 64]]], ["Obesity was more frequent in the historical group and might have worsened the effects of SARS-CoV-2.", [["Obesity", "DISEASE", 0, 7], ["SARS", "DISEASE", 89, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["SARS-CoV", "SPECIES", 89, 97], ["Obesity", "PROBLEM", 0, 7], ["more frequent", "OBSERVATION_MODIFIER", 12, 25], ["worsened", "OBSERVATION_MODIFIER", 65, 73]]], ["30 In the multivariate analysis of our data, this comorbidity, as well as the other betweengroup differences, did not affect the estimated effect of anakinra on the outcome.", [["anakinra", "CHEMICAL", 149, 157], ["anakinra", "SIMPLE_CHEMICAL", 149, 157], ["our data", "TEST", 35, 43], ["this comorbidity", "PROBLEM", 45, 61], ["anakinra", "TREATMENT", 149, 157]]], ["Nevertheless, we cannot rule out the possibility that the observed association could be due, at least in part, to confounding.Number at risk (number censored)In conclusion, in severe forms of COVID-19-related pneumonia requiring oxygen therapy, a 10-day treatment with subcutaneous anakinra was associated with the reduction of both need of mechanical ventilation and mortality, as compared with a historical group with similar characteristics.", [["subcutaneous", "ANATOMY", 269, 281], ["COVID-19", "CHEMICAL", 192, 200], ["pneumonia", "DISEASE", 209, 218], ["oxygen", "CHEMICAL", 229, 235], ["anakinra", "CHEMICAL", 282, 290], ["COVID-19", "CHEMICAL", 192, 200], ["oxygen", "CHEMICAL", 229, 235], ["oxygen", "SIMPLE_CHEMICAL", 229, 235], ["anakinra", "SIMPLE_CHEMICAL", 282, 290], ["COVID", "TEST", 192, 197], ["pneumonia", "PROBLEM", 209, 218], ["oxygen therapy", "TREATMENT", 229, 243], ["subcutaneous anakinra", "TREATMENT", 269, 290], ["mechanical ventilation", "TREATMENT", 341, 363], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["pneumonia", "OBSERVATION", 209, 218], ["oxygen therapy", "OBSERVATION", 229, 243], ["subcutaneous", "ANATOMY", 269, 281], ["anakinra", "OBSERVATION", 282, 290], ["reduction", "OBSERVATION_MODIFIER", 315, 324], ["mechanical ventilation", "OBSERVATION", 341, 363]]], ["In the context of this pandemic, with exponential curves of admittances in ICUs, the use of anakinra should be tested more extensively, preferentially through randomised trials, among patients with COVID-19 and symptoms suggesting a virus-induced cytokine storm.", [["anakinra", "CHEMICAL", 92, 100], ["anakinra", "SIMPLE_CHEMICAL", 92, 100], ["patients", "ORGANISM", 184, 192], ["cytokine", "PROTEIN", 247, 255], ["patients", "SPECIES", 184, 192], ["this pandemic", "PROBLEM", 18, 31], ["anakinra", "TREATMENT", 92, 100], ["COVID", "TEST", 198, 203], ["symptoms", "PROBLEM", 211, 219], ["a virus", "PROBLEM", 231, 238], ["cytokine storm", "OBSERVATION", 247, 261]]]], "PMC7221011": [["BackgroundCoronavirus disease 2019 (COVID-19) due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection is the biggest public health crises of recent times [1].", [["BackgroundCoronavirus disease", "DISEASE", 0, 29], ["COVID-19", "CHEMICAL", 36, 44], ["Acute Respiratory Syndrome", "DISEASE", 60, 86], ["SARS-CoV-2) infection", "DISEASE", 102, 123], ["SARS-CoV-2", "ORGANISM", 102, 112], ["Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2", "SPECIES", 53, 112], ["BackgroundCoronavirus disease", "PROBLEM", 0, 29], ["COVID", "TEST", 36, 41], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 53, 98], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["infection", "PROBLEM", 114, 123], ["Severe", "OBSERVATION_MODIFIER", 53, 59], ["Acute", "OBSERVATION_MODIFIER", 60, 65], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 66, 98], ["infection", "OBSERVATION", 114, 123]]], ["As per the World Health Organization\u2019s (WHO) update dated 21st April 2020, there have been 2,397,216 cases and 162,956 deaths worldwide [2].", [["deaths", "DISEASE", 119, 125]]], ["SARS-CoV-2 causes acute respiratory infection with varying severity in different age groups, wherein elderly tend to have severe disease, children are relatively spared till-date [3].", [["respiratory", "ANATOMY", 24, 35], ["SARS", "DISEASE", 0, 4], ["respiratory infection", "DISEASE", 24, 45], ["SARS-CoV-2", "ORGANISM", 0, 10], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["acute respiratory infection", "PROBLEM", 18, 45], ["varying severity", "PROBLEM", 51, 67], ["severe disease", "PROBLEM", 122, 136], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory", "ANATOMY", 24, 35], ["infection", "OBSERVATION", 36, 45], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["disease", "OBSERVATION", 129, 136]]], ["Several differences in the pathogenesis of COVID-19 between children and adults have been proposed to explain these differences [4].BackgroundInsights in the protective mechanism in children could help in development of therapeutic targets for at-risk elderly population.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 43, 51], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 182, 190], ["COVID", "TEST", 43, 48], ["differences", "OBSERVATION_MODIFIER", 8, 19]]], ["It is equally important to identify high-risk groups in children, so that recommendations regarding therapeutics and when available, vaccines can be made.", [["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["vaccines", "TREATMENT", 133, 141]]], ["Hence, the authors conducted a narrative review focussing on the clinical manifestations, disease pathogenesis, and possible factors explaining differences between adult and pediatric infection.", [["infection", "DISEASE", 184, 193], ["the clinical manifestations", "PROBLEM", 61, 88], ["disease pathogenesis", "PROBLEM", 90, 110], ["adult and pediatric infection", "PROBLEM", 164, 193], ["infection", "OBSERVATION", 184, 193]]], ["As COVID-19 has similarities to SARS, some findings from SARS CoV-1 pathogenesis are extrapolated to SARS-CoV-2 infection.", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 57, 61], ["SARS-CoV-2 infection", "DISEASE", 101, 121], ["COVID-19", "GENE_OR_GENE_PRODUCT", 3, 11], ["SARS CoV-1", "ORGANISM", 57, 67], ["SARS-CoV-2", "ORGANISM", 101, 111], ["COVID-19", "DNA", 3, 11], ["SARS CoV-1", "SPECIES", 57, 67], ["SARS-CoV-2", "SPECIES", 101, 111], ["COVID", "TEST", 3, 8], ["SARS", "PROBLEM", 32, 36], ["SARS CoV", "TEST", 57, 65], ["pathogenesis", "PROBLEM", 68, 80], ["SARS", "PROBLEM", 101, 105], ["CoV", "PROBLEM", 106, 109], ["2 infection", "PROBLEM", 110, 121], ["SARS", "OBSERVATION", 32, 36], ["infection", "OBSERVATION", 112, 121]]], ["The possibility of a change in spectrum of pediatric disease, as the pandemic evolves further, should also be kept in mind.Clinical Features and Outcomes of COVID-19 Among Adults and ChildrenAmong 44,762 laboratory-confirmed cases from China, only 416 (1%) and 549 (1%) were from age-groups <10 and 10\u201319 y, respectively [3].", [["Adults", "SPECIES", 172, 178], ["pediatric disease", "PROBLEM", 43, 60], ["COVID", "TEST", 157, 162], ["ChildrenAmong", "TEST", 183, 196], ["possibility of", "UNCERTAINTY", 4, 18], ["change", "OBSERVATION_MODIFIER", 21, 27], ["pediatric disease", "OBSERVATION", 43, 60]]], ["Test positivity rates among total tests were 3.9% and 6.3% in 0\u20134 y and 5\u201317 y age group compared to overall 14.4% positivity rates [5].", [["Test positivity rates", "TEST", 0, 21], ["total tests", "TEST", 28, 39], ["overall", "TEST", 101, 108], ["positivity rates", "TEST", 115, 131]]], ["Clinical features from the largest series of adults and children are summarised in Table 1.", [["adults", "ORGANISM", 45, 51], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["largest", "OBSERVATION_MODIFIER", 27, 34]]], ["Frequency of common symptoms was lower in children compared to adults, implying more asymptomatic infections in children [6].", [["infections", "DISEASE", 98, 108], ["children", "ORGANISM", 42, 50], ["children", "ORGANISM", 112, 120], ["children", "SPECIES", 42, 50], ["children", "SPECIES", 112, 120], ["common symptoms", "PROBLEM", 13, 28], ["asymptomatic", "OBSERVATION_MODIFIER", 85, 97], ["infections", "OBSERVATION", 98, 108]]], ["Median duration of fever in children was 3 d compared to 10 d in adult patients, implying shorter illness in children [7, 9].Clinical Features and Outcomes of COVID-19 Among Adults and ChildrenAccording to the Centers for Disease Control and Prevention (CDC) report, fewer children were admitted to hospital and intensive care unit (ICU) (5.7%\u201320% and 0.58%\u20132.0%, respectively) than adults aged 18\u201364 y (10%\u201333% and 1.4%\u20134.5%, respectively).", [["fever", "DISEASE", 19, 24], ["illness", "DISEASE", 98, 105], ["children", "ORGANISM", 28, 36], ["patients", "ORGANISM", 71, 79], ["children", "ORGANISM", 109, 117], ["children", "ORGANISM", 273, 281], ["children", "SPECIES", 28, 36], ["patients", "SPECIES", 71, 79], ["children", "SPECIES", 109, 117], ["Adults", "SPECIES", 174, 180], ["children", "SPECIES", 273, 281], ["fever", "PROBLEM", 19, 24], ["COVID", "TEST", 159, 164], ["Disease Control", "TREATMENT", 222, 237], ["fever", "OBSERVATION", 19, 24]]], ["But infants had higher hospitalization rates (15%\u201362%) than older children (aged 1\u201317 y) (4.1%\u201314%) and adults [6].", [["infants", "ORGANISM", 4, 11], ["children", "ORGANISM", 66, 74], ["infants", "SPECIES", 4, 11], ["children", "SPECIES", 66, 74]]], ["There were 3 deaths (0.1%) in children compared to overall 2.27% mortality [6].", [["deaths", "DISEASE", 13, 19], ["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38]]], ["Ages of these 3 children were not reported, but one case reported from Illinois was an infant [10].", [["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24], ["infant", "SPECIES", 87, 93]]], ["The Chinese case-series of 171 laboratory-confirmed children also reported one death in a 10-mo-old child, who suffered intussusception and multi-organ failure [7].", [["multi-organ", "ANATOMY", 140, 151], ["death", "DISEASE", 79, 84], ["intussusception", "DISEASE", 120, 135], ["multi-organ failure", "DISEASE", 140, 159], ["children", "ORGANISM", 52, 60], ["child", "ORGANISM", 100, 105], ["children", "SPECIES", 52, 60], ["intussusception", "PROBLEM", 120, 135], ["multi-organ failure", "PROBLEM", 140, 159], ["intussusception", "OBSERVATION", 120, 135], ["multi-organ", "ANATOMY", 140, 151], ["failure", "OBSERVATION", 152, 159]]], ["In a Chinese series of 728 laboratory-confirmed children, the proportion of \u2018severe and critical\u2019 cases was 8.2%, 2.1%, 0.6%, 1.1% and 5.1% for the age-groups of \u02c21, 1\u20135, 6\u201310, 11\u201315 and > 15 y, respectively [11].", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56], ["severe", "OBSERVATION_MODIFIER", 77, 83]]], ["These findings suggest that though overall children are less affected and have milder illness than adults, infants have more severe illness compared to older children.Respiratory Viruses ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?The Global Burden of Diseases 2016 Lower Respiratory Infections Collaborators estimated that acute lower respiratory infections (ALRI) caused 652,572 deaths [95% uncertainty interval (UI) 586,475-720,612] in children aged <5 y, 1,080,958 deaths (943,749-1,170,638) in adults aged >70 y, and 2,377,697 deaths (2,145,584\u20132,512,809) in people of all ages, worldwide in the year 2016 [12].", [["illness", "DISEASE", 86, 93], ["illness", "DISEASE", 132, 139], ["Respiratory Infections", "DISEASE", 289, 311], ["acute lower respiratory infections", "DISEASE", 341, 375], ["ALRI", "DISEASE", 377, 381], ["deaths", "DISEASE", 398, 404], ["deaths", "DISEASE", 486, 492], ["deaths", "DISEASE", 549, 555], ["children", "ORGANISM", 43, 51], ["infants", "ORGANISM", 107, 114], ["children", "ORGANISM", 158, 166], ["children", "ORGANISM", 456, 464], ["people", "ORGANISM", 581, 587], ["children", "SPECIES", 43, 51], ["infants", "SPECIES", 107, 114], ["children", "SPECIES", 158, 166], ["children", "SPECIES", 456, 464], ["people", "SPECIES", 581, 587], ["milder illness", "PROBLEM", 79, 93], ["more severe illness", "PROBLEM", 120, 139], ["COVID", "TEST", 232, 237], ["The Global Burden of Diseases", "PROBLEM", 248, 277], ["Lower Respiratory Infections", "PROBLEM", 283, 311], ["acute lower respiratory infections", "PROBLEM", 341, 375], ["UI", "TEST", 432, 434], ["Viruses", "OBSERVATION", 179, 186], ["Global", "OBSERVATION_MODIFIER", 252, 258], ["Burden", "OBSERVATION_MODIFIER", 259, 265], ["Diseases", "OBSERVATION", 269, 277], ["Lower", "OBSERVATION_MODIFIER", 283, 288], ["Respiratory Infections", "OBSERVATION", 289, 311], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["lower", "ANATOMY_MODIFIER", 347, 352], ["respiratory", "ANATOMY", 353, 364], ["infections", "OBSERVATION", 365, 375]]], ["Incidence of Respiratory Syncytial Virus (RSV) infection (per 1000 people) was about three times higher in under-5s [17 (95% UI 10\u00b76\u201326\u00b72)], compared to adults >70 y [6.3 (4.9\u20137.8)].", [["Respiratory Syncytial Virus (RSV) infection", "DISEASE", 13, 56], ["Respiratory Syncytial Virus", "ORGANISM", 13, 40], ["RSV", "ORGANISM", 42, 45], ["people", "SPECIES", 67, 73], ["Respiratory Syncytial Virus", "SPECIES", 13, 40], ["RSV", "SPECIES", 42, 45], ["Respiratory Syncytial Virus (RSV) infection", "PROBLEM", 13, 56], ["UI", "TEST", 125, 127], ["Respiratory", "ANATOMY", 13, 24], ["Syncytial Virus", "OBSERVATION", 25, 40]]], ["On the other hand, incidence of influenza is nearly 60% more in adults >70 y [15.8 (11.8\u201320.2)] as compared to under-5s [9.1 (5.4\u201314.8)].", [["influenza", "DISEASE", 32, 41], ["influenza", "PROBLEM", 32, 41], ["influenza", "OBSERVATION", 32, 41]]], ["Here also, the estimated CFR in adults >70 y is more than double of that in under-5s [12].", [["the estimated CFR", "TEST", 11, 28]]], ["Other studies on RSV burden also estimate a lower incidence of RSV ALRI in adults >65 y as compared to under-5s and a multiple-fold higher hospital CFR in adults >65 y [13, 14].Respiratory Viruses ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?Among children, the youngest children (0\u20135 mo) had a higher incidence of RSV-related ALRI and higher hospitalization rates as compared to older children, but in-hospital CFR were similar in all age-groups in under-5s [14].Respiratory Viruses ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?In the first year of the 2009 H1N1 influenza pandemic in the USA, in the initial months, the number of cases were maximum in children (April 12\u2013July 23, 2009: 0\u201317 y- 1,580,218 cases; 18\u201364 y- 1,430,258 cases; >65 y- 42,292 cases); in the subsequent time-periods, the age-group 18\u201364 y had maximum cases (August 1\u201331, 2009: 0\u201317 y- 579,037cases; 18\u201364 y- 870,804 cases; >65 y- 155,919 cases; and September 1, 2009\u2013April 10, 2010: 0\u201317 y- 17,341,749 cases; 18\u201364 y- 33,091,869 cases; >65 y- 5,745,602 cases).", [["ALRI", "DISEASE", 67, 71], ["RSV", "DISEASE", 331, 334], ["ALRI", "DISEASE", 343, 347], ["influenza pandemic", "DISEASE", 596, 614], ["RSV", "ORGANISM", 17, 20], ["RSV", "ORGANISM", 63, 66], ["children", "ORGANISM", 264, 272], ["children", "ORGANISM", 287, 295], ["RSV", "ORGANISM", 331, 334], ["children", "ORGANISM", 402, 410], ["children", "ORGANISM", 686, 694], ["children", "SPECIES", 264, 272], ["children", "SPECIES", 287, 295], ["children", "SPECIES", 402, 410], ["H1N1 influenza pandemic", "SPECIES", 591, 614], ["children", "SPECIES", 686, 694], ["RSV", "SPECIES", 17, 20], ["RSV", "SPECIES", 63, 66], ["RSV", "SPECIES", 331, 334], ["Other studies", "TEST", 0, 13], ["RSV burden", "PROBLEM", 17, 27], ["RSV ALRI", "PROBLEM", 63, 71], ["COVID", "TEST", 242, 247], ["RSV", "PROBLEM", 331, 334], ["COVID", "TEST", 545, 550], ["influenza", "PROBLEM", 596, 605], ["cases", "TEST", 1037, 1042], ["RSV ALRI", "OBSERVATION", 63, 71], ["Viruses", "OBSERVATION", 189, 196], ["Viruses", "OBSERVATION", 492, 499], ["H1N1", "OBSERVATION", 591, 595]]], ["The older individuals (>65 y) had lower attack rates as well as lower mortality, possibly due to immunity from prior exposure to H1N1 viruses [15].", [["H1N1 viruses", "DISEASE", 129, 141], ["individuals", "ORGANISM", 10, 21], ["H1N1 viruses", "SPECIES", 129, 141], ["lower attack rates", "PROBLEM", 34, 52], ["H1N1 viruses", "PROBLEM", 129, 141], ["possibly due to", "UNCERTAINTY", 81, 96]]], ["It appears that on appearance of a new respiratory viral infection, children are more likely to be affected, at least initially.SARS and MERS ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?SARS-CoV-1 and Middle East Respiratory Syndrome coronavirus (MERS-CoV) caused ALRI with high CFR (7\u201317% for SARS-CoV-1 and 19\u201346% for MERS-CoV) [16\u201318].", [["respiratory viral infection", "DISEASE", 39, 66], ["SARS", "DISEASE", 128, 132], ["SARS", "DISEASE", 203, 207], ["Respiratory Syndrome coronavirus", "DISEASE", 230, 262], ["ALRI", "DISEASE", 281, 285], ["SARS", "DISEASE", 311, 315], ["children", "ORGANISM", 68, 76], ["SARS-CoV-1", "ORGANISM", 203, 213], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 218, 262], ["MERS-CoV", "ORGANISM", 264, 272], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 337, 345], ["children", "SPECIES", 68, 76], ["SARS-CoV-1", "SPECIES", 203, 213], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 218, 262], ["MERS-CoV", "SPECIES", 264, 272], ["SARS-CoV-1", "SPECIES", 311, 321], ["MERS-CoV", "SPECIES", 337, 345], ["a new respiratory viral infection", "PROBLEM", 33, 66], ["COVID", "TEST", 187, 192], ["SARS", "TEST", 203, 207], ["CoV", "TEST", 208, 211], ["Middle East Respiratory Syndrome coronavirus", "PROBLEM", 218, 262], ["ALRI", "PROBLEM", 281, 285], ["high CFR", "TEST", 291, 299], ["SARS", "TEST", 311, 315], ["CoV", "TEST", 316, 319], ["MERS", "TEST", 337, 341], ["new", "OBSERVATION_MODIFIER", 35, 38], ["respiratory", "OBSERVATION_MODIFIER", 39, 50], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66], ["Middle", "ANATOMY_MODIFIER", 218, 224], ["Respiratory Syndrome", "ANATOMY", 230, 250]]], ["Age-wise CFR for SARS in Hong Kong was 0%, 2%, 10%, 13%, 25%, 47% and 66% out of 266, 418, 352, 260, 135, 147, and 177 cases in 0\u201324, 25\u201334, 35\u201344, 45\u201354, 55\u201364, 65\u201374, and \u2265 75 y age-group, respectively.", [["SARS", "DISEASE", 17, 21], ["SARS", "PROBLEM", 17, 21], ["cases", "TEST", 119, 124]]], ["SARS cases in age-group 0\u20139 and 10\u201319 y accounted for 2.9% and 5.0% of all patients, respectively [16].", [["SARS", "DISEASE", 0, 4], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["SARS cases", "TEST", 0, 10]]], ["Similarly, among all patients with MERS from Kingdom of Saudi Arabia between 2012 and 2015, only 32 (3.4%) out of 939 patients were aged \u226419 y.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 118, 126]]], ["There was no reported death in children due to SARS in one the series [19].", [["death", "DISEASE", 22, 27], ["SARS", "DISEASE", 47, 51], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["SARS", "PROBLEM", 47, 51], ["no", "UNCERTAINTY", 10, 12]]], ["No separate data are available for MERS-related CFR for infants and young children, but fatal cases have been reported in this group [20].", [["infants", "ORGANISM", 56, 63], ["children", "ORGANISM", 74, 82], ["infants", "SPECIES", 56, 63], ["children", "SPECIES", 74, 82]]], ["These findings suggest that SARS and MERS have significantly higher CFR compared to COVID-19 but like COVID-19, children tend to be less commonly and less severely affected.SARS and MERS ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?Human-to-human transmission of SARS-CoV and MERS-CoV occurred mainly in health care settings.", [["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 173, 177], ["SARS", "DISEASE", 279, 283], ["COVID-19", "CELL", 102, 110], ["children", "ORGANISM", 112, 120], ["Human", "ORGANISM", 248, 253], ["human", "ORGANISM", 257, 262], ["SARS-CoV", "ORGANISM", 279, 287], ["MERS-CoV", "ORGANISM", 292, 300], ["children", "SPECIES", 112, 120], ["Human", "SPECIES", 248, 253], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["SARS-CoV", "SPECIES", 279, 287], ["MERS-CoV", "SPECIES", 292, 300], ["SARS", "PROBLEM", 28, 32], ["significantly higher CFR", "PROBLEM", 47, 71], ["COVID", "TEST", 84, 89], ["COVID", "TEST", 232, 237], ["SARS", "PROBLEM", 279, 283], ["CoV", "PROBLEM", 297, 300], ["SARS", "OBSERVATION", 28, 32]]], ["This is probably due to less viral shedding before symptom onset, by which time they were most probably seeking medical care [21].", [["less viral shedding", "PROBLEM", 24, 43], ["probably due to", "UNCERTAINTY", 8, 23], ["less", "OBSERVATION_MODIFIER", 24, 28], ["viral", "OBSERVATION", 29, 34]]], ["It is estimated that transmission between family members occurred in only 13\u201321% of MERS cases and 22\u201339% of SARS cases [21].", [["MERS", "DISEASE", 84, 88], ["SARS", "DISEASE", 109, 113], ["MERS", "CANCER", 84, 88]]], ["The secondary attack rates reported for COVID-19 vary from 10 to 20% [22\u201324].Summary ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?Looking at studies on various respiratory viruses, children appear to be less susceptible to infection by SARS-CoV-1, MERS-CoV, and SARS-CoV-2, as compared to other viruses such as influenza and RSV.", [["respiratory viruses", "DISEASE", 176, 195], ["infection", "DISEASE", 239, 248], ["SARS", "DISEASE", 252, 256], ["SARS", "DISEASE", 278, 282], ["influenza", "DISEASE", 327, 336], ["RSV", "DISEASE", 341, 344], ["COVID-19", "CHEMICAL", 40, 48], ["children", "ORGANISM", 197, 205], ["SARS-CoV-1", "ORGANISM", 252, 262], ["MERS-CoV", "ORGANISM", 264, 272], ["SARS-CoV-2", "ORGANISM", 278, 288], ["RSV", "ORGANISM", 341, 344], ["children", "SPECIES", 197, 205], ["SARS-CoV-1", "SPECIES", 252, 262], ["MERS-CoV", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 278, 286], ["RSV", "SPECIES", 341, 344], ["The secondary attack rates", "PROBLEM", 0, 26], ["COVID", "TEST", 40, 45], ["COVID", "TEST", 130, 135], ["various respiratory viruses", "PROBLEM", 168, 195], ["infection", "PROBLEM", 239, 248], ["SARS", "TEST", 252, 256], ["CoV", "TEST", 257, 260], ["MERS", "PROBLEM", 264, 268], ["CoV", "PROBLEM", 269, 272], ["SARS", "PROBLEM", 278, 282], ["CoV", "TEST", 283, 286], ["other viruses", "PROBLEM", 305, 318], ["influenza", "PROBLEM", 327, 336], ["RSV", "PROBLEM", 341, 344], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["attack", "OBSERVATION", 14, 20], ["respiratory viruses", "OBSERVATION", 176, 195], ["infection", "OBSERVATION", 239, 248], ["viruses", "OBSERVATION", 311, 318], ["influenza", "OBSERVATION", 327, 336]]], ["The basic reproduction number (R0 value) represents the number of second-generation individuals that a patient can infect after entering a susceptible population under ideal conditions.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["The R0 values for SARS-CoV-1 and MERS-CoV were estimated to be 2\u20135 and < 1, respectively [25].", [["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 18, 28], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["SARS-CoV", "SPECIES", 18, 26], ["MERS-CoV", "SPECIES", 33, 41], ["The R0 values", "TEST", 0, 13], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["MERS-CoV", "TEST", 33, 41]]], ["There is a trend of association between higher pathogenicity and lower transmissibility.", [["higher pathogenicity and lower transmissibility", "PROBLEM", 40, 87], ["trend", "OBSERVATION_MODIFIER", 11, 16], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["pathogenicity", "OBSERVATION", 47, 60], ["lower transmissibility", "OBSERVATION", 65, 87]]], ["In case of influenza, while pandemic H1N1-virus binding to receptors mainly in the upper respiratory tract, caused relatively mild disease and became endemic in the population, the H7N9-virus binding to receptors mainly in the lower respiratory tract, is reported to have a fatality rate of approximately 40% and has so far resulted in only a few small clusters of human-to-human transmission [25].Summary ::: Is the Pattern of Age-Specific Burden of COVID-19 Unique?Striking difference in the pandemic 2009 influenza A to COVID-19, SARS and MERS is the fact that overall number of children affected is disproportionately low in the coronavirus associated diseases.", [["upper respiratory tract", "ANATOMY", 83, 106], ["lower respiratory tract", "ANATOMY", 227, 250], ["influenza", "DISEASE", 11, 20], ["influenza", "DISEASE", 508, 517], ["SARS", "DISEASE", 533, 537], ["coronavirus", "DISEASE", 633, 644], ["pandemic H1N1-virus", "ORGANISM", 28, 47], ["upper respiratory", "ORGANISM_SUBDIVISION", 83, 100], ["tract", "ORGANISM_SUBDIVISION", 101, 106], ["H7N9-virus", "ORGANISM", 181, 191], ["lower", "ORGANISM_SUBDIVISION", 227, 232], ["respiratory tract", "ORGANISM_SUBDIVISION", 233, 250], ["human", "ORGANISM", 365, 370], ["human", "ORGANISM", 374, 379], ["children", "ORGANISM", 582, 590], ["coronavirus", "ORGANISM", 633, 644], ["pandemic H1N1-virus", "SPECIES", 28, 47], ["H7N9-virus", "SPECIES", 181, 191], ["human", "SPECIES", 365, 370], ["human", "SPECIES", 374, 379], ["children", "SPECIES", 582, 590], ["coronavirus", "SPECIES", 633, 644], ["pandemic H1N1-virus", "SPECIES", 28, 47], ["H7N9-virus", "SPECIES", 181, 191], ["human", "SPECIES", 365, 370], ["human", "SPECIES", 374, 379], ["influenza", "PROBLEM", 11, 20], ["pandemic H1N1-virus binding", "PROBLEM", 28, 55], ["relatively mild disease", "PROBLEM", 115, 138], ["endemic", "PROBLEM", 150, 157], ["the H7N9-virus binding", "PROBLEM", 177, 199], ["a fatality rate", "TEST", 272, 287], ["COVID", "TEST", 451, 456], ["Striking difference", "PROBLEM", 467, 486], ["COVID", "TEST", 523, 528], ["SARS", "PROBLEM", 533, 537], ["the coronavirus associated diseases", "PROBLEM", 629, 664], ["influenza", "OBSERVATION", 11, 20], ["upper", "ANATOMY_MODIFIER", 83, 88], ["respiratory tract", "ANATOMY", 89, 106], ["mild", "OBSERVATION_MODIFIER", 126, 130], ["disease", "OBSERVATION", 131, 138], ["endemic", "OBSERVATION_MODIFIER", 150, 157], ["lower", "ANATOMY_MODIFIER", 227, 232], ["respiratory tract", "ANATOMY", 233, 250], ["few", "OBSERVATION_MODIFIER", 343, 346], ["small", "OBSERVATION_MODIFIER", 347, 352], ["clusters", "OBSERVATION_MODIFIER", 353, 361], ["difference", "OBSERVATION_MODIFIER", 476, 486], ["disproportionately", "OBSERVATION_MODIFIER", 603, 621], ["low", "OBSERVATION_MODIFIER", 622, 625], ["coronavirus", "OBSERVATION", 633, 644]]], ["One possible explanation is that the latter were associated with high CFR and started as outbreaks, which led to strict quarantine procedures and closing of potential hotspots for pediatric infections like schools and day-care centers.", [["infections", "DISEASE", 190, 200], ["high CFR", "PROBLEM", 65, 73], ["strict quarantine procedures", "TREATMENT", 113, 141], ["pediatric infections", "PROBLEM", 180, 200]]], ["As movement of children is highly limited in these times, most of the infections are spread from infected adult family members.", [["infections", "DISEASE", 70, 80], ["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["the infections", "PROBLEM", 66, 80], ["infections", "OBSERVATION", 70, 80]]], ["Even within families, individuals diagnosed with SARS-CoV-2 infection are isolated, which may reduce exposure of children.", [["SARS-CoV-2 infection", "DISEASE", 49, 69], ["SARS-CoV-2", "ORGANISM", 49, 59], ["children", "ORGANISM", 113, 121], ["CoV-2", "SPECIES", 54, 59], ["children", "SPECIES", 113, 121], ["SARS", "PROBLEM", 49, 53], ["CoV", "PROBLEM", 54, 57], ["2 infection", "PROBLEM", 58, 69], ["infection", "OBSERVATION", 60, 69]]], ["Among studies of household contacts, odds of infection in children were significantly less than elderly (OR: 0.26, 95%CI 0.13\u20130.54) and gradually increased with age [23, 24].Virology ::: Pathogenesis of COVID-19SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus, from beta-coronavirus genera of coronaviridae family.", [["infection", "DISEASE", 45, 54], ["children", "ORGANISM", 58, 66], ["COVID-19SARS-CoV-2", "ORGANISM", 203, 221], ["coronaviridae", "GENE_OR_GENE_PRODUCT", 313, 326], ["children", "SPECIES", 58, 66], ["infection", "PROBLEM", 45, 54], ["CI", "TEST", 118, 120], ["COVID", "TEST", 203, 208], ["CoV", "TEST", 216, 219], ["stranded RNA virus", "PROBLEM", 261, 279], ["infection", "OBSERVATION", 45, 54], ["increased", "OBSERVATION_MODIFIER", 146, 155]]], ["The nomenclature arises from surface spike (S) proteins giving the appearance of \u201ccrown\u201d (latin corona) on electron microscopy [1].", [["surface", "ANATOMY", 29, 36], ["surface spike (S) proteins", "PROTEIN", 29, 55], ["electron microscopy", "TEST", 107, 126]]], ["SARS-CoV-2 shares 88% genetic identity to two bat-derived SARS-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, pointing towards common zoonotic origin i.e., bats.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 58, 62], ["SARS-CoV-2", "ORGANISM", 0, 10], ["bat-derived SARS-like coronaviruses", "ORGANISM", 46, 81], ["bat-SL-CoVZC45", "ORGANISM", 83, 97], ["bat-SL-CoVZXC21", "ORGANISM", 102, 117], ["CoVZXC21", "DNA", 109, 117], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["genetic identity", "TEST", 22, 38], ["two bat", "TEST", 42, 49], ["SARS", "TEST", 58, 62], ["coronaviruses", "TEST", 68, 81], ["bat", "TEST", 83, 86], ["SL", "TEST", 87, 89], ["CoVZXC21", "TREATMENT", 109, 117], ["bat", "ANATOMY", 102, 105]]], ["Genetic material of SARS-CoV-2 has about 79% and 50% sequence identity to SARS-CoV-1 and MERS-CoV, respectively [26].Virology ::: Pathogenesis of COVID-19SARS-CoV-2 enters respiratory epithelial cells by attaching to angiotensin converting enzyme-2 (ACE-2) via S-protein; ACE-2 is also a receptor for SARS-CoV-1 [27].", [["respiratory epithelial cells", "ANATOMY", 172, 200], ["SARS", "DISEASE", 20, 24], ["SARS", "DISEASE", 74, 78], ["angiotensin", "CHEMICAL", 217, 228], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["SARS-CoV-1", "ORGANISM", 74, 84], ["MERS-CoV", "ORGANISM", 89, 97], ["COVID-19SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 146, 164], ["respiratory epithelial cells", "CELL", 172, 200], ["angiotensin converting enzyme-2", "GENE_OR_GENE_PRODUCT", 217, 248], ["ACE-2", "GENE_OR_GENE_PRODUCT", 250, 255], ["ACE-2", "GENE_OR_GENE_PRODUCT", 272, 277], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 301, 311], ["respiratory epithelial cells", "CELL_TYPE", 172, 200], ["angiotensin converting enzyme-2 (ACE-2", "PROTEIN", 217, 255], ["S-protein", "PROTEIN", 261, 270], ["ACE-2", "PROTEIN", 272, 277], ["SARS-CoV", "SPECIES", 20, 28], ["SARS-CoV-1", "SPECIES", 74, 84], ["MERS-CoV", "SPECIES", 89, 97], ["Genetic material", "TEST", 0, 16], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82], ["MERS", "TEST", 89, 93], ["COVID", "TEST", 146, 151], ["19SARS", "TEST", 152, 158], ["CoV", "TEST", 159, 162], ["respiratory epithelial cells", "PROBLEM", 172, 200], ["angiotensin", "TEST", 217, 228], ["enzyme-2", "TEST", 240, 248], ["ACE", "TEST", 250, 253], ["ACE", "TEST", 272, 275], ["SARS", "TEST", 301, 305], ["CoV", "TEST", 306, 309], ["respiratory epithelial cells", "OBSERVATION", 172, 200]]], ["Cellular entry is facilitated by proteolytic cleavage of ACE-2 by transmembrane serine protease-2 [27].", [["Cellular", "ANATOMY", 0, 8], ["serine", "CHEMICAL", 80, 86], ["Cellular", "CELL", 0, 8], ["ACE-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["transmembrane serine protease-2", "GENE_OR_GENE_PRODUCT", 66, 97], ["ACE-2", "PROTEIN", 57, 62], ["transmembrane serine protease", "PROTEIN", 66, 95], ["ACE", "TEST", 57, 60], ["transmembrane serine protease", "TREATMENT", 66, 95], ["entry", "OBSERVATION", 9, 14]]], ["Affinity of SARS-CoV-2 for ACE-2 is approximately 10\u201320 times higher than SARS-CoV-1, which could explain higher infectivity of SARS-CoV-2 [28].", [["SARS", "DISEASE", 128, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["ACE-2", "GENE_OR_GENE_PRODUCT", 27, 32], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 74, 84], ["ACE", "PROTEIN", 27, 30], ["SARS-CoV", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 74, 82], ["SARS-CoV", "SPECIES", 128, 136], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["ACE", "TEST", 27, 30], ["higher infectivity of SARS", "PROBLEM", 106, 132], ["CoV", "TEST", 133, 136], ["SARS", "OBSERVATION", 12, 16]]], ["ACE-2 is found on apical membranes of nasal, oral, nasopharyngeal and oropharyngeal mucosal epithelium, alveolar epithelium, endothelial cells of blood vessels and heart, renal tubules, and enterocytes in small intestine [29].", [["apical membranes", "ANATOMY", 18, 34], ["nasal", "ANATOMY", 38, 43], ["oral", "ANATOMY", 45, 49], ["nasopharyngeal", "ANATOMY", 51, 65], ["oropharyngeal mucosal epithelium", "ANATOMY", 70, 102], ["alveolar epithelium", "ANATOMY", 104, 123], ["endothelial cells", "ANATOMY", 125, 142], ["blood vessels", "ANATOMY", 146, 159], ["heart", "ANATOMY", 164, 169], ["renal tubules", "ANATOMY", 171, 184], ["enterocytes", "ANATOMY", 190, 201], ["small intestine", "ANATOMY", 205, 220], ["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["apical membranes", "CELLULAR_COMPONENT", 18, 34], ["nasal", "ORGANISM_SUBDIVISION", 38, 43], ["oral", "ORGANISM_SUBDIVISION", 45, 49], ["nasopharyngeal", "CANCER", 51, 65], ["oropharyngeal mucosal epithelium", "TISSUE", 70, 102], ["alveolar epithelium", "TISSUE", 104, 123], ["endothelial cells", "CELL", 125, 142], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 146, 159], ["heart", "ORGAN", 164, 169], ["renal tubules", "TISSUE", 171, 184], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 190, 201], ["intestine", "ORGAN", 211, 220], ["ACE", "PROTEIN", 0, 3], ["endothelial cells", "CELL_TYPE", 125, 142], ["ACE", "TEST", 0, 3], ["apical membranes of nasal, oral, nasopharyngeal and oropharyngeal mucosal epithelium", "PROBLEM", 18, 102], ["enterocytes in small intestine", "PROBLEM", 190, 220], ["apical", "ANATOMY_MODIFIER", 18, 24], ["membranes", "ANATOMY_MODIFIER", 25, 34], ["nasal", "ANATOMY", 38, 43], ["oral", "ANATOMY", 45, 49], ["nasopharyngeal", "ANATOMY", 51, 65], ["oropharyngeal mucosal", "ANATOMY", 70, 91], ["epithelium", "ANATOMY_MODIFIER", 92, 102], ["alveolar", "ANATOMY_MODIFIER", 104, 112], ["epithelium", "ANATOMY_MODIFIER", 113, 123], ["endothelial cells", "OBSERVATION", 125, 142], ["blood vessels", "ANATOMY", 146, 159], ["heart", "ANATOMY", 164, 169], ["renal tubules", "ANATOMY", 171, 184], ["enterocytes", "ANATOMY", 190, 201], ["small intestine", "ANATOMY", 205, 220]]], ["CD-147 (target for antibody, Meplazumab) and glucose regulated protein-78 are newly described receptors of SARS-CoV-2 for cellular entry [30, 31].Clinico-Immunological Phases ::: Pathogenesis of COVID-19Clinico-immunological progression suggests that COVID-19 can be divided into 3 phases: (1) Flu like illness with high viral load; (2) Critical phase (decreasing viral titres with accelerated inflammatory response causing lung and end-organ injury); and (3) Recovery phase.", [["cellular", "ANATOMY", 122, 130], ["lung", "ANATOMY", 424, 428], ["organ", "ANATOMY", 437, 442], ["CD-147", "CHEMICAL", 0, 6], ["Meplazumab", "CHEMICAL", 29, 39], ["glucose", "CHEMICAL", 45, 52], ["lung and end-organ injury", "DISEASE", 424, 449], ["Meplazumab", "CHEMICAL", 29, 39], ["glucose", "CHEMICAL", 45, 52], ["CD-147", "GENE_OR_GENE_PRODUCT", 0, 6], ["Meplazumab", "SIMPLE_CHEMICAL", 29, 39], ["glucose", "SIMPLE_CHEMICAL", 45, 52], ["regulated protein-78", "GENE_OR_GENE_PRODUCT", 53, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["cellular", "CELL", 122, 130], ["COVID-19", "CELL", 251, 259], ["Flu", "ORGANISM", 294, 297], ["lung", "ORGAN", 424, 428], ["organ", "ORGAN", 437, 442], ["Meplazumab", "PROTEIN", 29, 39], ["glucose regulated protein-78", "PROTEIN", 45, 73], ["CD", "TEST", 0, 2], ["antibody", "TEST", 19, 27], ["Meplazumab", "TEST", 29, 39], ["glucose regulated protein", "TEST", 45, 70], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115], ["cellular entry", "TEST", 122, 136], ["COVID", "TEST", 195, 200], ["COVID", "TEST", 251, 256], ["Flu like illness", "PROBLEM", 294, 310], ["high viral load", "PROBLEM", 316, 331], ["Critical phase (decreasing viral titres", "PROBLEM", 337, 376], ["accelerated inflammatory response", "PROBLEM", 382, 415], ["lung and end-organ injury", "PROBLEM", 424, 449], ["viral load", "OBSERVATION", 321, 331], ["inflammatory", "OBSERVATION_MODIFIER", 394, 406], ["lung", "ANATOMY", 424, 428], ["organ", "ANATOMY", 437, 442], ["injury", "OBSERVATION", 443, 449]]], ["SARS-CoV-2 titres in nasopharyngeal and endotracheal aspirate specimens are high during first week of symptoms followed by gradual decline starting at end of first week [32\u201335].", [["nasopharyngeal", "ANATOMY", 21, 35], ["endotracheal aspirate specimens", "ANATOMY", 40, 71], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["nasopharyngeal", "CANCER", 21, 35], ["endotracheal aspirate specimens", "MULTI-TISSUE_STRUCTURE", 40, 71], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["nasopharyngeal and endotracheal aspirate specimens", "TEST", 21, 71], ["symptoms", "PROBLEM", 102, 110], ["gradual decline", "PROBLEM", 123, 138], ["nasopharyngeal", "ANATOMY", 21, 35], ["endotracheal", "ANATOMY", 40, 52]]], ["In nasopharyngeal swabs from 76 patients, viral loads were significantly higher in severely affected (approximately 60 times) than mildly affected patients [36].", [["nasopharyngeal swabs", "ANATOMY", 3, 23], ["nasopharyngeal swabs", "CANCER", 3, 23], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 147, 155], ["nasopharyngeal swabs", "TEST", 3, 23], ["viral loads", "TEST", 42, 53], ["mildly affected patients", "PROBLEM", 131, 155], ["nasopharyngeal", "ANATOMY", 3, 17]]], ["Another study found that patients with severe illness had approximately 1 log10 higher viral titres (not statistically significant) [33].", [["illness", "DISEASE", 46, 53], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Another study", "TEST", 0, 13], ["severe illness", "PROBLEM", 39, 53], ["viral titres", "TEST", 87, 99], ["severe", "OBSERVATION_MODIFIER", 39, 45]]], ["A small series found no difference in viral loads between mild and severe disease.", [["A small series", "TEST", 0, 14], ["difference in viral loads between mild and severe disease", "PROBLEM", 24, 81], ["small", "OBSERVATION_MODIFIER", 2, 7], ["no", "UNCERTAINTY", 21, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["viral loads", "OBSERVATION", 38, 49], ["mild", "OBSERVATION_MODIFIER", 58, 62], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81]]], ["But the authors analyzed plasma RNAaemia and included only 2 and 4 patients with RNAaemia in severe and mild illness, respectively [37].", [["plasma", "ANATOMY", 25, 31], ["RNAaemia", "DISEASE", 81, 89], ["illness", "DISEASE", 109, 116], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["plasma RNAaemia", "TEST", 25, 40], ["RNAaemia in severe and mild illness", "PROBLEM", 81, 116], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["mild", "OBSERVATION_MODIFIER", 104, 108], ["illness", "OBSERVATION", 109, 116]]], ["After approximately 4\u20137 d, a proportion of patients enter critical phase which is associated with progressive decline in viral titres and worsening of inflammatory markers.", [["patients", "ORGANISM", 43, 51], ["inflammatory markers", "PROTEIN", 151, 171], ["patients", "SPECIES", 43, 51], ["progressive decline in viral titres", "PROBLEM", 98, 133], ["worsening of inflammatory markers", "PROBLEM", 138, 171], ["associated with", "UNCERTAINTY", 82, 97], ["progressive", "OBSERVATION_MODIFIER", 98, 109], ["decline", "OBSERVATION", 110, 117], ["viral titres", "OBSERVATION", 121, 133], ["worsening", "OBSERVATION_MODIFIER", 138, 147], ["inflammatory markers", "OBSERVATION", 151, 171]]], ["Patients with more severe disease have less steep and prolonged decline in viral titres [33].", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["more severe disease", "PROBLEM", 14, 33], ["prolonged decline in viral titres", "PROBLEM", 54, 87], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["disease", "OBSERVATION", 26, 33], ["less steep", "OBSERVATION_MODIFIER", 39, 49], ["prolonged", "OBSERVATION_MODIFIER", 54, 63], ["decline", "OBSERVATION_MODIFIER", 64, 71], ["viral titres", "OBSERVATION", 75, 87]]], ["Levels of inflammatory cytokines including IL-2, IL-6, IL-7, IL-10, GCSF, IP-10, MCP-1, MIP-1A, and TNF-\u03b1 are higher in critically ill patients than patients with mild disease [37, 38].", [["critically ill", "DISEASE", 120, 134], ["IL-2", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL-7", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["GCSF", "GENE_OR_GENE_PRODUCT", 68, 72], ["IP-10", "GENE_OR_GENE_PRODUCT", 74, 79], ["MCP-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["MIP-1A", "GENE_OR_GENE_PRODUCT", 88, 94], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 149, 157], ["inflammatory cytokines", "PROTEIN", 10, 32], ["GCSF", "PROTEIN", 68, 72], ["MCP", "PROTEIN", 81, 84], ["MIP", "PROTEIN", 88, 91], ["TNF-\u03b1", "PROTEIN", 100, 105], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 149, 157], ["inflammatory cytokines", "TEST", 10, 32], ["IL", "TEST", 43, 45], ["IL", "TEST", 49, 51], ["IL", "TEST", 55, 57], ["IL", "TEST", 61, 63], ["GCSF", "TEST", 68, 72], ["IP", "TEST", 74, 76], ["MCP", "TEST", 81, 84], ["MIP", "TEST", 88, 91], ["TNF", "TEST", 100, 103], ["mild disease", "PROBLEM", 163, 175], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["higher", "OBSERVATION_MODIFIER", 110, 116], ["mild", "OBSERVATION_MODIFIER", 163, 167], ["disease", "OBSERVATION", 168, 175]]], ["Number of T-cells, helper T-cells, and memory helper T-cells are decreased and na\u00efve helper T-cells is increased in severe group compared to mild group [39].", [["T-cells", "ANATOMY", 10, 17], ["helper T-cells", "ANATOMY", 19, 33], ["memory helper T-cells", "ANATOMY", 39, 60], ["na\u00efve helper T-cells", "ANATOMY", 79, 99], ["T-cells", "CELL", 10, 17], ["helper T-cells", "CELL", 19, 33], ["T-cells", "CELL", 53, 60], ["na\u00efve helper T-cells", "CELL", 79, 99], ["T-cells", "CELL_TYPE", 10, 17], ["helper T-cells", "CELL_TYPE", 19, 33], ["memory helper T-cells", "CELL_TYPE", 39, 60], ["na\u00efve helper T-cells", "CELL_TYPE", 79, 99], ["memory helper T-cells", "TEST", 39, 60], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["severe", "OBSERVATION_MODIFIER", 116, 122]]], ["Increase in IgG and IgM against SARS-CoV-2 antigens [internal nucleoprotein (NP) and receptor binding protein (RBP)] was seen around day 7\u201310 of symptoms, followed by gradual decrease in viral load [33, 34].", [["IgG", "GENE_OR_GENE_PRODUCT", 12, 15], ["IgM", "GENE_OR_GENE_PRODUCT", 20, 23], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 32, 51], ["internal nucleoprotein (NP) and receptor binding protein", "GENE_OR_GENE_PRODUCT", 53, 109], ["RBP", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgG", "PROTEIN", 12, 15], ["IgM", "PROTEIN", 20, 23], ["SARS-CoV-2 antigens", "PROTEIN", 32, 51], ["internal nucleoprotein", "PROTEIN", 53, 75], ["NP", "PROTEIN", 77, 79], ["receptor binding protein", "PROTEIN", 85, 109], ["RBP", "PROTEIN", 111, 114], ["SARS-CoV", "SPECIES", 32, 40], ["IgG", "TEST", 12, 15], ["IgM", "TEST", 20, 23], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["internal nucleoprotein (NP)", "TEST", 53, 80], ["receptor binding protein", "TEST", 85, 109], ["RBP", "TEST", 111, 114], ["symptoms", "PROBLEM", 145, 153], ["gradual decrease in viral load", "PROBLEM", 167, 197], ["viral load", "OBSERVATION", 187, 197]]], ["The persistent high virus titres, poorly controlled by dysfunctional immune system with elevated cytokine levels, point towards combined effect of virus mediated cytopathic effects and immune-mediated injury as the pathway of severe lung injury and multi-organ dysfunction during critical phase.", [["immune system", "ANATOMY", 69, 82], ["lung", "ANATOMY", 233, 237], ["multi-organ", "ANATOMY", 249, 260], ["lung injury", "DISEASE", 233, 244], ["multi-organ dysfunction", "DISEASE", 249, 272], ["immune system", "ANATOMICAL_SYSTEM", 69, 82], ["lung", "ORGAN", 233, 237], ["multi-organ", "ORGAN", 249, 260], ["cytokine", "PROTEIN", 97, 105], ["The persistent high virus titres", "PROBLEM", 0, 32], ["dysfunctional immune system", "PROBLEM", 55, 82], ["elevated cytokine levels", "PROBLEM", 88, 112], ["virus mediated cytopathic effects", "PROBLEM", 147, 180], ["immune-mediated injury", "PROBLEM", 185, 207], ["severe lung injury", "PROBLEM", 226, 244], ["multi-organ dysfunction", "PROBLEM", 249, 272], ["persistent", "OBSERVATION_MODIFIER", 4, 14], ["high virus titres", "OBSERVATION", 15, 32], ["elevated", "OBSERVATION_MODIFIER", 88, 96], ["cytokine levels", "OBSERVATION", 97, 112], ["virus", "OBSERVATION", 147, 152], ["cytopathic", "OBSERVATION_MODIFIER", 162, 172], ["severe", "OBSERVATION_MODIFIER", 226, 232], ["lung", "ANATOMY", 233, 237], ["injury", "OBSERVATION", 238, 244], ["multi-organ dysfunction", "OBSERVATION", 249, 272]]], ["Patients can succumb to illness during critical phase or gradually recover.Clinico-Immunological Phases ::: Pathogenesis of COVID-19Choice of therapeutic agents differs in different phases of illness.", [["illness", "DISEASE", 24, 31], ["COVID-19Choice", "CHEMICAL", 124, 138], ["Patients", "ORGANISM", 0, 8], ["COVID-19Choice", "SIMPLE_CHEMICAL", 124, 138], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 124, 129], ["therapeutic agents", "TREATMENT", 142, 160], ["illness", "PROBLEM", 192, 199], ["different phases", "OBSERVATION_MODIFIER", 172, 188]]], ["Personalized approach to therapeutics by establishing state of viral loads and inflammatory profile (pro- and anti-inflammatory cytokines levels) could be the best approach.", [["cytokines", "PROTEIN", 128, 137], ["viral loads", "TEST", 63, 74], ["inflammatory profile", "TEST", 79, 99], ["anti-inflammatory cytokines levels", "TEST", 110, 144]]], ["Overall, anti-viral therapy in initial phase and combination of anti-viral with immune-modulators in critical phase could be an appropriate choice.", [["anti-viral therapy", "TREATMENT", 9, 27], ["anti-viral", "TREATMENT", 64, 74], ["immune-modulators", "TREATMENT", 80, 97], ["anti-viral therapy", "OBSERVATION", 9, 27]]], ["As high viral titres are the most consistent feature of severe disease, more effective anti-viral drugs are the need of the hour.", [["high viral titres", "PROBLEM", 3, 20], ["severe disease", "PROBLEM", 56, 70], ["effective anti-viral drugs", "TREATMENT", 77, 103], ["most consistent feature", "UNCERTAINTY", 29, 52], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["disease", "OBSERVATION", 63, 70]]], ["Early effective anti-viral therapy could possibly prevent progression of disease to critical phase and improve outcomes and intensive care burden.Clinico-Immunological Phases ::: Pathogenesis of COVID-19There are no studies of viral loads, and cytokine levels in children with COVID-19.", [["children", "ORGANISM", 263, 271], ["cytokine", "PROTEIN", 244, 252], ["children", "SPECIES", 263, 271], ["Early effective anti-viral therapy", "TREATMENT", 0, 34], ["disease", "PROBLEM", 73, 80], ["COVID", "TEST", 195, 200], ["viral loads", "PROBLEM", 227, 238], ["cytokine levels", "TEST", 244, 259], ["COVID", "TEST", 277, 282], ["anti-viral therapy", "OBSERVATION", 16, 34], ["viral loads", "OBSERVATION", 227, 238]]], ["Immunological manifestations like lymphopenia (3.5%) and C-reactive protein (CRP) elevation (19.7%) are less common in children compared to adults (47% and > 50% respectively) [7].", [["lymphopenia", "DISEASE", 34, 45], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 57, 75], ["CRP", "GENE_OR_GENE_PRODUCT", 77, 80], ["children", "ORGANISM", 119, 127], ["C-reactive protein", "PROTEIN", 57, 75], ["CRP", "PROTEIN", 77, 80], ["children", "SPECIES", 119, 127], ["Immunological manifestations", "PROBLEM", 0, 28], ["lymphopenia", "PROBLEM", 34, 45], ["C-reactive protein", "TEST", 57, 75], ["CRP", "TEST", 77, 80], ["elevation", "TEST", 82, 91], ["lymphopenia", "OBSERVATION", 34, 45]]], ["Most of the children recover following initial short flu like illness without progressing to critical phase [7].Pathology of Lung Injury ::: Pathogenesis of COVID-19Lung specimens from early COVID-19 in two patients with concomitant lung cancer, showed proteinaceous and fibrinoid intra-alveolar exudates with mononuclear inflammation, multinucleated giant cells and type 2 pneumocyte hyperplasia [40].", [["Lung", "ANATOMY", 125, 129], ["COVID-19Lung specimens", "ANATOMY", 157, 179], ["lung cancer", "ANATOMY", 233, 244], ["proteinaceous", "ANATOMY", 253, 266], ["fibrinoid intra-alveolar exudates", "ANATOMY", 271, 304], ["mononuclear", "ANATOMY", 310, 321], ["multinucleated giant cells", "ANATOMY", 336, 362], ["illness", "DISEASE", 62, 69], ["Lung Injury", "DISEASE", 125, 136], ["lung cancer", "DISEASE", 233, 244], ["mononuclear inflammation", "DISEASE", 310, 334], ["hyperplasia", "DISEASE", 385, 396], ["children", "ORGANISM", 12, 20], ["Lung", "ORGAN", 125, 129], ["COVID-19Lung specimens", "CANCER", 157, 179], ["COVID-19", "CELL", 191, 199], ["patients", "ORGANISM", 207, 215], ["lung cancer", "CANCER", 233, 244], ["fibrinoid intra-alveolar exudates", "TISSUE", 271, 304], ["mononuclear", "CELL", 310, 321], ["multinucleated giant cells", "CELL", 336, 362], ["multinucleated giant cells", "CELL_TYPE", 336, 362], ["children", "SPECIES", 12, 20], ["patients", "SPECIES", 207, 215], ["initial short flu like illness", "PROBLEM", 39, 69], ["Lung Injury", "PROBLEM", 125, 136], ["COVID", "TEST", 157, 162], ["early COVID", "TEST", 185, 196], ["concomitant lung cancer", "PROBLEM", 221, 244], ["proteinaceous and fibrinoid intra-alveolar exudates", "PROBLEM", 253, 304], ["mononuclear inflammation", "PROBLEM", 310, 334], ["multinucleated giant cells", "PROBLEM", 336, 362], ["type 2 pneumocyte hyperplasia", "PROBLEM", 367, 396], ["Lung", "ANATOMY", 125, 129], ["Injury", "OBSERVATION", 130, 136], ["lung", "ANATOMY", 233, 237], ["cancer", "OBSERVATION", 238, 244], ["proteinaceous", "OBSERVATION_MODIFIER", 253, 266], ["fibrinoid", "OBSERVATION_MODIFIER", 271, 280], ["intra-alveolar exudates", "OBSERVATION", 281, 304], ["mononuclear inflammation", "OBSERVATION", 310, 334], ["multinucleated", "OBSERVATION_MODIFIER", 336, 350], ["giant cells", "OBSERVATION", 351, 362], ["pneumocyte hyperplasia", "OBSERVATION", 374, 396]]], ["Post-mortem specimen from 3 patients dying of acute respiratory failure (on day 1, day 6, and 2 wk of onset of respiratory failure), showed features of diffuse alveolar damage, hyaline bodies, type 2 pneumocyte hyperplasia and scanty mononuclear cells.", [["specimen", "ANATOMY", 12, 20], ["respiratory", "ANATOMY", 52, 63], ["respiratory", "ANATOMY", 111, 122], ["alveolar", "ANATOMY", 160, 168], ["hyaline bodies", "ANATOMY", 177, 191], ["pneumocyte hyperplasia", "ANATOMY", 200, 222], ["scanty mononuclear cells", "ANATOMY", 227, 251], ["respiratory failure", "DISEASE", 52, 71], ["respiratory failure", "DISEASE", 111, 130], ["alveolar damage", "DISEASE", 160, 175], ["hyperplasia", "DISEASE", 211, 222], ["patients", "ORGANISM", 28, 36], ["alveolar", "TISSUE", 160, 168], ["scanty mononuclear cells", "CELL", 227, 251], ["scanty mononuclear cells", "CELL_TYPE", 227, 251], ["patients", "SPECIES", 28, 36], ["Post-mortem specimen", "TEST", 0, 20], ["acute respiratory failure", "PROBLEM", 46, 71], ["respiratory failure", "PROBLEM", 111, 130], ["diffuse alveolar damage", "PROBLEM", 152, 175], ["hyaline bodies", "PROBLEM", 177, 191], ["type 2 pneumocyte hyperplasia", "PROBLEM", 193, 222], ["scanty mononuclear cells", "PROBLEM", 227, 251], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory failure", "OBSERVATION", 52, 71], ["respiratory failure", "OBSERVATION", 111, 130], ["diffuse", "OBSERVATION_MODIFIER", 152, 159], ["alveolar damage", "OBSERVATION", 160, 175], ["hyaline bodies", "OBSERVATION", 177, 191], ["type 2", "OBSERVATION_MODIFIER", 193, 199], ["pneumocyte hyperplasia", "OBSERVATION", 200, 222], ["scanty", "OBSERVATION_MODIFIER", 227, 233], ["mononuclear cells", "OBSERVATION", 234, 251]]], ["Occasional thrombi in small pulmonary arteries and fibrotic plugs could be seen [41\u201343].", [["thrombi", "ANATOMY", 11, 18], ["pulmonary arteries", "ANATOMY", 28, 46], ["thrombi", "DISEASE", 11, 18], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 28, 46], ["fibrotic plugs", "PATHOLOGICAL_FORMATION", 51, 65], ["Occasional thrombi in small pulmonary arteries", "PROBLEM", 0, 46], ["fibrotic plugs", "PROBLEM", 51, 65], ["thrombi", "OBSERVATION", 11, 18], ["small", "OBSERVATION_MODIFIER", 22, 27], ["pulmonary arteries", "ANATOMY", 28, 46], ["fibrotic", "OBSERVATION_MODIFIER", 51, 59], ["plugs", "OBSERVATION", 60, 65]]], ["These findings are similar to findings of SARS-CoV-1 infection [44].", [["SARS", "DISEASE", 42, 46], ["infection", "DISEASE", 53, 62], ["SARS-CoV-1", "ORGANISM", 42, 52], ["SARS-CoV-1", "SPECIES", 42, 52], ["SARS", "PROBLEM", 42, 46], ["1 infection", "PROBLEM", 51, 62]]], ["Immune staining for SARS-CoV-2 showed strong staining of alveolar epithelial cells including desquamated debris within alveoli and minimal staining of blood vessels or interstitium [42].", [["alveolar epithelial cells", "ANATOMY", 57, 82], ["debris", "ANATOMY", 105, 111], ["alveoli", "ANATOMY", 119, 126], ["blood vessels", "ANATOMY", 151, 164], ["interstitium", "ANATOMY", 168, 180], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["alveolar epithelial cells", "CELL", 57, 82], ["alveoli", "MULTI-TISSUE_STRUCTURE", 119, 126], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 151, 164], ["interstitium", "TISSUE", 168, 180], ["alveolar epithelial cells", "CELL_TYPE", 57, 82], ["SARS-CoV", "SPECIES", 20, 28], ["Immune staining", "TEST", 0, 15], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["alveolar epithelial cells", "PROBLEM", 57, 82], ["desquamated debris within alveoli", "PROBLEM", 93, 126], ["minimal staining of blood vessels", "PROBLEM", 131, 164], ["alveolar epithelial cells", "OBSERVATION", 57, 82], ["debris", "OBSERVATION", 105, 111], ["alveoli", "ANATOMY_MODIFIER", 119, 126], ["minimal", "OBSERVATION_MODIFIER", 131, 138], ["staining", "OBSERVATION", 139, 147], ["blood vessels", "ANATOMY", 151, 164], ["interstitium", "OBSERVATION_MODIFIER", 168, 180]]], ["These findings of strong virus staining of alveolar cells with few immune cells, point more towards direct virus mediated cell injury.", [["alveolar cells", "ANATOMY", 43, 57], ["immune cells", "ANATOMY", 67, 79], ["cell", "ANATOMY", 122, 126], ["alveolar cells", "CELL", 43, 57], ["immune cells", "CELL", 67, 79], ["cell", "CELL", 122, 126], ["alveolar cells", "CELL_TYPE", 43, 57], ["immune cells", "CELL_TYPE", 67, 79], ["strong virus staining of alveolar cells", "PROBLEM", 18, 57], ["few immune cells", "PROBLEM", 63, 79], ["direct virus mediated cell injury", "PROBLEM", 100, 133], ["strong", "OBSERVATION_MODIFIER", 18, 24], ["virus", "OBSERVATION", 25, 30], ["alveolar cells", "OBSERVATION", 43, 57], ["few", "OBSERVATION_MODIFIER", 63, 66], ["immune cells", "OBSERVATION", 67, 79], ["cell injury", "OBSERVATION", 122, 133]]], ["More post-mortem biopsies at different durations of illness, and pediatric autopsies and biopsies will provide additional information.Effect of ACE-2 ExpressionACE-2 is a counter-regulatory enzyme of renin-angiotensin-system which acts by converting angiotensin-2 to Ang-(1\u20137) form.", [["angiotensin", "CHEMICAL", 206, 217], ["angiotensin-2", "CHEMICAL", 250, 263], ["Ang", "CHEMICAL", 267, 270], ["post-mortem biopsies", "MULTI-TISSUE_STRUCTURE", 5, 25], ["biopsies", "CANCER", 89, 97], ["ACE-2 ExpressionACE-2", "GENE_OR_GENE_PRODUCT", 144, 165], ["renin", "GENE_OR_GENE_PRODUCT", 200, 205], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 250, 263], ["Ang-(1\u20137)", "SIMPLE_CHEMICAL", 267, 276], ["renin", "PROTEIN", 200, 205], ["post-mortem biopsies", "TEST", 5, 25], ["illness", "PROBLEM", 52, 59], ["pediatric autopsies", "TEST", 65, 84], ["biopsies", "TEST", 89, 97], ["ACE", "TEST", 144, 147], ["renin", "TEST", 200, 205], ["angiotensin-system", "TREATMENT", 206, 224], ["angiotensin", "TEST", 250, 261]]], ["In healthy state, ACE-2 activity maintains homeostasis between angiotensin-2 (vasoconstriction, inflammation, fibrosis and proliferation) and Ang-(1\u20137) pathways (vasodilatation, anti-apoptotic, anti-fibrosis, and anti-proliferation) [45].", [["angiotensin-2", "CHEMICAL", 63, 76], ["inflammation", "DISEASE", 96, 108], ["fibrosis", "DISEASE", 110, 118], ["Ang", "CHEMICAL", 142, 145], ["ACE-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 63, 76], ["Ang-(1\u20137)", "GENE_OR_GENE_PRODUCT", 142, 151], ["ACE", "PROTEIN", 18, 21], ["ACE", "TEST", 18, 21], ["angiotensin", "TEST", 63, 74], ["inflammation", "PROBLEM", 96, 108], ["fibrosis", "PROBLEM", 110, 118], ["proliferation", "PROBLEM", 123, 136], ["Ang", "TEST", 142, 145], ["vasodilatation", "TREATMENT", 162, 176], ["anti-apoptotic, anti-fibrosis", "TREATMENT", 178, 207], ["inflammation", "OBSERVATION", 96, 108], ["fibrosis", "OBSERVATION", 110, 118]]], ["After entering pneumocytes, SARS-CoV-2 downregulates ACE-2 expression, decreasing angiotensin-2 metabolism.", [["pneumocytes", "ANATOMY", 15, 26], ["angiotensin-2", "CHEMICAL", 82, 95], ["pneumocytes", "CELL", 15, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["ACE-2", "GENE_OR_GENE_PRODUCT", 53, 58], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 82, 95], ["pneumocytes", "CELL_TYPE", 15, 26], ["ACE", "PROTEIN", 53, 56], ["pneumocytes", "PROBLEM", 15, 26], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["ACE", "TEST", 53, 56], ["decreasing angiotensin", "TREATMENT", 71, 93], ["pneumocytes", "OBSERVATION", 15, 26], ["decreasing", "OBSERVATION_MODIFIER", 71, 81], ["angiotensin", "OBSERVATION", 82, 93]]], ["Elevated angiotensin-2 increases pulmonary vascular permeability and inflammation, hence worsening of lung injury [21, 46].", [["pulmonary vascular", "ANATOMY", 33, 51], ["lung", "ANATOMY", 102, 106], ["angiotensin-2", "CHEMICAL", 9, 22], ["inflammation", "DISEASE", 69, 81], ["lung injury", "DISEASE", 102, 113], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 9, 22], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 33, 51], ["lung", "ORGAN", 102, 106], ["Elevated angiotensin", "PROBLEM", 0, 20], ["pulmonary vascular permeability", "PROBLEM", 33, 64], ["inflammation", "PROBLEM", 69, 81], ["lung injury", "PROBLEM", 102, 113], ["angiotensin", "OBSERVATION", 9, 20], ["increases", "OBSERVATION_MODIFIER", 23, 32], ["pulmonary", "ANATOMY_MODIFIER", 33, 42], ["vascular", "ANATOMY", 43, 51], ["permeability", "OBSERVATION", 52, 64], ["inflammation", "OBSERVATION", 69, 81], ["worsening", "OBSERVATION_MODIFIER", 89, 98], ["lung", "ANATOMY", 102, 106], ["injury", "OBSERVATION", 107, 113]]], ["Angiotensin-2 levels have been found to be increased in COVID-19 patients compared to healthy adults [32].", [["Angiotensin", "CHEMICAL", 0, 11], ["Angiotensin-2", "GENE_OR_GENE_PRODUCT", 0, 13], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["Angiotensin-2 levels", "TEST", 0, 20], ["COVID", "TEST", 56, 61], ["increased", "OBSERVATION_MODIFIER", 43, 52]]], ["Angiotensin-2 levels have significant positive correlation with SARS-CoV-2 viral loads and lung injury severity, probably via ACE-2 down-regulation [32].", [["lung", "ANATOMY", 91, 95], ["Angiotensin", "CHEMICAL", 0, 11], ["lung injury", "DISEASE", 91, 102], ["Angiotensin-2", "GENE_OR_GENE_PRODUCT", 0, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["lung", "ORGAN", 91, 95], ["ACE-2", "GENE_OR_GENE_PRODUCT", 126, 131], ["ACE", "PROTEIN", 126, 129], ["SARS-CoV", "SPECIES", 64, 72], ["Angiotensin-2 levels", "TEST", 0, 20], ["significant positive correlation", "PROBLEM", 26, 58], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["viral loads", "TEST", 75, 86], ["lung injury severity", "PROBLEM", 91, 111], ["ACE", "TEST", 126, 129], ["lung", "ANATOMY", 91, 95], ["injury", "OBSERVATION", 96, 102]]], ["Elevated angiotensin-2 levels have also been seen with respiratory syncytial virus (RSV) and avian influenza pneumonia [47, 48].", [["angiotensin", "CHEMICAL", 9, 20], ["respiratory syncytial virus (RSV)", "DISEASE", 55, 88], ["influenza pneumonia", "DISEASE", 99, 118], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 9, 22], ["respiratory syncytial virus", "ORGANISM", 55, 82], ["RSV", "ORGANISM", 84, 87], ["avian influenza pneumonia", "SPECIES", 93, 118], ["respiratory syncytial virus", "SPECIES", 55, 82], ["RSV", "SPECIES", 84, 87], ["Elevated angiotensin-2 levels", "PROBLEM", 0, 29], ["respiratory syncytial virus", "PROBLEM", 55, 82], ["avian influenza pneumonia", "PROBLEM", 93, 118], ["angiotensin", "OBSERVATION", 9, 20], ["respiratory syncytial virus", "OBSERVATION", 55, 82], ["influenza", "OBSERVATION_MODIFIER", 99, 108], ["pneumonia", "OBSERVATION", 109, 118]]], ["ACE-2 levels decrease in old age and co-morbidities like hypertension and diabetes, possibly explaining worse lung injury and prognosis of SARS-CoV-2 in them [45, 49].", [["lung", "ANATOMY", 110, 114], ["hypertension", "DISEASE", 57, 69], ["diabetes", "DISEASE", 74, 82], ["lung injury", "DISEASE", 110, 121], ["SARS", "DISEASE", 139, 143], ["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 110, 114], ["ACE", "PROTEIN", 0, 3], ["SARS-CoV", "SPECIES", 139, 147], ["ACE", "TEST", 0, 3], ["co-morbidities", "PROBLEM", 37, 51], ["hypertension", "PROBLEM", 57, 69], ["diabetes", "PROBLEM", 74, 82], ["worse lung injury", "PROBLEM", 104, 121], ["SARS", "PROBLEM", 139, 143], ["CoV", "TEST", 144, 147], ["hypertension", "OBSERVATION", 57, 69], ["diabetes", "OBSERVATION", 74, 82], ["possibly explaining", "UNCERTAINTY", 84, 103], ["lung", "ANATOMY", 110, 114], ["injury", "OBSERVATION", 115, 121]]], ["In a phase-2 clinical trial of recombinant ACE-2 infusion in adults with acute respiratory distress syndrome (ARDS), there was significant decrease in angiotensin-2 levels, and increase in Ang-(1\u20137) and surfactant protein-4 levels [50].", [["respiratory", "ANATOMY", 79, 90], ["ACE-2", "CHEMICAL", 43, 48], ["acute respiratory distress syndrome", "DISEASE", 73, 108], ["ARDS", "DISEASE", 110, 114], ["angiotensin", "CHEMICAL", 151, 162], ["Ang", "CHEMICAL", 189, 192], ["ACE-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 151, 164], ["Ang-(1\u20137)", "GENE_OR_GENE_PRODUCT", 189, 198], ["surfactant protein-4", "GENE_OR_GENE_PRODUCT", 203, 223], ["recombinant ACE-2 infusion", "TREATMENT", 31, 57], ["acute respiratory distress syndrome", "PROBLEM", 73, 108], ["ARDS", "PROBLEM", 110, 114], ["significant decrease in angiotensin-2 levels", "PROBLEM", 127, 171], ["Ang", "TEST", 189, 192], ["surfactant protein", "TEST", 203, 221], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory distress", "OBSERVATION", 79, 99], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["decrease", "OBSERVATION_MODIFIER", 139, 147], ["increase", "OBSERVATION_MODIFIER", 177, 185]]], ["High levels of ACE-2 activity in children could be protective in children with COVID-19, leading to less severe disease in this age group compared to elderly.Effect of ACE-2 ExpressionHypothesis for the potential beneficial effect of ACE-2 in lung injury in COVID-19 is complicated by the fact that ACE-2 is also a primary receptor for SARS-CoV-2 in lungs.", [["lung", "ANATOMY", 243, 247], ["lungs", "ANATOMY", 350, 355], ["ACE-2", "CHEMICAL", 234, 239], ["lung injury", "DISEASE", 243, 254], ["COVID-19", "CHEMICAL", 258, 266], ["COVID-19", "CHEMICAL", 258, 266], ["ACE-2", "GENE_OR_GENE_PRODUCT", 15, 20], ["children", "ORGANISM", 33, 41], ["children", "ORGANISM", 65, 73], ["ACE-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["ACE-2", "GENE_OR_GENE_PRODUCT", 234, 239], ["lung", "ORGAN", 243, 247], ["ACE-2", "GENE_OR_GENE_PRODUCT", 299, 304], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 336, 346], ["lungs", "ORGAN", 350, 355], ["ACE", "PROTEIN", 15, 18], ["ACE", "PROTEIN", 299, 302], ["children", "SPECIES", 33, 41], ["children", "SPECIES", 65, 73], ["ACE-2 activity", "TREATMENT", 15, 29], ["COVID", "TEST", 79, 84], ["less severe disease", "PROBLEM", 100, 119], ["ACE", "TEST", 168, 171], ["ACE", "TEST", 234, 237], ["lung injury", "PROBLEM", 243, 254], ["ACE-2", "TREATMENT", 299, 304], ["SARS", "PROBLEM", 336, 340], ["CoV", "TEST", 341, 344], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["disease", "OBSERVATION", 112, 119], ["lung", "ANATOMY", 243, 247], ["injury", "OBSERVATION", 248, 254], ["lungs", "ANATOMY", 350, 355]]], ["While ACE-2 knockout mice showed worse lung injury with RSV and avian influenza infections, lungs of ACE-2 knockout rats had lesser virus titres, inflammatory cell infiltrates and injury score with SARS-CoV-1 infection compared to wild type rats [47, 48, 51].", [["lung", "ANATOMY", 39, 43], ["lungs", "ANATOMY", 92, 97], ["inflammatory cell", "ANATOMY", 146, 163], ["lung injury", "DISEASE", 39, 50], ["influenza infections", "DISEASE", 70, 90], ["infection", "DISEASE", 209, 218], ["ACE-2", "GENE_OR_GENE_PRODUCT", 6, 11], ["mice", "ORGANISM", 21, 25], ["lung", "ORGAN", 39, 43], ["RSV", "ORGANISM", 56, 59], ["avian influenza", "ORGANISM", 64, 79], ["lungs", "ORGAN", 92, 97], ["ACE-2", "GENE_OR_GENE_PRODUCT", 101, 106], ["rats", "ORGANISM", 116, 120], ["inflammatory cell", "CELL", 146, 163], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 198, 208], ["rats", "ORGANISM", 241, 245], ["ACE", "PROTEIN", 6, 9], ["mice", "SPECIES", 21, 25], ["avian", "SPECIES", 64, 69], ["rats", "SPECIES", 116, 120], ["rats", "SPECIES", 241, 245], ["mice", "SPECIES", 21, 25], ["RSV", "SPECIES", 56, 59], ["SARS-CoV-1", "SPECIES", 198, 208], ["ACE", "TEST", 6, 9], ["worse lung injury", "PROBLEM", 33, 50], ["RSV", "PROBLEM", 56, 59], ["avian influenza infections", "PROBLEM", 64, 90], ["ACE", "TEST", 101, 104], ["lesser virus titres", "PROBLEM", 125, 144], ["inflammatory cell infiltrates", "PROBLEM", 146, 175], ["injury score", "PROBLEM", 180, 192], ["SARS", "PROBLEM", 198, 202], ["CoV", "PROBLEM", 203, 206], ["1 infection", "PROBLEM", 207, 218], ["lung", "ANATOMY", 39, 43], ["injury", "OBSERVATION", 44, 50], ["RSV", "OBSERVATION", 56, 59], ["lungs", "ANATOMY", 92, 97], ["inflammatory cell infiltrates", "OBSERVATION", 146, 175], ["infection", "OBSERVATION", 209, 218]]], ["Among neonates, children, adults and elderly patients with ARDS, there was no difference in ACE, ACE-2 and ACE-2:ACE activity [52].Effect of ACE-2 ExpressionWith current evidence, it is difficult to ascertain which effect of lung ACE-2 activity is more important in SARS-CoV-2 infection i.e., protection against inflammation mediated lung injury or enhanced lung injury by facilitated virus entry.", [["lung", "ANATOMY", 225, 229], ["lung", "ANATOMY", 334, 338], ["lung", "ANATOMY", 358, 362], ["ARDS", "DISEASE", 59, 63], ["SARS", "DISEASE", 266, 270], ["infection", "DISEASE", 277, 286], ["inflammation", "DISEASE", 312, 324], ["lung injury", "DISEASE", 334, 345], ["lung injury", "DISEASE", 358, 369], ["neonates", "ORGANISM", 6, 14], ["children", "ORGANISM", 16, 24], ["adults", "ORGANISM", 26, 32], ["patients", "ORGANISM", 45, 53], ["ACE", "GENE_OR_GENE_PRODUCT", 92, 95], ["ACE-2", "GENE_OR_GENE_PRODUCT", 97, 102], ["ACE-2", "GENE_OR_GENE_PRODUCT", 107, 112], ["ACE", "GENE_OR_GENE_PRODUCT", 113, 116], ["ACE-2", "GENE_OR_GENE_PRODUCT", 141, 146], ["lung", "ORGAN", 225, 229], ["ACE-2", "GENE_OR_GENE_PRODUCT", 230, 235], ["SARS-CoV-2", "ORGANISM", 266, 276], ["lung", "ORGAN", 334, 338], ["lung", "ORGAN", 358, 362], ["children", "SPECIES", 16, 24], ["patients", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 266, 274], ["ARDS", "PROBLEM", 59, 63], ["ACE", "TEST", 92, 95], ["ACE", "TEST", 97, 100], ["ACE", "TREATMENT", 107, 110], ["ACE", "TEST", 141, 144], ["lung ACE", "TEST", 225, 233], ["SARS", "PROBLEM", 266, 270], ["CoV-2 infection", "PROBLEM", 271, 286], ["inflammation mediated lung injury", "PROBLEM", 312, 345], ["enhanced lung injury", "PROBLEM", 349, 369], ["facilitated virus entry", "PROBLEM", 373, 396], ["ARDS", "OBSERVATION", 59, 63], ["lung", "ANATOMY", 225, 229], ["infection", "OBSERVATION", 277, 286], ["lung", "ANATOMY", 334, 338], ["injury", "OBSERVATION", 339, 345], ["enhanced", "OBSERVATION_MODIFIER", 349, 357], ["lung", "ANATOMY", 358, 362], ["injury", "OBSERVATION", 363, 369]]], ["As COVID-19 is more severe in infants than older children, it is to be seen whether ACE-2 enhanced viral infection is responsible for this.", [["viral infection", "DISEASE", 99, 114], ["COVID-19", "GENE_OR_GENE_PRODUCT", 3, 11], ["infants", "ORGANISM", 30, 37], ["children", "ORGANISM", 49, 57], ["ACE-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["viral", "ORGANISM", 99, 104], ["COVID-19", "DNA", 3, 11], ["infants", "SPECIES", 30, 37], ["children", "SPECIES", 49, 57], ["ACE-2 enhanced viral infection", "PROBLEM", 84, 114], ["more severe", "OBSERVATION_MODIFIER", 15, 26], ["infection", "OBSERVATION", 105, 114]]], ["Recombinant ACE-2, ACE-inhibitors and angiotensin antagonists have been proposed as potential therapeutic options in adults.", [["angiotensin", "CHEMICAL", 38, 49], ["ACE-2", "GENE_OR_GENE_PRODUCT", 12, 17], ["ACE", "GENE_OR_GENE_PRODUCT", 19, 22], ["angiotensin antagonists", "GENE_OR_GENE_PRODUCT", 38, 61], ["adults", "ORGANISM", 117, 123], ["Recombinant ACE", "TREATMENT", 0, 15], ["ACE-inhibitors", "TREATMENT", 19, 33], ["angiotensin antagonists", "TREATMENT", 38, 61]]], ["Studies aimed at estimation of blood angiotensin-2 levels, and ACE-2 activity in lower respiratory tract samples in children with COVID-19 are needed.Mal-Adaptive Immune Response\u00a0in ElderlyAdult patients with severe COVID-19 have delayed clearance of SARS-CoV-2 [33].", [["blood", "ANATOMY", 31, 36], ["lower respiratory tract samples", "ANATOMY", 81, 112], ["angiotensin", "CHEMICAL", 37, 48], ["SARS", "DISEASE", 251, 255], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["angiotensin-2", "GENE_OR_GENE_PRODUCT", 37, 50], ["ACE-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["lower respiratory tract samples", "CANCER", 81, 112], ["children", "ORGANISM", 116, 124], ["patients", "ORGANISM", 195, 203], ["ACE", "PROTEIN", 63, 66], ["children", "SPECIES", 116, 124], ["patients", "SPECIES", 195, 203], ["Studies", "TEST", 0, 7], ["blood angiotensin", "TEST", 31, 48], ["ACE", "TEST", 63, 66], ["COVID", "TEST", 130, 135], ["severe COVID", "PROBLEM", 209, 221], ["delayed clearance of SARS", "PROBLEM", 230, 255], ["CoV", "TEST", 256, 259], ["lower", "ANATOMY_MODIFIER", 81, 86], ["respiratory tract", "ANATOMY", 87, 104], ["Immune Response", "OBSERVATION", 163, 178]]], ["Total lymphocyte, CD4+ and CD8+ T cell, helper T cell and memory T cell counts were significantly lower in patients with severely affected patients, pointing to depressed adaptive immunity [39].", [["Total lymphocyte", "ANATOMY", 0, 16], ["CD4+", "ANATOMY", 18, 22], ["T cell", "ANATOMY", 32, 38], ["helper T cell", "ANATOMY", 40, 53], ["memory T cell", "ANATOMY", 58, 71], ["depressed", "DISEASE", 161, 170], ["lymphocyte", "CELL", 6, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 18, 21], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["T cell", "CELL", 32, 38], ["helper T cell", "CELL", 40, 53], ["memory T cell", "CELL", 58, 71], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 139, 147], ["CD4", "PROTEIN", 18, 21], ["CD8", "PROTEIN", 27, 30], ["T cell", "CELL_TYPE", 32, 38], ["helper T cell", "CELL_TYPE", 40, 53], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 139, 147], ["Total lymphocyte", "TEST", 0, 16], ["CD4", "TEST", 18, 21], ["CD8", "TEST", 27, 30], ["memory T cell counts", "TEST", 58, 78], ["severely affected patients", "PROBLEM", 121, 147], ["depressed adaptive immunity", "PROBLEM", 161, 188], ["lymphocyte", "ANATOMY", 6, 16]]], ["Cytokines including IL-2, IL-6, and IL-10, and blood neutrophil counts are significantly elevated in severely ill patients, representing dysfunctional and exaggerated innate response causing lung injury [38].", [["blood neutrophil", "ANATOMY", 47, 63], ["lung", "ANATOMY", 191, 195], ["ill", "DISEASE", 110, 113], ["lung injury", "DISEASE", 191, 202], ["IL-2", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-6", "GENE_OR_GENE_PRODUCT", 26, 30], ["IL-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["blood neutrophil", "CELL", 47, 63], ["patients", "ORGANISM", 114, 122], ["lung", "ORGAN", 191, 195], ["Cytokines", "PROTEIN", 0, 9], ["IL", "PROTEIN", 36, 38], ["patients", "SPECIES", 114, 122], ["Cytokines", "TEST", 0, 9], ["IL", "TEST", 20, 22], ["IL", "TEST", 26, 28], ["IL", "TEST", 36, 38], ["blood neutrophil counts", "TEST", 47, 70], ["significantly elevated", "PROBLEM", 75, 97], ["dysfunctional and exaggerated innate response", "PROBLEM", 137, 182], ["lung injury", "PROBLEM", 191, 202], ["blood", "ANATOMY", 47, 52], ["neutrophil counts", "OBSERVATION", 53, 70], ["severely ill", "OBSERVATION_MODIFIER", 101, 113], ["lung", "ANATOMY", 191, 195], ["injury", "OBSERVATION", 196, 202]]], ["Innate immunity over-activity was also seen in human type 2 alveolar cell cultures infected with SARS-CoV-1, showing excessive mRNA expression of interferon-\u03b2, interferon-\u03bb (IL-29) and other pro-inflammatory cytokines [53].", [["type 2 alveolar cell cultures", "ANATOMY", 53, 82], ["human", "ORGANISM", 47, 52], ["alveolar cell cultures", "CELL", 60, 82], ["SARS-CoV-1", "ORGANISM", 97, 107], ["interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 146, 158], ["interferon-\u03bb", "GENE_OR_GENE_PRODUCT", 160, 172], ["IL-29", "GENE_OR_GENE_PRODUCT", 174, 179], ["human type 2 alveolar cell cultures", "CELL_LINE", 47, 82], ["interferon", "PROTEIN", 146, 156], ["\u03b2", "PROTEIN", 157, 158], ["interferon-\u03bb (IL-29", "PROTEIN", 160, 179], ["pro-inflammatory cytokines", "PROTEIN", 191, 217], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["SARS-CoV-1", "SPECIES", 97, 107], ["alveolar cell cultures", "TEST", 60, 82], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["excessive mRNA expression", "PROBLEM", 117, 142], ["interferon", "TREATMENT", 146, 156], ["interferon", "TREATMENT", 160, 170], ["IL", "TEST", 174, 176], ["alveolar cell", "ANATOMY", 60, 73]]], ["These responses point toward an uncontrolled virus-induced lung injury and secondary cytokine mediated injury.", [["lung", "ANATOMY", 59, 63], ["lung injury", "DISEASE", 59, 70], ["lung", "ORGAN", 59, 63], ["cytokine", "PROTEIN", 85, 93], ["an uncontrolled virus", "PROBLEM", 29, 50], ["lung injury", "PROBLEM", 59, 70], ["secondary cytokine mediated injury", "PROBLEM", 75, 109], ["uncontrolled", "OBSERVATION_MODIFIER", 32, 44], ["virus", "OBSERVATION", 45, 50], ["lung", "ANATOMY", 59, 63], ["injury", "OBSERVATION", 64, 70], ["secondary cytokine mediated injury", "OBSERVATION", 75, 109]]], ["Immune system response seems to be appropriate in children, as most of the children with COVID-19 have normal lymphocyte count [7].", [["lymphocyte", "ANATOMY", 110, 120], ["children", "ORGANISM", 50, 58], ["children", "ORGANISM", 75, 83], ["lymphocyte", "CELL", 110, 120], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 75, 83], ["COVID", "TEST", 89, 94], ["lymphocyte count", "OBSERVATION", 110, 126]]], ["Studies on sequential viral loads, lymphocyte subset and alveolar lining fluid cytokine profile are lacking in children.Trained Immunity ::: Protective Immunological Mechanisms in ChildrenTrained immunity is the functional re-programming of innate immune cells to a more activated state following initial antigen stimulation (infections or vaccination) through metabolic re-programming (enhanced Kreb's cycle) and epigenetic changes (acetylation and demethylation leading to enhanced transcription of IL-1\u03b2, IL-6 and TNF-\u03b1 genes).", [["lymphocyte", "ANATOMY", 35, 45], ["alveolar lining fluid", "ANATOMY", 57, 78], ["immune cells", "ANATOMY", 248, 260], ["infections", "DISEASE", 326, 336], ["lymphocyte", "CELL", 35, 45], ["alveolar", "MULTI-TISSUE_STRUCTURE", 57, 65], ["children", "ORGANISM", 111, 119], ["innate immune cells", "CELL", 241, 260], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 501, 506], ["IL-6", "GENE_OR_GENE_PRODUCT", 508, 512], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 517, 522], ["lymphocyte subset", "CELL_TYPE", 35, 52], ["cytokine", "PROTEIN", 79, 87], ["innate immune cells", "CELL_TYPE", 241, 260], ["IL-1\u03b2, IL-6 and TNF-\u03b1 genes", "DNA", 501, 528], ["children", "SPECIES", 111, 119], ["Studies", "TEST", 0, 7], ["sequential viral loads", "TEST", 11, 33], ["lymphocyte subset", "TEST", 35, 52], ["alveolar lining fluid cytokine profile", "TEST", 57, 95], ["innate immune cells", "TREATMENT", 241, 260], ["initial antigen stimulation", "TREATMENT", 297, 324], ["infections", "PROBLEM", 326, 336], ["metabolic re-programming", "TEST", 361, 385], ["enhanced Kreb's cycle", "TEST", 387, 408], ["epigenetic changes", "PROBLEM", 414, 432], ["acetylation and demethylation", "TREATMENT", 434, 463], ["IL", "TEST", 501, 503], ["IL", "TEST", 508, 510], ["TNF", "TEST", 517, 520], ["alveolar lining", "OBSERVATION", 57, 72], ["fluid cytokine", "OBSERVATION", 73, 87]]], ["It can affect progenitor cells of myeloid and monocyte cell lines as well as local cells (lung macrophages and dendritic cells) [54].Trained Immunity ::: Protective Immunological Mechanisms in ChildrenIt has been postulated that countries with routine Bacille Calmette-Guerin (BCG) vaccination have less COVID-19 related morbidity and mortality [55].", [["progenitor cells", "ANATOMY", 14, 30], ["myeloid", "ANATOMY", 34, 41], ["monocyte cell lines", "ANATOMY", 46, 65], ["cells", "ANATOMY", 83, 88], ["lung macrophages", "ANATOMY", 90, 106], ["dendritic cells", "ANATOMY", 111, 126], ["Bacille Calmette-Guerin", "CHEMICAL", 252, 275], ["progenitor cells", "CELL", 14, 30], ["myeloid", "CELL", 34, 41], ["monocyte cell lines", "CELL", 46, 65], ["cells", "CELL", 83, 88], ["lung macrophages", "CELL", 90, 106], ["dendritic cells", "CELL", 111, 126], ["Children", "ORGANISM", 193, 201], ["Bacille Calmette-Guerin", "ORGANISM", 252, 275], ["progenitor cells", "CELL_TYPE", 14, 30], ["myeloid and monocyte cell lines", "CELL_LINE", 34, 65], ["local cells", "CELL_TYPE", 77, 88], ["lung macrophages", "CELL_TYPE", 90, 106], ["dendritic cells", "CELL_TYPE", 111, 126], ["Children", "SPECIES", 193, 201], ["myeloid and monocyte cell lines", "TREATMENT", 34, 65], ["local cells (lung macrophages", "PROBLEM", 77, 106], ["routine Bacille Calmette", "TREATMENT", 244, 268], ["Guerin (BCG) vaccination", "TREATMENT", 269, 293], ["progenitor cells", "OBSERVATION", 14, 30], ["myeloid", "ANATOMY", 34, 41], ["monocyte cell lines", "OBSERVATION", 46, 65], ["local cells", "OBSERVATION", 77, 88], ["lung", "ANATOMY", 90, 94], ["macrophages", "OBSERVATION", 95, 106], ["dendritic cells", "OBSERVATION", 111, 126]]], ["Following BCG vaccination in adults, there is enhanced pattern recognition receptors expression in monocytes and elevation of Th1 and Th17 immune response to non-mycobacterial stimulation, up to 1 y following vaccination [56].", [["monocytes", "ANATOMY", 99, 108], ["monocytes", "CELL", 99, 108], ["Th1", "CELL", 126, 129], ["monocytes", "CELL_TYPE", 99, 108], ["BCG vaccination", "TREATMENT", 10, 25], ["monocytes", "TEST", 99, 108], ["elevation of Th1", "PROBLEM", 113, 129], ["non-mycobacterial stimulation", "TREATMENT", 158, 187], ["receptors expression", "OBSERVATION", 75, 95], ["monocytes", "ANATOMY", 99, 108], ["elevation", "OBSERVATION_MODIFIER", 113, 122], ["Th1", "ANATOMY", 126, 129]]], ["In a randomized trial, BCG vaccination was associated with reduced viremia with experimental attenuated yellow virus strain infection and epigenetic changes in monocytes [57].", [["monocytes", "ANATOMY", 160, 169], ["viremia", "DISEASE", 67, 74], ["infection", "DISEASE", 124, 133], ["yellow virus strain", "ORGANISM", 104, 123], ["monocytes", "CELL", 160, 169], ["monocytes", "CELL_TYPE", 160, 169], ["yellow virus", "SPECIES", 104, 116], ["a randomized trial", "TREATMENT", 3, 21], ["BCG vaccination", "TREATMENT", 23, 38], ["reduced viremia", "PROBLEM", 59, 74], ["experimental attenuated yellow virus strain infection", "PROBLEM", 80, 133], ["epigenetic changes in monocytes", "PROBLEM", 138, 169], ["attenuated", "OBSERVATION_MODIFIER", 93, 103], ["yellow virus", "OBSERVATION", 104, 116]]], ["IL-1\u03b2 response upregulation correlated with reduction of viremia [57].", [["viremia", "DISEASE", 57, 64], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1\u03b2", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["viremia", "PROBLEM", 57, 64], ["viremia", "OBSERVATION", 57, 64]]], ["BCG vaccination has been associated with decrease in acute upper respiratory infection (URI) in elders and decreased mortality in under-5 children [58, 59].", [["respiratory", "ANATOMY", 65, 76], ["upper respiratory infection", "DISEASE", 59, 86], ["URI", "DISEASE", 88, 91], ["upper respiratory", "ORGANISM_SUBDIVISION", 59, 76], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["BCG vaccination", "TREATMENT", 0, 15], ["acute upper respiratory infection", "PROBLEM", 53, 86], ["URI", "PROBLEM", 88, 91], ["associated with", "UNCERTAINTY", 25, 40], ["decrease", "OBSERVATION_MODIFIER", 41, 49], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory", "ANATOMY", 65, 76], ["infection", "OBSERVATION", 77, 86], ["decreased", "OBSERVATION_MODIFIER", 107, 116], ["mortality", "OBSERVATION_MODIFIER", 117, 126]]], ["BCG is also emerging as an interesting option to enhance immunity of at-risk population for severe COVID-19 disease such as elderly and healthcare workers [60, 61].", [["COVID", "DISEASE", 99, 104], ["BCG", "PROBLEM", 0, 3], ["severe COVID-19 disease", "PROBLEM", 92, 115]]], ["But, protective effect of BCG against infections is unlikely to last beyond 1\u20132 y [56].", [["BCG", "CHEMICAL", 26, 29], ["infections", "DISEASE", 38, 48], ["BCG", "SIMPLE_CHEMICAL", 26, 29], ["BCG", "TREATMENT", 26, 29], ["infections", "PROBLEM", 38, 48]]], ["It will be worthwhile to evaluate the role of BCG in infants and children with co-morbidities, especially in countries lacking universal BCG immunization.Trained Immunity ::: Protective Immunological Mechanisms in ChildrenMice infected with live adenoviral vaccine vector have been shown to induce self-sustained memory alveolar macrophages [62].", [["alveolar macrophages", "ANATOMY", 320, 340], ["infants", "ORGANISM", 53, 60], ["children", "ORGANISM", 65, 73], ["adenoviral", "ORGANISM", 246, 256], ["alveolar macrophages", "CELL", 320, 340], ["memory alveolar macrophages", "CELL_TYPE", 313, 340], ["infants", "SPECIES", 53, 60], ["children", "SPECIES", 65, 73], ["adenoviral", "SPECIES", 246, 256], ["co-morbidities", "PROBLEM", 79, 93], ["universal BCG immunization", "TREATMENT", 127, 153], ["live adenoviral vaccine vector", "TREATMENT", 241, 271], ["alveolar macrophages", "OBSERVATION", 320, 340]]], ["Live vaccines against measles and polio have shown to improve childhood mortality, in additional to the specific infections [63].", [["measles and polio", "DISEASE", 22, 39], ["infections", "DISEASE", 113, 123], ["measles", "ORGANISM", 22, 29], ["Live vaccines", "TREATMENT", 0, 13], ["measles", "PROBLEM", 22, 29]]], ["Trained immunity due to routine live vaccines (against measles, mumps, rubella, and influenza) and frequent viral infections could be an important protective mechanism against SARS-CoV-2 infection in children.Cross Immunity to Other Coronavirus Infections ::: Protective Immunological Mechanisms in ChildrenCross-reactive antibodies (CR3022) targeting highly conserved domain of SARS-CoV-1 and SARS-CoV-2 showed low affinity for SARS-CoV-2 [64].", [["measles, mumps, rubella", "DISEASE", 55, 78], ["influenza", "DISEASE", 84, 93], ["viral infections", "DISEASE", 108, 124], ["SARS-CoV-2 infection", "DISEASE", 176, 196], ["Coronavirus Infections", "DISEASE", 233, 255], ["mumps", "ORGANISM", 64, 69], ["SARS-CoV-2", "ORGANISM", 176, 186], ["children", "ORGANISM", 200, 208], ["ChildrenCross-reactive antibodies", "GENE_OR_GENE_PRODUCT", 299, 332], ["CR3022", "SIMPLE_CHEMICAL", 334, 340], ["SARS-CoV-1", "ORGANISM", 379, 389], ["SARS-CoV-2", "ORGANISM", 394, 404], ["ChildrenCross-reactive antibodies", "PROTEIN", 299, 332], ["CR3022", "PROTEIN", 334, 340], ["SARS-CoV-2", "DNA", 394, 404], ["CoV-2", "SPECIES", 181, 186], ["children", "SPECIES", 200, 208], ["SARS-CoV-2", "SPECIES", 176, 186], ["SARS-CoV-1", "SPECIES", 379, 389], ["SARS-CoV", "SPECIES", 394, 402], ["SARS-CoV", "SPECIES", 429, 437], ["routine live vaccines", "TREATMENT", 24, 45], ["measles", "PROBLEM", 55, 62], ["mumps", "PROBLEM", 64, 69], ["rubella", "PROBLEM", 71, 78], ["influenza", "PROBLEM", 84, 93], ["frequent viral infections", "PROBLEM", 99, 124], ["SARS", "PROBLEM", 176, 180], ["2 infection", "PROBLEM", 185, 196], ["reactive antibodies", "TEST", 313, 332], ["SARS", "TEST", 379, 383], ["CoV", "TEST", 384, 387], ["SARS", "TEST", 394, 398], ["CoV", "TEST", 399, 402], ["low affinity", "PROBLEM", 412, 424], ["SARS", "PROBLEM", 429, 433], ["CoV", "TEST", 434, 437], ["infection", "OBSERVATION", 187, 196], ["reactive antibodies", "OBSERVATION", 313, 332]]], ["Antibodies against conserved epitopes of influenza following influenza infection have been shown to have heterosubtypic influenza immunity [65, 66].", [["influenza", "DISEASE", 41, 50], ["influenza infection", "DISEASE", 61, 80], ["influenza", "DISEASE", 120, 129], ["Antibodies", "TREATMENT", 0, 10], ["influenza", "PROBLEM", 41, 50], ["influenza infection", "PROBLEM", 61, 80], ["heterosubtypic influenza immunity", "PROBLEM", 105, 138], ["influenza", "OBSERVATION", 41, 50]]], ["As coronavirus infections are common causes of URI in children, protective role of antibodies from other coronavirus infections against SARS-CoV-2 cannot be ruled out.", [["coronavirus infections", "DISEASE", 3, 25], ["URI", "DISEASE", 47, 50], ["coronavirus infections", "DISEASE", 105, 127], ["SARS", "DISEASE", 136, 140], ["coronavirus", "ORGANISM", 3, 14], ["children", "ORGANISM", 54, 62], ["coronavirus", "ORGANISM", 105, 116], ["SARS-CoV-2", "ORGANISM", 136, 146], ["antibodies", "PROTEIN", 83, 93], ["children", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 136, 144], ["coronavirus infections", "PROBLEM", 3, 25], ["URI", "PROBLEM", 47, 50], ["antibodies", "PROBLEM", 83, 93], ["other coronavirus infections", "PROBLEM", 99, 127], ["SARS", "PROBLEM", 136, 140], ["CoV", "PROBLEM", 141, 144], ["URI", "OBSERVATION", 47, 50]]], ["There are also concerns of antibody-dependent enhancement of disease severity due to low affinity antibodies from other coronavirus infections including SARS, which need considerations while developing vaccines and administering convalescent plasma in severe SARS-CoV-19 [67].", [["plasma", "ANATOMY", 242, 248], ["coronavirus infections", "DISEASE", 120, 142], ["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 259, 263], ["coronavirus", "ORGANISM", 120, 131], ["plasma", "ORGANISM_SUBSTANCE", 242, 248], ["low affinity antibodies", "PROTEIN", 85, 108], ["SARS-CoV-19", "SPECIES", 259, 270], ["antibody-dependent enhancement of disease severity", "PROBLEM", 27, 77], ["low affinity antibodies", "PROBLEM", 85, 108], ["other coronavirus infections", "PROBLEM", 114, 142], ["SARS", "PROBLEM", 153, 157], ["vaccines", "TREATMENT", 202, 210], ["convalescent plasma", "TEST", 229, 248], ["severe SARS", "PROBLEM", 252, 263], ["CoV", "TEST", 264, 267], ["antibody", "OBSERVATION", 27, 35], ["dependent", "OBSERVATION_MODIFIER", 36, 45], ["enhancement", "OBSERVATION_MODIFIER", 46, 57], ["disease", "OBSERVATION", 61, 68], ["low affinity", "OBSERVATION_MODIFIER", 85, 97], ["coronavirus", "OBSERVATION_MODIFIER", 120, 131], ["infections", "OBSERVATION", 132, 142]]], ["Till now, there are no reports of COVID-19 in patients who suffered from SARS or MERS previously.Developmental Changes in ImmunityAntigen na\u00efve immature immune system in young infants and ageing related relative immune deficiency/ dysfunction in elderly, predisposes these populations to severe ALRI to viruses like RSV and seasonal influenza [68].", [["immune system", "ANATOMY", 153, 166], ["SARS", "DISEASE", 73, 77], ["MERS", "DISEASE", 81, 85], ["immune deficiency/ dysfunction", "DISEASE", 212, 242], ["ALRI", "DISEASE", 295, 299], ["RSV", "DISEASE", 316, 319], ["influenza", "DISEASE", 333, 342], ["patients", "ORGANISM", 46, 54], ["infants", "ORGANISM", 176, 183], ["RSV", "ORGANISM", 316, 319], ["patients", "SPECIES", 46, 54], ["infants", "SPECIES", 176, 183], ["RSV", "SPECIES", 316, 319], ["RSV", "SPECIES", 316, 319], ["SARS", "PROBLEM", 73, 77], ["Developmental Changes", "PROBLEM", 97, 118], ["relative immune deficiency", "PROBLEM", 203, 229], ["dysfunction", "PROBLEM", 231, 242], ["these populations", "PROBLEM", 267, 284], ["severe ALRI to viruses", "PROBLEM", 288, 310], ["RSV", "PROBLEM", 316, 319], ["seasonal influenza", "PROBLEM", 324, 342], ["immune deficiency", "OBSERVATION", 212, 229]]], ["As highlighted above, still younger children fare better than the elderly in most scenarios.Developmental Changes in ImmunityPredominant response to infectious stimulus in young infants is innate response and less prominent adaptive response.", [["children", "ORGANISM", 36, 44], ["infants", "ORGANISM", 178, 185], ["children", "SPECIES", 36, 44], ["infants", "SPECIES", 178, 185], ["Developmental Changes", "PROBLEM", 92, 113], ["infectious stimulus", "TREATMENT", 149, 168], ["ImmunityPredominant", "OBSERVATION_MODIFIER", 117, 136], ["infectious", "OBSERVATION_MODIFIER", 149, 159], ["less prominent", "OBSERVATION_MODIFIER", 209, 223]]], ["In a study from Latin America of children from age groups 6\u20139, 22\u201326, and 48\u201360 mo, younger children had higher release of cytokines IL-6, IL-8, IL-10 and TNF-alpha to toll like-receptor (TLR) stimulation i.e., more robust innate response.", [["children", "ORGANISM", 33, 41], ["children", "ORGANISM", 92, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 133, 137], ["IL-8", "GENE_OR_GENE_PRODUCT", 139, 143], ["IL-10", "GENE_OR_GENE_PRODUCT", 145, 150], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 155, 164], ["toll like-receptor", "GENE_OR_GENE_PRODUCT", 168, 186], ["TLR", "GENE_OR_GENE_PRODUCT", 188, 191], ["cytokines", "PROTEIN", 123, 132], ["IL-6", "PROTEIN", 133, 137], ["TNF-alpha", "PROTEIN", 155, 164], ["TLR", "PROTEIN", 188, 191], ["children", "SPECIES", 33, 41], ["children", "SPECIES", 92, 100], ["cytokines IL", "TEST", 123, 135], ["IL", "TEST", 139, 141], ["IL", "TEST", 145, 147], ["TNF", "TREATMENT", 155, 158], ["receptor (TLR) stimulation", "TREATMENT", 178, 204]]], ["The percentage of CD4+ na\u00efve T-cells decreased while memory T cells increased with age [69].", [["CD4+ na\u00efve T-cells", "ANATOMY", 18, 36], ["memory T cells", "ANATOMY", 53, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 18, 21], ["memory T cells", "CELL", 53, 67], ["CD4", "PROTEIN", 18, 21], ["na\u00efve T-cells", "CELL_TYPE", 23, 36], ["memory T cells", "CELL_TYPE", 53, 67], ["CD4", "TEST", 18, 21], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["An inadequate adaptive response could explain worse course of illness seen in COVID-19 affected young infants compared to older children.", [["illness", "DISEASE", 62, 69], ["infants", "ORGANISM", 102, 109], ["children", "ORGANISM", 128, 136], ["infants", "SPECIES", 102, 109], ["children", "SPECIES", 128, 136], ["illness", "PROBLEM", 62, 69]]], ["Also, maternal antibodies protecting neonates and young infants, are unlikely to act against novel viruses like SARS-CoV-2 [70].Developmental Changes in ImmunityAgeing related immune-senescence in the elderly predisposes them to increased incidence and severity of ALRIs.", [["SARS", "DISEASE", 112, 116], ["ALRIs", "DISEASE", 265, 270], ["neonates", "ORGANISM", 37, 45], ["infants", "ORGANISM", 56, 63], ["SARS-CoV-2", "ORGANISM", 112, 122], ["ALRIs", "PATHOLOGICAL_FORMATION", 265, 270], ["maternal antibodies", "PROTEIN", 6, 25], ["infants", "SPECIES", 56, 63], ["SARS-CoV", "SPECIES", 112, 120], ["maternal antibodies protecting neonates", "PROBLEM", 6, 45], ["novel viruses", "PROBLEM", 93, 106], ["CoV", "TEST", 117, 120], ["Developmental Changes", "PROBLEM", 128, 149], ["severity of ALRIs", "PROBLEM", 253, 270]]], ["RSV infection in aged cotton rats showed prolonged viral replication and delayed rise in cytokine levels compared to younger rats [71].", [["RSV infection", "DISEASE", 0, 13], ["RSV", "ORGANISM", 0, 3], ["cotton rats", "ORGANISM", 22, 33], ["rats", "ORGANISM", 125, 129], ["cytokine", "PROTEIN", 89, 97], ["rats", "SPECIES", 29, 33], ["rats", "SPECIES", 125, 129], ["RSV", "SPECIES", 0, 3], ["cotton", "SPECIES", 22, 28], ["RSV infection", "PROBLEM", 0, 13], ["cotton rats", "TEST", 22, 33], ["prolonged viral replication", "PROBLEM", 41, 68], ["delayed rise in cytokine levels", "PROBLEM", 73, 104], ["infection", "OBSERVATION", 4, 13], ["viral replication", "OBSERVATION", 51, 68], ["rise", "OBSERVATION_MODIFIER", 81, 85]]], ["Multiple innate immunity aberrations have been reported in elderly: reduced dendritic cell number and function, decreased TLR induction, upregulation of proinflammatory cytokines, decreased macrophage and neutrophil function, reduced NK-cell activity, decreased \u03b3\u03b4 T cell proliferation and number [72, 73].", [["dendritic cell", "ANATOMY", 76, 90], ["macrophage", "ANATOMY", 190, 200], ["neutrophil", "ANATOMY", 205, 215], ["NK-cell", "ANATOMY", 234, 241], ["\u03b3\u03b4 T cell", "ANATOMY", 262, 271], ["dendritic cell", "CELL", 76, 90], ["TLR", "GENE_OR_GENE_PRODUCT", 122, 125], ["macrophage", "CELL", 190, 200], ["neutrophil", "CELL", 205, 215], ["NK-cell", "CELL", 234, 241], ["\u03b3\u03b4 T cell", "CELL", 262, 271], ["TLR", "PROTEIN", 122, 125], ["proinflammatory cytokines", "PROTEIN", 153, 178], ["\u03b3\u03b4 T cell", "CELL_TYPE", 262, 271], ["Multiple innate immunity aberrations", "PROBLEM", 0, 36], ["decreased TLR induction", "TREATMENT", 112, 135], ["proinflammatory cytokines", "PROBLEM", 153, 178], ["decreased macrophage", "PROBLEM", 180, 200], ["neutrophil function", "TEST", 205, 224], ["reduced NK-cell activity", "PROBLEM", 226, 250], ["decreased \u03b3\u03b4 T cell proliferation", "PROBLEM", 252, 285], ["immunity aberrations", "OBSERVATION", 16, 36], ["dendritic cell number", "OBSERVATION", 76, 97], ["decreased", "OBSERVATION_MODIFIER", 112, 121], ["TLR", "OBSERVATION_MODIFIER", 122, 125], ["proinflammatory cytokines", "OBSERVATION", 153, 178], ["decreased", "OBSERVATION_MODIFIER", 180, 189], ["macrophage", "OBSERVATION_MODIFIER", 190, 200], ["neutrophil function", "OBSERVATION", 205, 224], ["cell activity", "OBSERVATION", 237, 250], ["decreased", "OBSERVATION_MODIFIER", 252, 261], ["cell proliferation", "OBSERVATION", 267, 285]]], ["These factors lead to excessively pro-inflammatory response to infections; as well as delay in or lack of switch from an innate immune response to an adaptive immune response [21].", [["infections", "DISEASE", 63, 73], ["These factors", "PROBLEM", 0, 13], ["excessively pro-inflammatory response to infections", "PROBLEM", 22, 73], ["an innate immune response", "TREATMENT", 118, 143], ["infections", "OBSERVATION", 63, 73]]], ["In patients with SARS, the survivors had a gene expression profile indicative of development of an adaptive immune response while deceased showed persistently elevated levels of pro-inflammatory cytokines encoded by the interferon-stimulated genes [74].Effects of Lung DevelopmentWhile ageing, lungs gradually have impaired regenerative potential [75].", [["Lung", "ANATOMY", 264, 268], ["lungs", "ANATOMY", 294, 299], ["SARS", "DISEASE", 17, 21], ["patients", "ORGANISM", 3, 11], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 220, 247], ["Lung", "ORGAN", 264, 268], ["lungs", "ORGAN", 294, 299], ["pro-inflammatory cytokines", "PROTEIN", 178, 204], ["interferon-stimulated genes", "DNA", 220, 247], ["patients", "SPECIES", 3, 11], ["SARS", "PROBLEM", 17, 21], ["persistently elevated levels of pro-inflammatory cytokines", "PROBLEM", 146, 204], ["pro-inflammatory cytokines", "OBSERVATION", 178, 204], ["Lung", "ANATOMY", 264, 268], ["DevelopmentWhile", "OBSERVATION", 269, 285], ["lungs", "ANATOMY", 294, 299], ["impaired", "OBSERVATION_MODIFIER", 315, 323], ["regenerative", "OBSERVATION_MODIFIER", 324, 336]]], ["In a study of young (2\u20133 mo) and aged (16\u201318 mo) mice, influenza virus infection led to more severe alveolar damage, and delayed regeneration of alveolar type II cells and pro-SPC-positive bronchiolar epithelial cells in older mice [76].", [["alveolar", "ANATOMY", 100, 108], ["alveolar type II cells", "ANATOMY", 145, 167], ["pro-SPC-positive bronchiolar epithelial cells", "ANATOMY", 172, 217], ["influenza virus infection", "DISEASE", 55, 80], ["alveolar damage", "DISEASE", 100, 115], ["mice", "ORGANISM", 49, 53], ["influenza virus", "ORGANISM", 55, 70], ["alveolar", "TISSUE", 100, 108], ["alveolar type II cells", "CELL", 145, 167], ["pro-SPC", "CELL", 172, 179], ["bronchiolar epithelial cells", "CELL", 189, 217], ["mice", "ORGANISM", 227, 231], ["alveolar type II cells", "CELL_TYPE", 145, 167], ["pro-SPC-positive bronchiolar epithelial cells", "CELL_TYPE", 172, 217], ["mice", "SPECIES", 49, 53], ["influenza virus", "SPECIES", 55, 70], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 49, 53], ["influenza virus", "SPECIES", 55, 70], ["influenza virus infection", "PROBLEM", 55, 80], ["more severe alveolar damage", "PROBLEM", 88, 115], ["delayed regeneration of alveolar type II cells", "PROBLEM", 121, 167], ["pro-SPC", "TEST", 172, 179], ["positive bronchiolar epithelial cells", "PROBLEM", 180, 217], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["alveolar damage", "OBSERVATION", 100, 115], ["alveolar type II cells", "OBSERVATION", 145, 167], ["positive", "OBSERVATION_MODIFIER", 180, 188], ["bronchiolar epithelial cells", "OBSERVATION", 189, 217]]], ["Good regenerative capacity could explain overall less severity and early recovery of COVID-19 in children compared to older patients.Effects of Lung DevelopmentIt will be interesting to see if there is any difference in affinity of SARS-CoV-2 to different parts of respiratory epithelium with age and if pediatric infections are limited to upper respiratory tract?", [["Lung", "ANATOMY", 144, 148], ["respiratory epithelium", "ANATOMY", 265, 287], ["upper respiratory tract", "ANATOMY", 340, 363], ["SARS", "DISEASE", 232, 236], ["infections", "DISEASE", 314, 324], ["COVID-19", "GENE_OR_GENE_PRODUCT", 85, 93], ["children", "ORGANISM", 97, 105], ["patients", "ORGANISM", 124, 132], ["Lung", "ORGAN", 144, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 232, 242], ["respiratory epithelium", "TISSUE", 265, 287], ["upper respiratory", "ORGANISM_SUBDIVISION", 340, 357], ["tract", "ORGANISM_SUBDIVISION", 358, 363], ["children", "SPECIES", 97, 105], ["patients", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 232, 240], ["COVID", "TEST", 85, 90], ["SARS", "PROBLEM", 232, 236], ["respiratory epithelium", "PROBLEM", 265, 287], ["pediatric infections", "PROBLEM", 304, 324], ["upper respiratory tract", "PROBLEM", 340, 363], ["regenerative capacity", "OBSERVATION", 5, 26], ["less severity", "OBSERVATION_MODIFIER", 49, 62], ["Lung", "ANATOMY", 144, 148], ["respiratory epithelium", "ANATOMY", 265, 287], ["upper", "ANATOMY_MODIFIER", 340, 345], ["respiratory tract", "ANATOMY", 346, 363]]], ["Due to greater upper airway resistance in children, aerosol particles deposit more in tracheobronchial tree than alveoli [77].", [["upper airway", "ANATOMY", 15, 27], ["tracheobronchial tree", "ANATOMY", 86, 107], ["alveoli", "ANATOMY", 113, 120], ["upper airway", "MULTI-TISSUE_STRUCTURE", 15, 27], ["children", "ORGANISM", 42, 50], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 86, 107], ["alveoli", "MULTI-TISSUE_STRUCTURE", 113, 120], ["children", "SPECIES", 42, 50], ["greater upper airway resistance in children", "PROBLEM", 7, 50], ["aerosol particles deposit", "TREATMENT", 52, 77], ["greater", "OBSERVATION_MODIFIER", 7, 14], ["upper", "ANATOMY_MODIFIER", 15, 20], ["airway", "ANATOMY", 21, 27], ["resistance", "OBSERVATION", 28, 38], ["tracheobronchial", "ANATOMY", 86, 102], ["tree", "ANATOMY_MODIFIER", 103, 107]]], ["This could lead to more bronchiolitis-like infections and less pneumonia with SARS-CoV-2 infection in children.Co-morbid ConditionsIn adults with COVID-19, co-morbidities like heart diseases, cerebrovascular diseases, and obesity are associated with increased mortality [78, 79].", [["heart", "ANATOMY", 176, 181], ["cerebrovascular", "ANATOMY", 192, 207], ["bronchiolitis", "DISEASE", 24, 37], ["infections", "DISEASE", 43, 53], ["pneumonia", "DISEASE", 63, 72], ["SARS-CoV-2 infection", "DISEASE", 78, 98], ["heart diseases", "DISEASE", 176, 190], ["cerebrovascular diseases", "DISEASE", 192, 216], ["obesity", "DISEASE", 222, 229], ["CoV-2", "ORGANISM", 83, 88], ["children", "ORGANISM", 102, 110], ["heart", "ORGAN", 176, 181], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 192, 207], ["children", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 78, 86], ["more bronchiolitis", "PROBLEM", 19, 37], ["like infections", "PROBLEM", 38, 53], ["less pneumonia", "PROBLEM", 58, 72], ["SARS", "PROBLEM", 78, 82], ["2 infection", "PROBLEM", 87, 98], ["COVID", "TEST", 146, 151], ["heart diseases", "PROBLEM", 176, 190], ["cerebrovascular diseases", "PROBLEM", 192, 216], ["obesity", "PROBLEM", 222, 229], ["increased mortality", "PROBLEM", 250, 269], ["more", "OBSERVATION_MODIFIER", 19, 23], ["bronchiolitis", "OBSERVATION", 24, 37], ["infections", "OBSERVATION", 43, 53], ["less", "OBSERVATION_MODIFIER", 58, 62], ["pneumonia", "OBSERVATION", 63, 72], ["CoV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 89, 98], ["heart", "ANATOMY", 176, 181], ["diseases", "OBSERVATION", 182, 190], ["cerebrovascular", "ANATOMY", 192, 207], ["diseases", "OBSERVATION", 208, 216], ["obesity", "OBSERVATION", 222, 229]]], ["Upregulation of ACE-2 in smokers may contribute to poor outcomes of respiratory infections in them; the same will be applicable to elderly smokers [80, 81].", [["respiratory", "ANATOMY", 68, 79], ["respiratory infections", "DISEASE", 68, 90], ["ACE-2", "GENE_OR_GENE_PRODUCT", 16, 21], ["smokers", "ORGANISM", 25, 32], ["ACE", "PROTEIN", 16, 19], ["Upregulation of ACE", "TREATMENT", 0, 19], ["respiratory infections", "PROBLEM", 68, 90], ["respiratory", "ANATOMY", 68, 79], ["infections", "OBSERVATION", 80, 90]]], ["As most of these morbidities are not commonly seen in children, children are placed in a favourable position.", [["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 64, 72]]], ["Second-hand smoking could be a risk factor for children.Co-morbid ConditionsIn a study of infants with RSV ALRI, presence of prematurity, co-existing heart disease, and recurrent wheezing were associated with increased mortality [82].", [["heart", "ANATOMY", 150, 155], ["smoking", "CHEMICAL", 12, 19], ["RSV ALRI", "DISEASE", 103, 111], ["prematurity", "DISEASE", 125, 136], ["heart disease", "DISEASE", 150, 163], ["wheezing", "DISEASE", 179, 187], ["children", "ORGANISM", 47, 55], ["infants", "ORGANISM", 90, 97], ["RSV", "ORGANISM", 103, 106], ["heart", "ORGAN", 150, 155], ["children", "SPECIES", 47, 55], ["infants", "SPECIES", 90, 97], ["RSV", "SPECIES", 103, 106], ["a study", "TEST", 79, 86], ["RSV ALRI", "PROBLEM", 103, 111], ["prematurity", "PROBLEM", 125, 136], ["co-existing heart disease", "PROBLEM", 138, 163], ["recurrent wheezing", "PROBLEM", 169, 187], ["increased mortality", "PROBLEM", 209, 228], ["hand", "ANATOMY", 7, 11], ["prematurity", "OBSERVATION", 125, 136], ["heart", "ANATOMY", 150, 155], ["disease", "OBSERVATION", 156, 163], ["recurrent", "OBSERVATION_MODIFIER", 169, 178], ["wheezing", "OBSERVATION", 179, 187]]], ["Similarly, among children dying of influenza infection in USA, 57% had at-least one high risk condition, including neurological disorders (33%), pulmonary disorders (26%) (including asthma, 16%), genetic disorders (12%) and cardiac diseases (11%) [83].", [["neurological", "ANATOMY", 115, 127], ["pulmonary", "ANATOMY", 145, 154], ["cardiac", "ANATOMY", 224, 231], ["influenza infection", "DISEASE", 35, 54], ["neurological disorders", "DISEASE", 115, 137], ["pulmonary disorders", "DISEASE", 145, 164], ["asthma", "DISEASE", 182, 188], ["genetic disorders", "DISEASE", 196, 213], ["cardiac diseases", "DISEASE", 224, 240], ["children", "ORGANISM", 17, 25], ["pulmonary", "ORGAN", 145, 154], ["cardiac", "ORGAN", 224, 231], ["children", "SPECIES", 17, 25], ["influenza infection", "PROBLEM", 35, 54], ["high risk condition", "PROBLEM", 84, 103], ["neurological disorders", "PROBLEM", 115, 137], ["pulmonary disorders", "PROBLEM", 145, 164], ["asthma", "PROBLEM", 182, 188], ["genetic disorders", "PROBLEM", 196, 213], ["cardiac diseases", "PROBLEM", 224, 240], ["influenza", "OBSERVATION_MODIFIER", 35, 44], ["infection", "OBSERVATION", 45, 54], ["pulmonary", "ANATOMY", 145, 154], ["disorders", "OBSERVATION", 155, 164], ["cardiac", "ANATOMY", 224, 231], ["diseases", "OBSERVATION", 232, 240]]], ["From USA COVID-19 data, of the 3 pediatric deaths, all had associated underlying conditions [84].", [["deaths", "DISEASE", 43, 49]]], ["Pending detailed reports, young infants and children with similar co-morbidities should be considered as high-risk population for COVID-19.", [["infants", "ORGANISM", 32, 39], ["children", "ORGANISM", 44, 52], ["infants", "SPECIES", 32, 39], ["children", "SPECIES", 44, 52], ["similar co-morbidities", "PROBLEM", 58, 80], ["COVID", "TEST", 130, 135]]], ["There is a need to study risk factors for severe SARS-CoV-2 infection in children, to identify population most appropriate for clinical trials and administration of anti-viral therapies and vaccines (once available).Other MechanismsThere are increasing reports of thrombotic complications with severe COVID-19 [85, 86].", [["SARS-CoV-2 infection", "DISEASE", 49, 69], ["thrombotic complications", "DISEASE", 264, 288], ["COVID-19", "CHEMICAL", 301, 309], ["SARS-CoV-2", "ORGANISM", 49, 59], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["SARS-CoV-2", "SPECIES", 49, 59], ["severe SARS", "PROBLEM", 42, 53], ["CoV", "PROBLEM", 54, 57], ["2 infection", "PROBLEM", 58, 69], ["clinical trials", "TREATMENT", 127, 142], ["anti-viral therapies", "TREATMENT", 165, 185], ["vaccines", "TREATMENT", 190, 198], ["thrombotic complications", "PROBLEM", 264, 288], ["severe COVID", "PROBLEM", 294, 306], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["SARS", "OBSERVATION", 49, 53], ["infection", "OBSERVATION", 60, 69], ["increasing", "OBSERVATION_MODIFIER", 242, 252], ["thrombotic", "OBSERVATION", 264, 274], ["severe", "OBSERVATION_MODIFIER", 294, 300]]], ["With presence of ACE-2 on vascular endothelium and association of severe disease with raised D-dimer levels, potential role of endotheliopathy and microangiopathy in COVID-19 pathogenesis needs evaluation [78].", [["vascular endothelium", "ANATOMY", 26, 46], ["endotheliopathy", "DISEASE", 127, 142], ["microangiopathy", "DISEASE", 147, 162], ["ACE-2", "GENE_OR_GENE_PRODUCT", 17, 22], ["vascular endothelium", "TISSUE", 26, 46], ["D-dimer", "GENE_OR_GENE_PRODUCT", 93, 100], ["ACE", "PROTEIN", 17, 20], ["D-dimer", "PROTEIN", 93, 100], ["ACE", "TEST", 17, 20], ["severe disease", "PROBLEM", 66, 80], ["raised D-dimer levels", "PROBLEM", 86, 107], ["endotheliopathy", "PROBLEM", 127, 142], ["microangiopathy", "PROBLEM", 147, 162], ["COVID", "TEST", 166, 171], ["evaluation", "TEST", 194, 204], ["ACE", "OBSERVATION", 17, 20], ["vascular endothelium", "ANATOMY", 26, 46], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["disease", "OBSERVATION", 73, 80], ["endotheliopathy", "OBSERVATION", 127, 142], ["microangiopathy", "OBSERVATION", 147, 162]]], ["There are no such reports in children yet.", [["children", "ORGANISM", 29, 37], ["children", "SPECIES", 29, 37], ["no", "UNCERTAINTY", 10, 12]]], ["There had been cases where patients initially turned negative for SARS-CoV-2, returned positive (not reported in children yet) [87].", [["SARS", "DISEASE", 66, 70], ["patients", "ORGANISM", 27, 35], ["SARS-CoV-2", "ORGANISM", 66, 76], ["children", "ORGANISM", 113, 121], ["patients", "SPECIES", 27, 35], ["children", "SPECIES", 113, 121], ["SARS-CoV", "SPECIES", 66, 74], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74]]], ["But these patients were asymptomatic and likely represent carrier state than re-infection.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["asymptomatic", "PROBLEM", 24, 36], ["carrier state", "PROBLEM", 58, 71], ["re-infection", "PROBLEM", 77, 89], ["likely represent", "UNCERTAINTY", 41, 57]]], ["Duration of long-term immunity is yet to be established for the novel virus.Other MechanismsSummary of potential factors protecting children against SARS-CoV-19 infection are summarized in Table 2.Future Directions", [["SARS-CoV-19 infection", "DISEASE", 149, 170], ["children", "ORGANISM", 132, 140], ["SARS-CoV-19", "ORGANISM", 149, 160], ["children", "SPECIES", 132, 140], ["SARS-CoV-19", "SPECIES", 149, 160], ["long-term immunity", "TREATMENT", 12, 30], ["the novel virus", "PROBLEM", 60, 75], ["SARS", "PROBLEM", 149, 153], ["CoV", "PROBLEM", 154, 157], ["infection", "PROBLEM", 161, 170]]]]}